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This thesis consists of studies addressing the impact of leprosy control activities on the 
occurrence of leprosy and its impairments. Assessing this impact is difficult because the 
epidemiology of leprosy is fraught with uncertainties. Knowledge of processes governing 
leprosy transmission is limited, and controlled studies enabling direct assessment of the 
impact of interventions on transmission have never been conducted. Nevertheless, 
decisions regarding the extent and organisation of leprosy control programmes need to be 
made. This applies in particular to the present era, which has witnessed drastic 
epidemiological improvements in some developing countries, but no change in others. 
This introductory chapter provides a background to the studies presented in 
Chapters 2-8. First, essential knowledge of leprosy infection, disease and its 
consequences, and transmission is summarised (1.1). Next, the history of leprosy control 
and available control options are described briefly (1.2). Section 1.3 summarises patterns 
in the global occurrence of leprosy and related health problems from 1985 onwards. 
Section 1.4 introduces our epidemiological modelling approach for investigating the 
potential impact of leprosy control, and summarises earlier modelling work. Finally, the 
research questions of this thesis and outlines of the chapters are given (1.5). 
1.1 Leprosy  
Leprosy is a chronic infectious disease which affects the peripheral nerves and the skin. It 
is often referred to as ‘the oldest disease known to man’ (1). The earliest written records 
describing leprosy come from India and date back to about 600 BC. The earliest remains 
of people confirmed to be affected with leprosy stem from Egyptian excavations which 
disclosed leprous skulls buried in the second century BC. 
Infection and disease 
Leprosy is caused by the bacillus Mycobacterium leprae. This bacillus was one of the first 
agents to be linked to an infectious disease. M. leprae was discovered in 1873 by Hansen in 
a Norwegian leprosy research hospital (2). Despite this early discovery, leprosy is even 
today a disease which is not well understood. The inability to culture M. leprae is an 
important reason.  
Establishing leprosy infection is difficult. A recent study which employed serological 
testing indicated leprosy infection to be far more common than leprosy disease (3), which 
confirms suggestions from the 1980s (4, 5). In recent years, considerable progress has 
been made in the development of diagnostic tools for leprosy infection, including skin 
and serological tests and molecular polymerase chain reaction tests (3). Still, it is not 
possible to predict who will develop leprosy disease and who will not. Genetic factors 
appear to influence resistance to leprosy infection and to development and expression of 
disease (6), but the importance of these factors is unclear. 
The duration of the incubation period of leprosy is also uncertain. Estimates were made 
for American and English war veterans who served in areas endemic for leprosy and later 
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developed leprosy disease (4). The estimated duration ranged from half a year to 21 years. 
It has been suggested that disease may not only develop after primary infection, but also 
from endogenous reactivation of dormant bacilli acquired earlier in life (5). 
In this thesis, leprosy disease refers to presence of signs that can be diagnosed through 
physical examination. Disease manifestations vary widely because cellular responses which 
constitute the body’s main defence against M. leprae vary strongly between individuals (4). 
Previously, the most common classification system used was the Ridley-Jopling system 
which recognises a spectrum with five groups and an ‘indeterminate’ class. Cellular 
immunity is strong at one end of the spectrum (polar tuberculoid leprosy, or TT), and 
absent at the other end (polar lepromatous leprosy, or LL). Skin and nerve lesions caused 
by leprosy have few bacilli at the tuberculoid, and many bacilli at the lepromatous side of 
the spectrum. Microscopic examination of skin smears for bacilli is often applied as an 
additional diagnostic procedure for classifying leprosy patients (i.e. those with signs of 
leprosy). A considerable proportion of tuberculoid patients may heal spontaneously. The 
three intermediate groups of the Ridley-Jopling system are referred to as borderline 
leprosy (BT, BB and BL). Movements of patients across the leprosy spectrum occur, and 
borderline leprosy is much less stable than the two polar forms of leprosy (TT and LL).  
Transmission 
The discovery of M. leprae in 1874 disproved the hereditary theory of leprosy. But even 
today the debate about the mode of transmission of M. leprae is not closed. Leprosy is 
considered to be transmitted almost exclusively within the human population. The two 
most common hypotheses for leprosy transmission are skin-to-skin contact and airborne 
transmission, with discharge of bacilli from the nasal mucosa of infectious individuals and 
entry of bacilli through the respiratory tract (6). Nowadays most leprologists favour the 
airborne hypothesis, which is supported by several observations: nasal excretion of 
leprosy bacilli is much more common than from any other part of the body in leprosy 
patients and untreated lepromatous patients excrete large numbers of bacilli from the 
nose (7). Also, occurrence of M. leprae DNA in the nose of healthy individuals has been 
shown to be widespread in leprosy endemic populations (3). 
The question of who is to what extent contributing to transmission remains unresolved. 
Traditionally, lepromatous (LL) patients were thought to be the main source of infection. 
But compared to the general population, the risk of developing leprosy is also 
considerably higher for household contacts of non-lepromatous patients (8-10). This may 
in part be due to common sources of infection outside the household. The idea that 
patients are the only source of infection is currently being challenged. Individuals 
incubating for leprosy disease could transmit leprosy, for there is no reason why the 
shedding of bacilli would start only with the onset of signs of leprosy disease, which 
involve nerve and skin. A possibly important role for self-healing infections which do not 
result in disease, but which do have a transient period of nasal excretion, has also been 
suggested. It can therefore not be excluded that transmission by leprosy patients may be 
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less important than transmission by those who do not (yet) have any signs of the disease 
(7). Transmission may also be indirect: transmission through insect bites can for instance 
not be excluded (11). Finally, animal sources (e.g. armadillos) and environmental sources 
of infection (e.g. soil, water) may possibly be relevant for the persistence of leprosy (12). 
Socio-economic conditions  
A review of international literature suggested that socio-economic conditions play an 
important role in leprosy (11). Declines in numbers of new patients are thought to be 
related to socio-economic improvement. Several factors that may play a role have been 
identified: housing conditions, number of persons per household per room, family size, 
nutrition and schooling.  
Impairment and disability 
Mild self-healing forms of leprosy with only one single skin lesion do occur, but leprosy 
can also be a chronic and destructive disease. Leprosy is a public health problem because 
it may cause impairment, and subsequently, disability and handicap. Impairment is related 
to the preference of M. leprae for peripheral nerves. The initial signs of leprosy are skin 
lesions and/or neuritis (nerve thickening, tenderness and pain) and/or nerve function 
impairment (loss of motor, sensory or autonomic nerve function). Nerve function 
impairment can develop before initiation of chemotherapy, during this treatment, and 
even after its completion. New nerve function impairment can develop silently (i.e. no 
spontaneous complaints of nerve pain, paraesthesia and/or nerve tenderness on 
palpation), but can also be part of a clinically apparent reversal reaction (RR) or erythema 
nodosum leprosum (ENL) reaction (13). High bacillary loads within nerves of 
lepromatous leprosy patients may in itself also cause nerve function impairment (14). 
Nerve function impairment is a primary complication of leprosy as it is directly associated 
with M. leprae. Secondary complications include plantar and palmar ulceration, 
contractures of digits, stiffness of joints, and disintegration of bones of hands and feet 
(15). Secondary complications may be caused by unprotected use of hands and feet with 
nerve function impairment. Peripheral nerve damage may also cause lagophthalmus 
(inability to close the eye lid) with corneal ulceration and subsequent blindness as possible 
secondary complications.  
A grading system is employed to measure the severity of impairment. This system evolved 
over time, and was last revised in 1998 (16, 17). A grade of 0-2 is assigned to each of six 
body sites (both eyes, hands and feet; Table 1.1), and an overall grade for a patient is 
determined as the maximum of these six grades. The grades are a composite measure for 
nerve function impairment and secondary complications. They are often referred to as 
‘WHO disability grades’ instead of the more appropriate ‘WHO impairment grades’. 
Many leprosy control programmes provide information on impairment in their routine 
reports, but usually only the proportion and number of new patients with overall grade 2 
are provided.  
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Due to impairment, patients may develop disabilities and handicaps: it may become 
difficult or even impossible for someone to carry out activities necessary for daily life and 
income generation. For instance, manual dexterity may be affected because of insensitivity 
and muscle paralysis. Walking may become difficult or impossible because of ulcers or 
disintegration of bones of the foot. Limitations in eye sight may hinder orientation in 
space, mobility and many other aspects of living. A further consequence is that a disabled 
individual may experience disadvantages that limit or prevent fulfilment of his or her 
normal role in society (handicap). Ultimately, leprosy patients may lose social status and 
become progressively isolated from society, family and friends (destitution). The gross 
deformities which used to be encountered regularly in neglected leprosy patients, 
contributed to the social stigma which is still attached to the disease. 
1.2 Leprosy control 
The various dimensions of leprosy are addressed by specific interventions. Early detection 
of patients is essential for preventing impairment. Subsequent chemotherapy cures 
patients bacteriologically, and as a secondary effect may reduce transmission. Other 
measures that may reduce transmission will be described below. Timely detected nerve 
function impairment can often be recovered through treatment with corticosteroids. 
Impaired and disabled patients may receive physiotherapy, and aids and appliances such 
as protective footwear, gloves, splints, spectacles and modified tools. Reconstructive and 
plastic surgery can be offered to patients with deformities of hands, feet or face. Measures 
such as vocational training and sheltered workshops aim at rehabilitation of leprosy 
patients. Finally, health education of the public, for instance through mass media, creates 
awareness of early signs of leprosy, and aims to change attitudes towards leprosy and 
leprosy patients.  
Table 1.1 WHO grading system for measuring the severity of impairment for hands, feet and eyes. 
 Hands and Feet 
Grade 0 No anaesthesia, no visible deformity or damage 
Grade 1 Anaesthesia present, but no visible deformity or damage 
Grade 2 Visible deformity or damage present 
 Eyes 
Grade 0 No corneal anaesthesia; no evidence of visual loss 
Grade 1 Corneal anaesthesia; vision not severely affected as a result a 
Grade 2 Vision severely affected due to leprosy and/or lagophtalmos and/or iridocyclitis and/or corneal 
opacities a 
a Vision is considered severely affected in case of inability to count fingers at six metres or if vision is less 
than 6/60. 
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Chemotherapy-based control 
For centuries, leprosy ‘control’ consisted of measures for segregating leprosy patients 
from the general community. Isolation undoubtedly nurtured the stigma attached to 
leprosy (4). In the 1940s, dapsone (DDS or diaminodiphenyl sulfone) was found to be an 
effective drug for treating leprosy patients. Being cheap and not very toxic, dapsone 
monotherapy soon became the mainstay of leprosy control programmes around the 
world (4). With the introduction of domiciliary treatment regimens, a trend away from 
institutionalisation of patients was encouraged. Dapsone is thought to quickly remove the 
infectiousness of patients (18). Supposedly, this would lead to reductions in levels of 
leprosy transmission. However, the initial optimism of conquering leprosy within the 
foreseeable future turned into frustration. Dapsone often required long term or even life-
long treatment, which led to poor patient compliance (19). Negative social attitudes 
towards leprosy and leprosy patients complicated case detection (i.e. the detection of new 
leprosy patients) and treatment compliance. In addition, treatment became increasingly 
ineffective due to widespread development of secondary resistance of M. leprae – i.e. 
resistance acquired as a result of inadequate treatment – against dapsone. Low dosages of 
dapsone and low compliance predisposed the development of secondary resistance (18). 
Dapsone resistance in previously untreated patients (primary resistance) was also found 
frequently. This type of resistance probably results from infection with drug-resistant 
organisms that originate from another patient with secondary resistance. Most primary 
resistant patients had a low degree of resistance: they were still expected to respond to 
treatment with dapsone in full dosage (20, 21). Nonetheless, by the early 1980s it was 
clear that dapsone monotherapy was steadily losing its usefulness.  
In the 1960s, the availability of better drugs, including rifampicin which is highly 
bactericidal, made treatment through combinations of drugs possible (22). The rationale 
for using multiple drugs is to prevent development of resistance: mutant bacilli that are 
not sensitive to rifampicin will be killed by one of the other drugs. In 1981, the World 
Health Organization (WHO) recommended to treat leprosy patients with a standard 
multidrug therapy regimen including rifampicin (MDT). Although more expensive than 
dapsone, MDT has important advantages: (a) relatively short duration of treatment; (b) 
low relapse rates following completion of treatment; (c) so far, there is no evidence of 
treatment failures attributable to drug resistance. Toxicity of dapsone and MDT is not a 
problem, although side-effects occur occasionally.  
MDT is provided free of charge and is very well accepted by national health services (19). 
The introduction of MDT also contributed to improvements in the organisation of 
leprosy control. A quick cure contributed to earlier self-reporting, and to better treatment 
compliance. Ultimately, the social stigma attached to leprosy may even be reduced 
through increasing awareness of its curability (23). MDT was implemented gradually: in 
1993, 49% of patients worldwide under treatment were reported to receive MDT (24), 
versus 99% in 1998 (25). As with dapsone, the advent of MDT raised great optimism in at 
least part of the leprosy community. It was suggested that “through early diagnosis and 
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effective treatment, the transmission of the disease could virtually be stopped over a 
period of time” (19). However, such an impact has not yet been demonstrated. 
Assessment of the impact that chemotherapy-based control has on leprosy transmission is 
one of the objectives of this thesis.  
For treatment with MDT, patients are classified into paucibacillary (PB) and multibacillary 
(MB) leprosy. Initially, patients were assigned to PB and MB on the basis of the Ridley-
Jopling system and results of skin smear testing. In 1998, it was concluded that patients 
could be classified on the basis of skin lesion counts, which led to new definitions of PB 
and MB leprosy (PB: 1-5 lesions, MB: more than 5 lesions) (17). PB patients are to be 
treated with two drugs (rifampicin and dapsone) for a period of six months (26). MB 
patients receive three drugs (rifampicin, dapsone and clofazimine). The recommended 
duration of treatment for MB leprosy was gradually shortened: from “at least two years, 
and ... whenever possible, until skin smears negativity” (26), to 24 months (27), to 12 
months (28). Nowadays, WHO also considers a single dose of a different regimen, ROM 
(rifampicin, ofloxacin and minocycline), acceptable as an alternative for the treatment of 
single-lesion PB leprosy in programmes which maintain strict diagnostic criteria and 
which detect very large numbers of such patients (28). WHO does not recommend use of 
ROM for single-lesion PB leprosy in other programmes, because catering to a third 
regimen (ROM) would complicate logistics and information systems, and because use of 
ROM may lead to over-diagnosis of non-leprosy skin patches as leprosy. WHO has been 
criticised for simplifying the management of leprosy through the discontinuation of 
smears and the shortening of the recommended treatment duration for MB patients, 
without conducting thorough scientific research (29). In 2002, it was proposed to study 
the effectiveness of uniform treatment of PB and MB patients for a period of six months 
with the standard MB/MDT regimen (30). 
Immunoprophylaxis and chemoprophylaxis 
The use of BCG (Bacille Calmette-Guérin) vaccination for tuberculosis (TB) dates back 
to the 1920s. TB is also caused by a mycobacterium, M. tuberculosis. BCG was 
incorporated in the Expanded Programme on Immunization’s (EPI) infant vaccination 
schedule in 1974 as a preventive measure against tuberculosis. The rationale for this is 
that BCG protects against serious childhood forms of tuberculosis; its protective efficacy 
against adult pulmonary forms of tuberculosis varies widely in different parts of the world 
(31). 
BCG may also be valuable for leprosy control. In randomised controlled trials (RCTs), 
the efficacy of BCG in preventing leprosy ranged from 20% to 80%, with low values in 
South-East Asia (32, 33). It is unclear whether, and to which extent, BCG’s protective 
efficacy against leprosy wanes with time. A trial from Venezuela and another RCT in 
Malawi showed that the protective efficacy of BCG against leprosy is enhanced with 
repeated administration (34). However, the Malawi RCT showed an association between 
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revaccination and increased risk of tuberculosis in HIV-infected individuals, prohibiting 
mass revaccination campaigns.  
Recently, other vaccines have also been tested. A RCT in South India demonstrated two 
vaccines, ICRC and BCG plus heat-killed M. leprae, to have higher protective efficacy than 
BCG (35). On the other hand, the Malawi RCT and the Venezuela trial failed to show 
evidence that the addition of killed M. leprae enhances the protective efficacy of BCG (34). 
So far, trial results for leprosy have had little effect on vaccination policies. An exception 
is the policy of repeat BCG vaccination of contacts of leprosy patients, that is routinely 
carried out in some places (34). In most countries, BCG is only administered at birth (or 
at the first contact with the health services) (31). The estimated worldwide coverage of 
infant BCG vaccination gradually increased from 15% in 1980 to around 80% throughout 
the 1990s (36). The protection imparted by BCG also has an indirect effect: those who 
are prevented from developing leprosy will also not transmit leprosy to others. It has been 
claimed that BCG has been a factor in the decline of leprosy in certain populations (37). 
However, the proportion of leprosy patients that has been prevented by BCG up till now 
is probably rather low because (a) in most countries, only infants are vaccinated; (b) 
children usually constitute only a minority in the detection of leprosy; (c) the protective 
efficacy of BCG may wane with time; (d) BCG coverages may have been low, especially 
in the 1980s. The latter implies that the proportion of present adult populations ever 
having received BCG will in general be low. In this thesis, the impact of BCG vaccination 
of infants on leprosy transmission is explored along with the investigation of the impact 
of chemotherapy-based control.  
The possibility of chemoprophylaxis using dapsone or a derivative, acedapsone, in the 
prevention of leprosy has been investigated extensively. The protective efficacy of 
treatment ranged from 34% to 54% in a meta-analysis of five RCTs in which household 
contacts of leprosy patients were followed (38). The protective efficacy of (ace)dapsone 
prophylaxis was suggested to be around 60% when studies with other designs were 
considered as well. Increasing dapsone resistance in the 1970s prohibited further 
development of dapsone-based chemoprophylaxis policies. The scientific interest for 
chemoprophylaxis disappeared largely in the 1980s and 1990s following the introduction 
of MDT, but revived in recent years. This is mainly due to the fact that global case 
detection rates of leprosy have remained stable throughout the 1990s (see section 1.3), 
and associated concern that MDT may not be sufficient to interrupt the transmission of 
leprosy. To date, chemoprophylaxis is not part of routine leprosy control programmes. A 
drawback of prophylactic treatment with dapsone in addition to resistance was the 
duration of treatment: in some of the RCTs, the treatment duration was several years. The 
efficacy of prophylactic treatment using only a few doses of newer drugs is not well 
known. Only one study was conducted: single dose rifampicin was given to a remote 
island population in French Polynesia in 1988. The estimated efficacy of this mass 
intervention was 40-50% (38). To further investigate the impact of chemoprophylaxis, 
two studies using two prophylactic doses of either ROM (rifampicin, ofloxacin and 
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minocycline; first study) or rifampicin (second study) were started in island populations in 
1996 and 2000 (39, 40). In addition, two randomised controlled trials using single dose 
rifampicin in contacts of leprosy patients started in 2000 and 2002, respectively (41, 42).  
1.3 Global situation  
Leprosy control programmes routinely provide information on the number of patients 
detected, the percentage of new patients presenting with WHO grade 2 impairment, and 
the total number of patients who are registered within the programmes. Aggregated 
information from 1985 onwards is summarised below. 
Published trends in annual case detection vary widely between areas. A systematic review 
of these trends was lacking (what are the exact trends?, can they be explained?), and is 
presented in this thesis. Despite of the wide variability between areas, the global annual 
case detection trend over 1985-2000 was rather constant, except for an elevation in 
1998-2000 (43, 44). On average, about 650,000 cases were detected per year in the period 
1990-2000. Table 1.2 provides a breakdown of global case detection by WHO Regions 
and countries for the year 1998. 
Of the seven million new patients detected globally during 1985-1996, 550,000 (8%) 
presented with WHO grade 2 impairment (45). The percentage with WHO grade 2 
decreased from 10% in 1985 to 7% in 1995 and 4% in 2000 (44, 45). Due to possible 
underreporting of cases with impairment and overdiagnosis of leprosy, the actual 
percentages of new patients with grade 2 impairment at the time of detection may have 
been higher, especially in most recent years.  
The number of individuals living with impairment caused by leprosy has not been 
monitored systematically. By consequence, only crude estimates are available about the 
number of individuals living with impairment caused by leprosy, which reflects the impact 
that leprosy has on public health. In 1995, WHO estimated the number of individuals 
with impairment caused by leprosy to be between one and two million (46). In 1998, the 
Seventh WHO Expert Committee On Leprosy mentioned that “there may be about three 
million persons with leprosy-related impairments and disabilities in the world, including 
about two million with grade 2 disabilities and about one million with grade 1 disabilities” 
(17). The number of individuals living with impairment depends on how many patients 
who were detected in the past already had impairment at the time of their detection, on 
changes in the impairment status of patients during chemotherapy treatment and after 
release from treatment, and on survival probabilities. The presence of impairments at the 
time of detection is believed to be associated with longer delays between onset of disease 
and detection. Both this association and the occurrence of changes in the impairment 
status of patients during and after treatment are investigated in this thesis.  
In leprosy, the number of patients in registers of control programmes is denoted as 
‘prevalence’ or ‘registered prevalence’. The trend in global registered prevalence since 
1985 contrasts sharply with the case detection trend. The registered prevalence fell almost 
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everywhere in the world (43, 48, 49). Overall, the fall was dramatic: from 4.0 million 
patients in 1985 to 750,000 around the year 2000 (43). There are two important reasons 
for this fall. Firstly, there was no consistency in register keeping: following the 
introduction of MDT, many (ex-)patients not in need of chemotherapy, but possibly with 
impairments or disabilities, were removed from programme registers (29, 50). Secondly, 
patients became registered for shorter periods of time, simply because MDT has a much 
shorter treatment duration than dapsone. ‘Registered prevalence’ is often incorrectly used 
as a synonym for the number of leprosy patients receiving chemotherapy; ‘on-treatment 
Table 1.2 Case detection for countries with at least 2000 detected cases, for the WHO Regions and global case 
detection, 1998. 
Country / region a,b 
Cases
detected
in 1998
Contribution to
global case
detection (%) Country / region a,b 
Cases
detected
in 1998
Contribution to
global case 
detection (%)
    Africa     South-East Asia 
Ethiopia 4,457 <1% Bangladesh 12,351 2%
Guinea 3,684 <1% India 634,901 79%
Madagascar 8,957 1% Indonesia 18,367 2%
Mozambique 3,764 <1% Myanmar 14,357 2%
Niger 2,549 <1% Nepal 6,570 <1%
Nigeria 7,230 <1% Other countries 2,523 <1%
Tanzania 3,535 <1% Total 689,069 86%
Other countries c 17,354 2%     Western Pacific 
Total 51,530 6% China 2,051 <1%
    Americas Philippines 3,490 <1%
Brazil d 42,055 5% Viet Nam 2,162 <1%
Other countries 5,163 <1% Other countries 2,914 <1%
Total 47,218 6% Total 10,617 1%
    Eastern Mediterrenean  
Sudan 2,077 <1%     World 
Other countries 3,846 <1% Total 804,357 100%
Total 5,923 <1%  
a Less than 100 cases were reported in Europe. 
b Case detection figures for countries were taken from (47) and for WHO Regions and global case detection 
from (44). Case detection figures for “other countries” were derived from the figures for the WHO Regions and 
listed countries. 
c Case detection in the Democratic Republic of the Congo exceeded 2000 cases; exact information is not 
available. 
d The case detection figure for Brazil was taken from (43). 
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prevalence’ is a more correct term. The detection figures illustrate that the fall in 
registered prevalence is not due to decreases in case detection.  
In 1991, the World Health Assembly (WHA) set a target to “eliminate leprosy as a public 
health problem”. This target was defined as an on-treatment prevalence of less than 1 per 
10,000 population, and was announced achieved at a global level in May 2001, despite of 
the fact that global case detection did not fall. Recently, WHO was criticised heavily for 
its emphasis on the elimination target; there is no evidence that reaching the target will 
result in transmission reductions (29). It is feared that proclaiming of achievement of the 
elimination target will result in loss of commitment and resources for leprosy control 
programmes. In the year 2000, WHO scheduled that the elimination target would be 
reached at national level in all countries by the end of the year 2005 (51). It remains to be 
seen whether this goal will be achieved, and what the role will be of operational factors 
which do not affect leprosy transmission. For instance, treating more single lesion leprosy 
cases with single dose ROM instead of MDT (see section 1.2) will reduce the on-
treatment prevalence, but will not affect transmission and case detection. 
1.4 Modelling approach  
The impact of interventions on trends in the transmission of leprosy over time can be 
assessed by analysing intervention studies and programme registries. Proper statistical 
assessment is very difficult however, due to limitations of the available datasets in 
combination with epidemiological features of leprosy, as is explained below. We therefore 
developed an epidemiological framework for modelling leprosy transmission, which plays 
a key role in this thesis and builds on earlier modelling work for tuberculosis and leprosy. 
In this section the rationale for the modelling approach is provided, and earlier modelling 
work is addressed.  
Limitations of leprosy intervention studies and programme registries 
Various intervention studies, such as studies into the effectiveness of MDT in curing 
patients, and RCTs for BCG vaccination and chemoprophylaxis, established the 
effectiveness of interventions for leprosy at the individual level. Extrapolation of the 
study results to assess the impact of the interventions on trends in transmission in 
populations is difficult for several reasons. In RCTs, there were no areas with and without 
the intervention, because randomisation was not by geographical area. In addition, routine 
leprosy control activities were continued during intervention studies, which may have 
blurred the effects of the study interventions on transmission in the study area. Also, the 
study periods of the studies were not sufficiently long, which is a problem because 
changes in leprosy transmission in populations only unfold gradually, due to the long and 
variable incubation period of leprosy. Studies designed to determine how interventions 
that have been proven beneficial at individual level affect trends in transmission have 
never been conducted. This is not surprising: not only would such studies be very costly 
due to the long study period needed, it is also not ethical to withhold interventions that 
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have been proven beneficial at individual level from study populations in intervention 
studies. 
Related issues complicate the assessment of the impact of interventions on trends in 
transmission on the basis of longitudinal data from leprosy control programmes. In 
interpreting downward trends in case detection (the closest proxy indicator for 
transmission), competing explanations must be considered: both chemotherapy-based 
control and BCG vaccination may have contributed, and socio-economic conditions may 
have improved. Disentangling these explanations with statistical techniques (e.g. 
regression analysis, time-series analysis) is difficult, especially because this would require 
datasets that describe long-term trends in geographical areas with comparable general 
conditions, but with different well-documented interventions. We could not identify such 
datasets. In addition, variability in control efforts and methods over time must be taken 
into account when interpreting observed case detection trends. For instance, leprosy 
control activities were intensified both in the early and in the late 1990s (45, 52), which 
hinders the assessment of trends in transmission underlying the case detection data of 
countries and control programmes of the 1990s. 
Transmission models 
Leprosy involves a transmission cycle, like any other infectious disease. Because of this, 
interventions not only have direct effects but also indirect effects, which are difficult to 
assess. For instance, chemotherapy not only cures a patient, but also prevents 
transmission by this patient and by those who would have been infected by this patient if 
he/she were left untreated. Similarly, BCG vaccination not only prevents leprosy cases 
due to the protection afforded (direct effect), but also the transmission that the prevented 
cases might have caused (indirect effect).  
Epidemiological transmission models for an infectious disease explicitly describe the 
transmission process, the course of infection and disease, and the way interventions act. 
This allows for exploration of both the direct and indirect effects of interventions. By 
using a transmission model in addition to statistical techniques in analyses of datasets, 
more knowledge can be gained about the features of a disease that determine the 
potential impact of interventions, and about the impact of these interventions. The 
consequences of gaps in knowledge about a disease can be addressed by varying 
assumptions about uncertain aspects of the disease in so-called sensitivity analyses. 
Transmission models also enable the prediction of future trends in the transmission and 
incidence of a disease, and prospective evaluation and comparison of the impact of 
interventions. Epidemiological transmission models are therefore commonly used. The 
first models were introduced one century ago to investigate the regular recurrence of 
measles epidemics and the relationship between numbers of mosquitoes and the 
incidence of malaria (53). Over time, models of varying complexity were developed for a 
wide range of diseases, for instance including childhood diseases, sexually transmitted 
diseases, and diseases caused by microparasites or macroparasites whose transmission 
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cycle involves intermediate hosts. The development of models for tuberculosis, which is 
like leprosy caused by a mycobacterium, was initiated in the 1960s and still continues (e.g. 
(54-60)). The first model for leprosy was developed in the 1970s by Lechat (61).  
Group-compartmental models 
The SIR-model is the most basic model used for infectious diseases (53). It has three 
compartments: ‘susceptible’, ‘infected’ and ‘recovered’. In a SIR-model, new-borns are 
susceptible. Susceptibles can acquire infection due to transmission, and can subsequently 
recover. The infected group is assumed to be infectious, and recovery is assumed to imply 
immunity for new infections. Everyone can die. A SIR-model has three state variables 
which describe the fractions of the total population in each of the compartments. The 
behaviour of a SIR-model over time is reflected in the changes in its state variables. These 
changes can be described and analysed mathematically because they are fully determined 
by four parameters: a birth rate, a transmission parameter which reflects the 
infectiousness of the compartment ‘infected’, a recovery rate which specifies how fast 
recovery from ‘infected’ takes place, and a death rate which applies to each of the three 
compartments.  
The SIR-model is a so-called group-compartmental model. It can be modified and/or 
extended to describe specific diseases more realistically. For instance, a higher death rate 
can be used for the ‘infected’ compartment to account for the fact that a disease may have 
fatal consequences. And the ‘recovered’ compartment can be omitted for diseases for 
which recovery does not lead to immunity: in this case, recovery leads to a transition back 
to the ‘susceptible’ compartment. Most tuberculosis models are group-compartmental 
models (e.g. (58, 60)). A general feature of tuberculosis models is that the ‘infected’ 
compartment is split up into several compartments: most tuberculosis infections do not 
lead to disease, but some will proceed to infectious pulmonary disease or non-infectious 
disease (pulmonary or extrapulmonary). Similarly, in modelling leprosy, one might 
distinguish ‘PB leprosy’ and ‘MB leprosy’ and account for long incubation periods. 
Group-compartmental models can be made age specific: a new copy of each 
compartment can be used for each age group considered. Sex-specificity is another 
option. Group-compartmental models are often used to explore the impact of 
interventions. To account for vaccination, one can add a ‘vaccinated’ compartment. 
Chemotherapy treatment of infections implies an increase of the recovery rate, and thus a 
shortening of the duration of the infectious period. The above shows that the complexity 
of group-compartmental models can be increased step by step. Simulation techniques are 
used to analyse the behaviour of group-compartmental models when mathematical 
analysis becomes very complicated or impossible.  
Lechat’s leprosy models 
Inspired by early tuberculosis models, Lechat developed a group-compartmental model 
for leprosy and refined it later (61, 62). The models were used to predict the impact on 
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the transmission of leprosy of case detection in combination with either dapsone 
monotherapy or MDT treatment (63-65). Both dapsone and MDT were predicted to have 
an almost immediate impact on the incidence (which refers to onset of disease). With 
dapsone, the incidence decreased by less than 8% per year. In contrast, the impact of 
MDT was predicted to be much faster: the decrease in incidence was about 25% per year. 
The decline in case detection was of the same order of magnitude. Such fast and high 
declines in annual case detection after the introduction of MDT have not been reported 
in literature, see also Chapters 2 and 3. The predictions therefore appear to be 
overoptimistic. 
Lechat made a few assumptions which led to the favourable predictions, and which are in 
conflict with present-day knowledge about leprosy epidemiology. Firstly, an average 
duration for the incubation period of MB leprosy of 2.2 years was used, which is much 
shorter than the available data suggest (4). This causes the turn-around time of the 
transmission cycle to be much too short. Secondly, the assumed delay between onset of 
disease and start of treatment was too short (see e.g. (66-68)), which is important because 
patients starting MDT transmit only during this delay. Thirdly, patients were assumed to 
remain fully infectious during the first year of dapsone treatment (see (18)), which 
resulted in overestimation of the impact of MDT-based as compared to dapsone-based 
control.  
Lechat also used his models to investigate the impact of hypothetical vaccines (‘BCG-like’ 
and other) (62, 63). In the simulations, the vaccines were administered at only one point 
in time, and to entire populations or fractions of them, independent of age. Due to the 
targeting of all age groups, the vaccination strategies almost immediately had an impact 
on incidence trends. The simulated vaccination policies differ from those implemented in 
practice. The policy in most developing countries is to give BCG once in young 
childhood. The rationale for this is to prevent serious childhood forms of tuberculosis 
(see section 1.2). Further questions addressed by Lechat include the assessment of the 
impact of isolation of patients and of improved compliance to dapsone monotherapy on 
transmission (63), of the consequences of the emergence of primary dapsone resistance 
(62), and of the cost-effectiveness of interventions (64, 69). 
Leprosy epidemiology is fraught with uncertainties, several of which are not taken into 
account in Lechat’s models. Some examples are:  
• Does natural immunity occur, and if so, how frequently?  
• How long is the incubation period of leprosy? 
• Are individuals incubating for leprosy disease already infectious?  
• Does most transmission by infectious individuals occur soon after onset of disease?  
The framework for modelling leprosy transmission, SIMLEP, that we developed is 
conceptually quite similar to Lechat’s models. However, SIMLEP is more flexible in 
possibilities for varying assumptions, and a wide range of models can be defined within 
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SIMLEP including models that can deal with the four questions listed above. Figure 1.1 
gives an example of a SIMLEP model in which all transmission is caused by individuals 
with MB leprosy disease. With the group-compartmental SIMLEP framework, existing 
longitudinal data can be analysed in order to explore which uncertain aspects of 
transmission, course of infection and disease determine the impact of control strategies 
on transmission most. In this thesis, the extensive database on the disappearance of 
leprosy from Norway between 1850-1920 is employed for this purpose (70). The question 
to what extent the Norwegian policy of isolation of patients – which resembles 
chemotherapy in terms of preventing transmission – contributed to the decline is also 
Figure 1.1 Example of a SIMLEP model describing the natural history of leprosy infection and disease.
Newborns are susceptible. Susceptibles can become infected due to transmission. New infections either self-
heal, or incubate to one of two forms of leprosy disease: infectious disease which does not self-heal
(‘multibacillary disease’), or non-contagious self-healing disease (‘paucibacillary disease’). Everyone can die.
The arrows represent birth, death and state changes, and the dashed arrow represents transmission. 
susceptible
infected - incubating
PB:
paucibacillary disease
MB:
multibacillary diseaseself-healed
death
birth
transmission
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investigated. Socio-economic improvement is considered as alternative explanation: the 
decline coincided with continuous growth of the Norwegian economy (70). In SIMLEP, 
strategies of BCG vaccination and chemotherapy-based control – nowadays the only 
interventions that are implemented at a large scale – can be specified in detail, and can be 
varied over time. Using the results of the Norway study, the impact of these strategies can 
be assessed with more scrutiny, and scenario predictions for the future of leprosy can be 
made.  
1.5 Research questions and outline of the thesis 
This thesis aims to investigate the impact of present day control activities on the 
transmission and incidence of leprosy, and on the occurrence of leprosy induced 
impairment. The specific research questions are: 
1. What were the trends in leprosy case detection rates in recent decades?  
2. Can these trends be explained, and do they provide evidence for an impact of leprosy 
control on transmission?  
3. To what extent have isolation of patients and socio-economic improvement 
contributed to the disappearance of leprosy from Norway? 
4. Which uncertain aspects of leprosy epidemiology contribute most to the uncertainty 
about the impact of leprosy control on transmission? 
5. What is the impact of present day control – case detection and chemotherapy, BCG 
vaccination – on the transmission of leprosy? 
6. What is the relationship between the delay in case detection and the impairment status 
of patients at the time of detection, and how does the impairment status change 
during treatment and after release from treatment? 
Chapter 2 systematically reviews published time trends in case detection in leprosy 
endemic areas and countries from different continents (question 1). The variation in 
trends within individual areas is investigated using information on leprosy control 
activities. Special attention is given to the question whether the introduction of MDT has 
led to changes in case detection trends, and to possible implications for transmission 
(question 2). On the basis of combined information from various data sources, Chapter 3 
presents trends in case detection and case detection rate (CDR) since 1985 for 14 
important endemic countries which together dominate the global case detection figures 
(question 1); explanation of the trends is problematic due to lack of information on 
control activities.  
Chapter 4 gives a detailed description of the epidemiological transmission modelling 
framework SIMLEP that we developed to address the questions 3-5. The full set of 
mathematical equations describing SIMLEP is given in an appendix to Chapter 4.  
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In Chapter 5, SIMLEP is used to analyse the disappearance of leprosy from Norway 
between 1850 and 1920. Estimates and uncertainty limits for the contributions of the 
Norwegian policy of isolation of patients versus socio-economic improvement are 
derived (question 3). The aspects of leprosy epidemiology which are responsible for the 
uncertainty limits are identified (question 4).  
Chapter 6 presents a scenario analysis of trends in the transmission and incidence of 
leprosy. Uncertain aspects of leprosy epidemiology and BCG vaccination are accounted 
for. The scenarios assume that dapsone monotherapy is replaced by MDT in 1990. For 
each scenario, SIMLEP is first fitted to the historical trend in average case detection rate 
for major endemic countries, and incidence rates are projected up to 2020. Subsequently, 
the annual decline in the projected incidence rate over 2000-2020, which reflects the 
decline in transmission, is calculated (question 5).  
The relationship between the delay in case detection and the impairment status of patients 
at the start of treatment with chemotherapy (question 6, first part) is investigated in 
Chapter 7. This is done on the basis of intake data on new leprosy patients enrolled in a 
long-term prospective study in Ethiopia – the ALERT MDT Field Evaluation Studies, or 
AMFES – of the consequences of the use of MDT for the individual patient. Follow-up 
data from the same study are used in Chapter 8 to assess the impairment status of 
patients both at release from treatment, and two to four years later (question 6, second 
part).  
In the General Discussion (Chapter 9), concise answers are given to the six research 
questions, and the answers are discussed. In addition, the prospects for reducing the 
global prevalence of leprosy induced impairment are investigated on the basis of the 
results of the scenario analysis from Chapter 5 and of the studies on impairment caused 
by leprosy from Chapters 7 and 8. Finally, conclusions and recommendations are given. 
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2.1 Summary 
Background A systematic review of the trends in leprosy incidence is lacking. The question 
of whether leprosy transmission has declined, remains, therefore, unanswered. This study 
investigates trends in new case detection rates (NCDRs) in selected leprosy-endemic areas 
from different continents. 
Methods A literature search using specific inclusion criteria was performed. Average annual 
rates of change in NCDRs were obtained by exponential curve fitting. The variation in 
trends within individual areas was investigated using direct and indirect information on 
leprosy control activities. 
Results This review covers 16 areas in the Pacific, Asia, Africa and Latin America. For 10 
out of the 16 areas, the trend was seen to be declining consistently over the last 10 years 
or longer. Near stabilization or stabilization after decline was observed for two areas. For 
three areas, interpretation of recent NCDRs was difficult due to changes in control, but 
two of them showed a decline over the study period. A consistently increasing trend was 
observed over the last 20 years in the one remaining area. The observed downward trends 
could not be attributed to reduced control activities or changed diagnostic criteria. A 
general acceleration of downward trends in NCDR after the introduction of multidrug 
therapy (MDT) has not so far occurred. 
Conclusion Our main conclusion is that despite many differences between the studies and 
study areas, the review demonstrates a considerable tendency of downward NCDR 
trends. Lack of information and changing control conditions necessitate caution in 
interpreting NCDR trends in individual areas. A general impact of MDT on NCDR 
trends is so far not visible. The coming years will be crucial for MDT-based control to 
prove its ability to reduce leprosy incidence. 
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2.2 Introduction 
The prevalence of leprosy, as measured by number of cases registered for treatment, and 
the new case detection rate (NCDR) are the conventional indicators for monitoring 
trends in leprosy control and elimination programs. 
Dapsone was the only available drug for several decades. In dapsone-based programs, 
treatment duration was variable, often for 10 years or even lifelong. Registered prevalence 
would be cumulative figures affected by mortality and migration of patients. 
From the early 1980s onward, dapsone has gradually been replaced by the more effective 
multidrug therapy (MDT). Under MDT, the leprosy elimination goal has been formulated 
as a reduction in prevalence to a level below 1 per 10,000 population by the year 2000 (1). 
There will only be a direct relationship between registered prevalence and NCDRs when 
new cases are put on treatment and when the recommended MDT treatment duration 
does not change over time. Under this condition, trends in registered prevalence and in 
NCDRs will little differ during the MDT era. 
Trends in NCDRs reflect trends in incidence rates provided that no significant changes 
occur in case detection efforts, self reporting behavior, and diagnostic procedures and 
criteria. Incidence is here defined as the first appearance of clinically detectable signs 
which would lead to the diagnosis of “leprosy”. The NCDR does not depend on the 
duration of treatment. Therefore, the NCDR is a better indicator than registered 
prevalence for monitoring trends in transmission over extended time periods during 
which both dapsone- and MDT-based programs have been carried out. 
Crude worldwide data suggest that the number of newly detected cases has remained 
roughly constant for 10 years. It stood around 560,000 in 1994 (2). The present paper 
provides an overview of trends in NCDRs for different areas of the world, which were 
selected on the basis of peer-reviewed publications satisfying quality and completeness 
criteria. Other information, e.g. on changes in case detection efforts and on the 
impairment status of newly detected cases, is used in order to assess whether trends in 
NCDRs indeed reflect trends in incidence. The impact of the main interventions – early 
detection, chemotherapy treatment and BCG vaccination, which generally has been 
rationalized as a preventive measure against tuberculosis but which may be equally or 
more effective against leprosy (3) – on NCDR trends is discussed. This discussion 
includes the possible consequences of MDT introduction on incidence. 
2.3 Materials and methods 
The publications for this review were selected as follows. A literature search in Medline 
from 1986 onward was performed. A publication was selected as a candidate for the 
review when its abstract in Medline made reference to information on new case detection, 
incidence or the prevalence of leprosy. Candidate publications for which the denominator 
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of the NCDRs was well defined and for which newly detected cases were representative 
for the new case load in an area were included in the next selection step. Examples of 
rejections are publications on new cases which were by majority imported, or on new 
cases reporting to a hospital in an area where other case detection activities took place. 
Only publications which presented a series of at least 10 NCDRs over a period including 
1986 and covering at least 10 years of continuous case detection, or which contained 
references pertaining to the same study which present these series, were maintained in the 
last selection step. The only source used apart from scientific journals is the proceedings 
of the meeting on “Leprosy profiles with special attention to MDT implementation” 
(Tokyo: Sasakawa Memorial Health Foundation, 1991).  
In order to interpret the observed NCDRs and to assess whether their trends reflect 
trends in incidence, the selected journal publications and proceedings were scrutinized for 
information on (changes in) other epidemiological indicators and (changes in) operational 
aspects of control programs. Relevant information includes population size and density; 
the profile of newly detected cases (impairment and disability status, single lesion 
proportion, type index, smear positivity); mean age at detection and age-specific new case 
detection rates (both by year of detection and by year of birth); prevalence rates at the 
start and end of the study period; occurrence of relapses; diagnostic criteria and 
procedures; delay until detection; drug regimens used; organization of control and the 
continuity of control services over time (e.g., case detection methods, transition from a 
vertical to a horizontal control program, history of BCG vaccination) and, finally, 
evidence for socioeconomic development. 
Spearman’s rank correlation coefficients between calendar year and NCDR were 
calculated. Exponential curves were fitted to the NCDRs over the period covered by the 
time series. The explained proportion of the variation in the time series, the R2 coefficient 
for the fitted curves, was calculated. R2 is a measure of goodness of fit of the curve to the 
data. 
2.4 Results 
The journal publications and proceedings which were selected cover 16 areas, namely, 7 
Asian, 5 African and 3 Latin American areas and French Polynesia (Pacific islands). The 
number of cases detected, population size and NCDR study period are given in Table 2.1. 
The prevalence rate and NCDR at the start and at the end of the study period vary widely 
among the areas under review (Table 2.2). The study period exceeds 25 years for six areas. 
The NCDRs for all areas are plotted on a logarithmic scale (Figure 2.1). On visual 
inspection, a downward trend can be observed for most areas. In areas with monotonous 
declines, trends are (about) linear on a logarithmic scale. This supports the use of 
exponential curve fitting of the data (i.e. constant proportional annual changes in the 
NCDR). Curve fitting confirmed the decline of the NCDR for all areas except Brazil and 
Guyana, which show small increases in the NCDR (Tables 2.3 and 2.4). 
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The five areas with the smallest rates of decline, below 5%, are situated in Asia and the 
Pacific: French Polynesia, Wenshan Prefecture (China), the country Thailand, The 
Philippines and Visakhapatnam District, India. The declines for all other areas exceed 8%, 
with a maximal decline of 19% for the Uele Region in Zaire (Table 2.3). 
Table 2.1 Areas selected in a literature search for a trend analysis of new case detection rates. 
Area Study period 
New cases 
detected 
in 1988 
  Population 
  in millions 
  (1986-1990) 
Population density 
in persons per sq. km. 
(1986-1990) h 
      Pacific Islands  
French Polynesia 1946-1990 7a 0.2 61 
      Asia     
Wenshan Prefecture (China) 1958-1993 130b 2.8 83 
Weifang Prefecture (China) 1955-1993 30b 8.7 511 
Philippines 1955-1990 2,442 59    197 
Visakhapatnam District (India) 1977-1993 3,375 3.1 228i 
Bhutan 1982-1992 73 0.6 f 13 
Thailand (country) 1964-1990 2,200b 55    107 
Thailand (3 N. provinces) 1976-1990 –c –c –c 
      Africa     
Uele Region (Zaire) 1975-1988 213 1.7 –c 
Malawi 1977-1993 907 8.2 69 
Ethiopia (country) 1975-1988 4,700b 46    41 
Shoa Region (Ethiopia) 1975-1989 1,100b 11    129 
Rwanda 1977-1987 44d 6.6 251 
      Latin America     
Brazil 1950-1987 19,685d 143    17 
Guyana 1975-1987 60e 0.8g 4 
Mexico 1980-1989 284 78    40 
a Data aggregated into 3-year periods; newly detected cases in 1988-1990 = 21. 
b NCDR in 1988 x population size for 1986-1990. 
c Not available. 
d Newly detected cases in 1987. 
e NCDR in 1987 x estimated population size for 1990. 
f Official population size for 1990, 1.4 million, is probably inaccurate (4). 
g Estimated population size for 1990 as by The World Bank. World Development Report 1993. New York: 
Oxford University Press, 1993. 
h Areas for regions as by publication, for countries as by The Times Atlas of The World. London: Times Books, 
1995. 
i Population density for Andhra Pradesh State (Health Monitor. Pune, India: Foundation for Research in Health 
Systems, 1993) which encorporates Visakhapatnam District. 
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In concordance with the curve fitting results, all Spearman’s rank correlation coefficients 
are negative, except for Brazil and Guyana (Table 2.3). For the small average annual 
changes of the NCDR, natural fluctuations are expected to be an important source of 
variation in the data. It is, therefore, not surprising that Brazil, Guyana, and the areas with 
lower declines also have smaller Spearman’s rank correlation coefficients and R2 
coefficients. The relatively high coefficients of French Polynesia can be explained from
Table 2.2 New case detection rate (NCDR) and prevalence rate in the 16 areas at the beginning and at the end 
of the study period. 
 NDCR/1000/year Prevalence rate/1000 
Study period 
Area Years Length 
Start of 
period 
End of 
period 
Start of
period 
End of 
period 
      Pacific Islands    
French Polynesia 46-90 45    0.25    0.04     2.4    0.14 
      Asia             
Wenshan Prefecture (China) 58-93 36    0.71    0.04     1.4    0.12 
Weifang Prefecture (China) 55-93 39    0.29    0.0004     0.27    0.004 
Philippines 55-90 36    0.07    0.05     0.41    0.67 
Visakhapatnam District (India) 77-93 17    1.1    0.8     2.3    0.8 
Bhutan 82-92 11    0.19    0.07 
 
   4.2    0.24 
Thailand (country) 64-90 27    0.21    0.03     5    0.23 
Thailand (3 N. provinces) 76-90 15    0.16    0.06 
 
   2.5    0.14 
      Africa             
Uele Region (Zaire) 75-88 14    2.22    0.12       10.8    0.6 
Malawi 77-93 17    0.47    0.06     3.1 a    0.16 b 
Ethiopia (country) 75-88 14    0.33    0.10     2.6 c    – d 
Shoa Region (Ethiopia) 75-89 15    0.28    0.08     1.9    0.33 
Rwanda 77-87 11    0.012    0.007     0.26 e    0.17 
      Latin America             
Brazil 50-87 38    0.09    0.13     – d    1.8 f 
Guyana 75-87 13    0.08    0.07 
 
   0.9    0.2 
Mexico 80-89 10    0.009    0.003     0.23    0.2 
a Prevalence rate in 1980. 
b Prevalence rate in 1991. 
c Average prevalence rate for period 1976-1981. 
d Not available. 
e Prevalence rate in 1982. 
f Prevalence rate in 1989 (5). 
  
 
Figure 2.1 Trend in new case detection rate (NCDR) for 14 of the 16 areas covered by this review. Not given are
the three northeastern provinces of Thailand and Ethiopia, which show trends similar to Thailand and the Shoa
Region in Ethiopia. Rates from before 1955 were only available for French Polynesia and Brazil. The rates for
the period 1991-1993 for Weifang are smaller than 0.001 per 1000 per year. ▼ = introduction of treatment
regimens containing rifampin, usually MDT. 
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the aggregation of data into 3-year periods, which dampens much of the year-to-year 
variability. 
The individual areas are analyzed in more detail and related to available information on 
control programs and case detection methods. 
Pacific islands 
French Polynesia (6, 7). A new leprosy control program was implemented in French 
Polynesia by the end of the 1940s. The NCDR declined between 1946 and 1967 and 
remained roughly stable until 1987. Transmission induced by relapses of nearly half of the 
multibacillary (MB) patients after dapsone monotherapy might have contributed to the 
stabilization according to Cartel, et al. (6). The leprosy control program organizes active 
case finding among household contacts and passive case finding. MDT was introduced in 
Table 2.3 Analysis of new case detection rates: average annual decline of NCDR corresponding to exponential 
curve fit, Spearman’s rank correlation coefficient between calender year and NCDR and R2 coefficient of 
exponential curve fit. 
Area 
Average 
annual decline 
Rank 
correlation 
R2 
coefficient 
      Pacific Islands      
French Polynesia 3.5% -0.84  0.77 
      Asia    
Wenshan Prefecture (China) 4.9% -0.85  0.67 
Weifang Prefecture (China) 13.4% -0.99  0.93 
Philippines 2.0% -0.44  0.27 
Visakhapatnam District (India) 0.9% -0.26  0.05 
Bhutan 9.4% -0.95  0.91 
Thailand (country) 3.8% -0.60  0.36 
Thailand (3 N. provinces) 8.3% -0.67  0.49 
      Africa    
Uele Region (Zaire) 19.0% -0.91  0.77 
Malawi 11.2% -1.00  0.99 
Ethiopia (country) 9.7% -1.00  0.90 
Shoa Region (Ethiopia) 8.9% -0.93  0.90 
Rwanda 10.3% -0.91  0.65 
      Latin America   
Brazil -0.7%  0.26 0.08 
Guyana -2.5%  0.23 0.07 
Mexico 12.8%  -0.95 0.93 
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1982, resulting in intensified active case finding in household contacts and improved 
management and follow up of patients. The relapse rate with MDT so far was nil. The 
NCDR clearly decreased in the last 3-year period, 1988-1990.  
Asia 
Wenshan Prefecture (China) (8). Leprosy control was initiated in the late 1950s as part of the 
national program. In the first years, much effort was placed on case finding, possibly 
explaining the higher NCDRs of 1958 and 1959. A downward trend was observed over 
the period 1962-1993. The two upward peaks of the NCDR coincide with the 
establishment of a network of eight county skin disease control stations (1973) and the 
introduction of rifampin in combination with dapsone (1979). The beginning of MDT in 
1986 was followed by increased control activities, and no clear decline in the NCDR is 
visible since. 
Weifang Prefecture (China) (8, 9). A leprosy control program was initiated in 1955. A 
consistent decline in NCDRs is observed with some elevations coinciding with so-called 
clue surveys for Shandong Province to which Weifang belongs. These surveys were 
carried out in 1955-1958, 1965-1966, 1971-1972, 1975-1976 and 1983-1984. More 
intensified case finding took place in the 1980s. MDT was introduced in 1986. Only 10, 9, 
5, 4 and again 5 new cases were detected in the successive years between 1989 and 1993 
in a population of 8.7 million in 1992. These recent cases were mainly self reporting. 
The Philippines (10). Case finding methods were not explicitly described. Five-year NCDRs 
were available for 1955-1985, and also annual data for 1987 to 1990. Leprosy control 
activities were resumed from 1946 onward. Mobile skin clinics were established between 
1955 and 1959. Only a small decline of the NCDR was observed over the years 
1955-1975, followed by a more rapid decline over the decade 1975-1985. Transition from 
a vertical control system to an integrated health service approach took almost two 
decades, but was completed before the start of MDT in 1988. The NCDR has risen 
sharply during 1986-1989, i.e. just before and during MDT introduction. 
Visakhapatnam District (India) ((11) and Report on the workshop on impact of MDT on 
trend of leprosy. Madras: Indian Association of Leprologists, 1994). Data were presented 
from mid-year to mid-year; Figure 2.1 displays the year 1976-1977 as the calendar year 
1977. A significant downward trend is not observed. The early peak in NCDR in 1980 
Table 2.4 Declines in new case detection rates in the 16 study areas. 
Average annual decline No. areas 
< 0% 2 
0% – 5% 5 
8% – 20% 9 
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remains unexplained. Both the proportion voluntary reporting cases among total new 
cases and the NCDR for actively detected cases among the examined population (annual 
decline 4.5%) showed important fluctuations. General population surveys are the most 
important component of active case finding. It is also carried out through contact surveys 
and school surveys. MDT was introduced in 1984-1985. 
Bhutan (4). A vertical program had already been operational for some years before the 
establishment of the National Leprosy Control Programme in 1981. MDT was introduced 
in 1982 and data were presented from 1982 onward. The population of Bhutan had a 
natural growth rate during the study period, but there was also large scale emigration. The 
NCDRs were, therefore, based on the same population size for all years. Contact and 
group surveys continued throughout. Mass surveys were held on a regular basis until 1988 
and were subsequently gradually replaced by focal surveys in areas of previously known 
high prevalence. The proportion self reporting, the proportion with disability, and the 
proportion with high smear positivity among newly detected cases increased during the 
study period (4). Interpretation of the quite regular downward trend in NCDR is, 
therefore, in our opinion not straightforward. The MDT coverage was below 10% in 
1982 and above 80% from 1988 onward, with a coverage of 89% by the end of 1992. 
Thailand (12, 13). A specialized program was established in Thailand in 1955, and revision 
to an integrated program started in 1970. A sharp decline in the NCDR was observed in 
1971. The integration was completed in 1977, covering 67 of the 73 provinces of 
Thailand. The NCDR increased from 1972 onward, peaked in 1981, and declined ever 
since, with an average annual decline of 10.0% for the period 1979-1990 as compared to 
3.8% for the study period as a whole. During the years 1984-1990, MDT gradually 
replaced dapsone monotherapy. Household contact surveillance, rapid village surveys 
(mobile clinics), school surveys, and skin clinic services have been practiced regularly 
throughout, although the degree of intensity of some of these methods varied over time. 
The three highly endemic northeastern provinces for which the specialized program 
approach was maintained have a similar trend as Thailand as a whole (13). 
Africa 
Uele Region (Zaire) (14, 15). The leprosy control system was interrupted from 1964 to 1974 
and was gradually reorganized afterward. Case finding is passive; the control program 
includes up to 20 mobile teams that contact patients monthly. The NCDR fell sharply in 
the initial years after 1974, which might be due to a reduction of false-positives in case 
ascertainment (14). An initial backlog in case detection cannot be excluded. For the 
period 1980-1988, exponential curve fitting gives an average annual decline of 5% as 
compared to 19% for the study period as a whole. Combined treatment regimens, 
containing rifampin, have been administered from 1981 onward. Leprosy control 
activities have been progressively integrated into a structure of primary health care 
introduced in 1983. 
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Malawi (16-18). Methods of leprosy control work during 1973-1983 have been described 
by Boerrigter and Ponnighaus (16). A mobile service organized patient treatment and 
passive case finding through periodic leprosy clinics. School surveys covered most pupils 
at least once during 1974-1983. A review of patients on treatment along with the 
introduction of MDT in 1983-1984 caused a great reduction in the prevalence rate. As a 
consequence, the number of staff – and self reporting opportunities according to 
Boerrigter and Ponnighaus (17) – were reduced. Otherwise, detection activities have 
remained comparable throughout 1973-1993 (17, 18). The decline of the NCDR is 
strikingly regular over the entire study period. 
Shoa Region (Ethiopia) (19). Case detection was almost exclusively passive. Leprosy clinics 
were either run in general health services or, if nonexistent, in other settings. The 
observed average decline for the study period as a whole is largely caused by a drop in the 
NCDR over the period 1980-1985. MDT was introduced in 1983. The pattern for 
Ethiopia as a whole (20) is similar to that of Shoa Region, but the paper presents less 
information on control. 
Rwanda (21). A nongovernmental organization organized leprosy control in cooperation 
with the authorities from 1964 to 1984. MDT was introduced in 1982. Exponential curve 
fitting up to 1984 gives an average annual decline of 5.3% as compared to 10.3% for the 
study period as a whole. The overall average annual decline can, hence, for an important 
part be attributed to the dip in the years 1985-1986. With respect to this dip, Stes and 
Malatre stated (21): “The steep dip during 1985-6, the years of transition, may be due to 
diminished control activities while the Service National de Lutte Contra la Lèpre was 
being set up. The 1987 rise could then be seen as a ‘catching-up’ manoeuvre of previously 
undetected cases, and is probably a good sign”. This implies that the overall average 
annual decline should be interpreted with caution. The National Service particularly 
insists on the integration of leprosy control with primary health care. Case detection in 
Rwanda is based on voluntary reporting at dispensaries or health services on visits of 
mobile units. Information campaigns are organized and new patients are invited to bring 
their children and household contacts for examination. 
Latin America 
Brazil (5, 22). Significant upward or downward trends in NCDRs for the period 1950-
1987 were not observed. During 1950-1968, when data registration was poor, policy 
guidelines were not clear, and personnel training and motivation were deficient, the 
NCDR declined by 3% per year (22). Integration of leprosy control activities into primary 
health care was started by the end of the 1960s. From 1969 to 1987, control programs 
were improved by the implementation of technical guidelines, decentralization of case 
finding and case holding and better logistic facilities. The NCDR increased by 6% per 
year during the period 1969-1987 (R2 = 0.92, Spearman’s rank correlation = 0.96). 
Region-wise analysis revealed that the observed increase affected the entire country (22). 
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A combination of dapsone and rifampin was given to all MB cases from 1976 onward; 
gradual implementation of MDT for all new cases started in 1986. 
Guyana (23). Case finding methods are not described explicitly. The present Guyana 
Leprosy Control Programme began in 1971. Multibacillary patients received dapsone, 
clofazimine and rifampin together from 1978 onward. The NCDR increased in the late 
1970s following program expansion on receipt of external budgetary support. It peaked 
directly after the introduction of MDT in December 1981 and declined afterward. The 
low NCDRs of the early years and the subsequent increase cause the average annual 
increase of the NCDR. 
Mexico (24). Case finding methods have not been described explicitly. The vertical 
National Leprosy Control Program was started in 1960, and was incorporated into the 
state health services in 1981. At that time, treatment started to include rifampin and 
clofazimine in several different combinations. The organization of operations was, in this 
phase, somewhat irregular. In 1989, the program had a national office with several 
functions, including supervision. A comprehensive program for leprosy control is carried 
out in the zone with the highest prevalence. The Mexican NCDR showed a quite regular 
fall during the study period (1980-1989). A plan for the implementation of MDT was 
developed in 1989 by the National Leprosy Control Office. 
2.5 Discussion 
Overall pattern 
The data from all three continents and the Pacific Islands show a downward trend in the 
NCDR for most areas considered. The magnitude of the decline does not seem to depend 
on the population size, population density or leprosy endemicity level - the latter 
apparently also being independent of population size and population density - of the area 
(Tables 2.1, 2.2 and 2.3). 
Marked differences can be observed in rate of decline between areas and also within areas 
over the study period. For most areas, including all African areas, this rate exceeds 8%. 
The rate of decline is below 5% in 4 out of the 5 areas in Asia and the Pacific Islands with 
study periods longer than 25 years (Tables 2.2 and 2.3). Clearly, it was difficult to achieve 
a sustained decline over long time periods in these areas. Publication bias can also not be 
excluded in the sense that time series over longer periods are more prone to be published, 
whereas short-term trends might only be published in case of success, i.e., clearly 
declining trends. 
Passive and active case detection 
NCDR decline did not depend on case detection methods, but it was more variable in 
areas were case detection involved active components (e.g. household contact surveys, 
school surveys and general population surveys). Active case finding was often used in 
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Asia and the Pacific Islands. Passive case finding was generally most important in the 
African areas. 
Departures from overall trend 
In some areas, like Uele Region (Zaire) and Wenshan Prefecture (China), sharp initial 
declines in the NCDR were observed. This might be an artifact caused by detection of 
many “old” prevalent cases during the first years of leprosy control programs. Only later, 
newly detected cases will be mostly cases having contracted leprosy recently. If the first 
years are disregarded, most areas show declines that continue over the full study period or 
at least over the last decade. 
A less favorable picture emerges in three areas where the NCDR remained constant 
during long periods (French Polynesia, Wenshan Prefecture, Visakhapatnam District) and 
in two areas with no evidence of a consistent trend during the study period (The 
Philippines and Guyana). Relapses in French Polynesia were already mentioned. In 
Wenshan, control activities were increased after the implementation of MDT. A steady 
pattern over the study period is observed in Visakhapatnam. In Guyana, the NCDR 
increased following program expansion on receipt of external budget support, and peaked 
directly after the introduction of MDT. Intensified case finding must have caused the 
exceptional rise in NCDR just before and during MDT introduction in The Philippines. 
Clear peaks in new case detection at MDT introduction also have also been reported 
from, e.g., Madagascar (2). For Visakhapatnam, the absence of a clear peak in the NCDR 
at MDT introduction can be explained by a phased introduction of MDT. 
A distinctly different picture is observed in Brazil: its NCDR increased throughout the 
entire country during 1969-1987. Considering the clear increase in trends in Brazil and its 
individual regions and because a lower rate of NCDR increase was observed for 
lepromatous plus borderline cases than for tuberculoid cases, Motta and Zuniga suggest 
that the increase in NCDR is not only the consequence of improved awareness by health 
units, but also reflects a real increase in incidence (22). The Brazilian Coordinator for 
Sanitary and Dermatology comments that the main operational changes that influence the 
data did happen after 1986, and supports the suggestion that epidemiological factors 
contribute to the increase in the NCDR in Brazil up to 1987 (Maria Leida de Oliveira, 
personal communication). We are not aware of consistently increasing trends in the 
NCDR in other areas. 
Operational factors and declining trends 
Operational factors might have been responsible for declines in the NCDR. Reductions 
in case detection efforts are of particular concern. Reductions have not been reported 
explicitly, although detection methods changed in Bhutan (replacement of mass surveys 
by focal surveys). Integration of leprosy control activities into the general health services 
might also lead to a reduction in case detection efforts. The NCDR was already falling at 
the time of integration in the Uele Region and in Rwanda. The transition period toward 
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integration (1970-1977) coincides with reduced NCDRs in Thailand: the reduction was, 
however, temporary. Reductions in health personnel in the leprosy program did not 
coincide with the sharp declines in NCDR in Malawi (17). 
An increase of impairments and disabilities in an existing control program deserves 
attention since it might suggest late diagnosis and, hence, reduced control activities. 
Information on this aspect was incomplete. A definite (but slight) increase in the 
impairment and disability status of new patients in areas with persistingly declining trends 
was only seen in Bhutan. The proportion with a high smear positivity among newly 
detected cases in Bhutan also increased (4). Insufficient information prohibited an 
analysis of the proportion single lesion cases among newly detected cases, which is an 
indicator for the share of active case detection efforts. 
Indicator for declining incidence: increasing age at detection 
In Thailand, the mean age at detection increased by nearly 7 years over the last 15 years of 
the study period while new case detection decreased. Age shifts under declining 
endemicity were observed in Nigeria, Japan, Venezuela (25), Portugal (26), Norway (27) 
and Shandong province in China (9). The age shift occurred under varying levels of 
NCDR and could already be discerned after 10 years of declining incidence in, e.g., 
Nigeria and Japan. The age shifts in Thailand, Norway and Shandong province were of 
the same order. 
Study of trends in age-specific detection rates is more informative. In Thailand, detection 
rates declined in all age groups between 1976-1980 and 1986-1990. The highest detection 
rates were observed for age groups older than 35 throughout 1976-1990. During this 
period, the maximum case detection level first occurred in the age group 45-54 and, in 
later years, in the age group 55-64. Declining rates for onset of disease for all age groups 
together with an increasing relative risk for the oldest as compared to the youngest age 
group were, over time, observed in Portugal (26), Norway (27) and Shandong Province 
(9). Interestingly, increases in age at onset were not observed over time for these three 
areas when rates were analyzed by year of birth. Details by year of birth were not available 
for Thailand. 
A shift to detection at older ages combined with increased disability might point to longer 
delays in detection. However, in Thailand the proportion of patients with impairments 
and disability did not show a clear increase. This suggests that the age shift in detection is 
not the consequence of longer delays in detection alone and, thus, reflects a real age shift 
in incidence. For the other areas with persistently declining trends, information on the age 
at detection was either not available, or of limited usefulness because of only a short time-
period or small numbers involved, or not representative because of increasing 
proportions of children being examined. 
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Type index among new cases 
The type index (proportion lepromatous or MB among newly detected cases) has been 
advocated as an indicator for changing trends in leprosy incidence [Report on the group 
discussions on the needs and prospects for epidemiological tools in leprosy control. 
WHO workshop on epidemiology of leprosy in relation to control. Lepr Rev 1992; 63 
(Suppl): 114s-122s.]. This index is, however, sensitive for classification criteria and case 
detection efforts. Reduced case detection efforts can lead to an increase in the type index 
because of both self cure and downgrading of tuberculoid (or paucibacillary) cases. An 
increasing type index during intensification of control has also been observed (Wenshan 
Prefecture after MDT implementation). In addition, long term declines of leprosy have 
been observed together with both an increasing and a decreasing type index (25, 26). In 
the present review, the behavior of the type index among newly detected cases also 
showed much variation, which could not easily be explained. 
Variation between studies 
The reviewed studies differ in many aspects. Examples are: terminology used, level of 
detail of available information, length of study periods, leprosy endemicity levels and 
applied case detection methods, and control strategies over time. NCDRs from the 
studies were, therefore, analyzed separately with respect to control conditions and 
underlying trends. One should be careful in directly comparing the trend statistics 
(Table 2.3) of the areas. 
Do trends in the NCDR reflect trends in underlying incidence? 
According to the 1988 WHO Expert Committee definition, a case of leprosy is defined as 
a person showing clinical signs of leprosy, with or without bacteriological confirmation of 
the diagnosis, and requiring chemotherapy (28). Clinical diagnosis is commonly based on 
the three cardinal signs of leprosy: anesthetic skin lesion(s), enlarged peripheral nerve(s) 
and the presence of Mycobacterium leprae in slit-skin smears or in nasal mucus scrapings 
(29). Diagnosis is not always straightforward. The establishment of loss of sensation in 
skin lesions can, for example, be difficult. Changes in diagnostic criteria and procedures, 
in the quality of these procedures, and in case detection efforts (including alertness for 
leprosy) affect NCDRs. Larger proportions of new cases with very early leprosy having 
single lesions, with questionable diagnostic specificity and a tendency toward self-healing, 
can be expected in the case of active case detection when surveys are undertaken at 
shorter intervals (30). Changes in certain administrative and managerial decisions, such as 
targets for case detection and incentives for MDT activities, are also expected to influence 
NCDRs (11). The above considerations indicate that trends in NCDRs not necessarily 
reflect trends in underlying incidence. Although evidence was hardly available in the 
reviewed papers, changes that might prohibit extrapolation of trends in NCDRs to trends 
in incidence cannot be excluded. Information on the occurrence of relapses and possible 
inclusion of relapses in NCDRs is also sparse in the reviewed papers.  
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Selection of papers 
A possible publication bias in the sense of a tendency to publish on high-quality control 
programs covering long periods of time or indicating successful leprosy control was 
already mentioned, and cannot be excluded in a review of this type. 
The inclusion criteria aimed at selecting papers which report on data that have been 
collected regularly over time in specific areas. Less refined data are available for large 
geographical regions and although they should be interpreted cautiously, they are 
definitely important (2). Between 1993 and 1994, new case detection rates for WHO 
Regions as a whole decreased by 4.5% and 7.8% for, respectively, the Americas and 
South-East Asia, and increased by 20.8%, 25.9% and 3.3% for, respectively, Africa, the 
Eastern Mediterranean and the Western Pacific. A reduced NCDR in India explains much 
of the South-East Asian decrease. Considerable improvement in case detection as a 
consequence of setting the leprosy elimination target is reported for the African and 
Eastern Mediterranean Regions. Worldwide leprosy detection has remained about 
constant over the period 1985-1995 (2). 
Interaction with tuberculosis 
Exposure to other mycobacteria and the risk for leprosy are probably associated. It has, in 
particular, been argued that M. tuberculosis protects against M. leprae (31). In the Leprosy 
Prevention Trial (Tamil Nadu, India), however, tuberculin positivity only had very limited 
influence on susceptibility for leprosy (M. D. Gupte, unpublished data from LPT). A 
study of a possible correlation between trends in leprosy and tuberculosis calls for a 
thorough analysis of the appropriate additional information on tuberculosis incidence - 
tuberculin surveys might be more informative than tuberculosis NCDRs - and on the 
continuity of data collection activities and tuberculosis control activities. 
Role of socioeconomic development 
It is generally believed that leprosy incidence declines with improving socioeconomic 
standards (32). The NCDR was already below 1:100,000 in 1985 in Weifang and a further 
decline in Weifang was steep in the period 1985-1993 while there was no clear decline in 
Wenshan. During the same period, the economic development is said to have been 
somewhat slow in Wenshan, whereas Weifang experienced rapid growth (8). The gross 
prefectural product per capita showed a highly significant negative correlation with both 
the prevalence rate and the NCDR over the period 1985-1991 in both Weifang and 
Wenshan Prefecture. The correlation of these rates with average annual income over this 
period is also negative for Weifang, but positive for Wenshan. The latter finding is “... 
likely due to the increased control activities in Wenshan since the implementation of 
MDT in 1986 ...” (8). Examples of declines in the incidence rate coinciding with rapid 
socioeconomic development from the literature are: Japan (excluding Okinawa), Okinawa 
itself (although later) and Taiwan (33). Okinawa Prefecture had the slowest rate of 
economic development in Japan (34). 
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Role of BCG vaccination 
BCG vaccination has been shown to provide protection against leprosy. Protective 
efficacies from 20% to 80% have been reported (3). Hence, BCG is expected to prevent 
new leprosy infections and, subsequently, new sources of infection. BCG vaccination was 
mentioned for 8 out of the 16 areas in this analysis. Details on vaccination programs are, 
however, not given and assessment of their impact is therefore not possible. Referring to 
detection being generally low in children and high in adults, with low detection in 
indeterminate leprosy, BCG is argued to have played some role in leprosy morbidity 
reduction in Weifang Prefecture (8). This might, however, be questioned because the 
proportion of ages 0-14 among new cases had been declining in the successive 5-year 
periods between 1955-1959 and 1975-1979 in Shandong province (incorporating Weifang 
Prefecture) (9); whereas Shandong initiated BCG vaccination only in the 1970s. 
Role of chemotherapy 
Chemotherapy is thought to have played a role of its own in several areas. Becx-Bleumink 
identifies dapsone monotherapy as the most probable reason for the decline in Ethiopia 
(19). The motivation is that BCG coverage of newborns was less than 25% in the 1980s 
and probably not higher in the 1970s and earlier; whereas, in addition, improvement in 
the socioeconomic conditions of the rural Ethiopian population during the last decades 
would at most have been very marginal. A second example is the possible role of 
chemotherapy control in the initial decline of the NCDR (1946-1966) in French Polynesia 
where economic development really only started after 1962, and where systematic BCG 
vaccination was introduced by the mid-1960s (6). 
The impact of chemotherapy is generally difficult to assess because socioeconomic 
development, BCG vaccination, and control through chemotherapy often go hand in 
hand. MDT is at present, however, regarded as the mainstay for leprosy control by WHO 
(1). The rationale for this WHO policy is clear. Early diagnosis and effective treatment do 
not only cure individual patients, but may significantly reduce leprosy transmission. This 
requires a drug regimen that is easily accepted by leprosy patients, such as MDT, which 
became available in the 1980s. The advantages of MDT include the absence of treatment 
failures due to drug resistance, very low relapse rates following completion of treatment, 
fixed and relatively short duration of treatment, and very low frequency of side-effects (1). 
MDT improves patient compliance, encourages early self reporting, motivates health 
workers, and can induce a considerable upgrading of leprosy control activities (35).  
Dapsone monotherapy renders patients noninfectious within a reasonable short period of 
time but lacks the favorable indirect effects of MDT. An acceleration of declining trends 
in NCDRs after MDT introduction might, therefore, largely be attributed to these indirect 
effects of MDT. The combined use of its main bactericidal drug, rifampin, with other 
drugs preceded the introduction of MDT in some areas. Accelerations of declining trends 
after the introduction of these combined regimens or MDT can be observed only in the 
country of Thailand and in Weifang Prefecture, where case finding intensified in the 
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1980s and where the NCDR was already very low at MDT introduction in 1986 (Figure 
2.1). In French Polynesia, where the NCDR had stabilized, the NCDR dropped in the last 
3-year period, 5 years after MDT introduction. 
Skepticism on the possible impact of chemotherapy exists, and the literature provides 
some examples. A stabilization of NCDRs which could not be attributed to operational 
factors was observed in the dapsone-based programs of two Leprosy Control Units of the 
Gandhi Memorial Leprosy Foundation (Sevagram, T. Narsipur) (In retrospect & 
prospect. Wardha: Gandhi Memorial Leprosy Foundation, 1974). A controlled attempt to 
assess the impact of drug therapy (rifampin) on incidence failed to show any effect after 5 
years in Myanmar (31). Another finding relates to tuberculosis: similar declines in 
tuberculosis prevalence were reported from a special intervention (with chemotherapy) 
area and the “control” area were no special treatment facilities had been introduced (36). 
Various explanations can be given for the absence of accelerations under MDT. The 
incubation period of leprosy is not well known but usually believed to be several years, 
implying that it might still be too early to see pronounced accelerations. Reductions in 
transmission might also be masked by increased case detection efforts as part of MDT 
implementation policies (e.g. The Philippines). It is also possible that not yet detected 
cases are responsible for transmission. This might imply that detection is too late to 
reduce transmission much, possibly even to the extent of prohibiting an impact of leprosy 
chemotherapy on transmission. A related observation is an average period between the 
patient’s first observation of signs of leprosy and diagnosis of 2.3 years in Ethiopia (July 
1987 - July 1989) (19). The delay until detection in Wenshan Prefecture was between 2 
and 5 years for 24% and longer than 5 years for 8.2% of newly detected cases (period 
1986-1993) (8). 
WHO is also studying the relationship between incidence and new case detection (2). 
Preliminary results of collaborative studies indicate that the majority of cases are detected 
late, even in programs that have used MDT for many years: “... in the majority of 
countries, only a small proportion of newly detected cases (10%) are true incident cases; 
about 75% of newly detected cases started 3-5 years earlier and about 15% are detected 5 
to 10 years after the onset of the disease.” The gap between the estimated number of 
cases and those actually registered for treatment is said to be very large in some countries 
(Bangladesh, Indonesia, Viet Nam, Mali, Niger and Sudan). Big gaps between estimated 
and registered prevalence were also noticed in places in India, where sample surveys were 
undertaken or where intensive case detection campaigns were carried out even after 4 
years of MDT implementation. A study in six subcenters, however, revealed a large 
proportion of cases detected during surveys to be cases of “early leprosy” (11). 
Several other mechanisms for transmission have been mentioned. These include 
subclinically infected persons (37), carriers of M. leprae in the nose within endemic 
populations (37-40) and animal reservoirs and the presence of M. leprae in the soil (41). It 
has been hypothesized that everyone in an endemic population will harbor M. leprae at 
some time, and that clinical leprosy arises from a pool of subclinical infection and not by 
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transmission from an individual index case (42). If some of these factors indeed play a 
role in transmission, then early detection and chemotherapy treatment of cases might very 
well be insufficient to have a major impact on leprosy trends. The importance of these 
factors is, however, not clear and, at present, cannot be established for want of 
appropriate investigation tools. 
Conclusion 
Our main conclusion is that despite many differences between the studies and study areas, 
the review demonstrates a considerable tendency of downward NCDR trends. Lack of 
information and changing control conditions necessitate caution in interpreting NCDR 
trends in individual areas. A general impact of MDT on NCDR trends is so far not 
visible. The coming years will be crucial for MDT-based control to prove its ability to 
reduce leprosy incidence. 
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3.1 Summary 
Trends in case detection and case detection rate (CDR) since 1985 are described at 
regional and national levels. Annual case detection by WHO Region was available for 
1994-2000. Using different sources, complete time series for case detection were 
constructed for 1985-1998 for a group of 33 endemic countries cumulatively (top 33), and 
for 14 individual countries (top 14). Population statistics were used to derive CDRs. India 
contributed 79% to global case detection in 1998. Africa, the Americas and South-East 
Asia each contributed about 30% when India is excluded. During 1994-2000, case 
detection did not decrease in these three WHO Regions. The 33 countries contributed 
99% and 98% to global case detection in 1994 and 1998, respectively. Cumulative case 
detection for the top 33 minus India gradually increased, overall almost doubling. The 
contribution of the top 14 to case detection of the top 33 hardly changed over time, 
equalling 96% in 1998 (81% when India is excluded). In terms of annual case detection, 
Brazil was always ranked second after India; it accounted for 27% of 1998 case detection 
in the top 33 except India. In 1998, seven of the top 14 countries – including India and 
Brazil – had CDRs above 2 per 10,000. The CDR did not exceed 1 per 10,000 for the 
other half. Decreasing tendencies in CDR, either for the whole period or in the 1990s, are 
observed for four of the top 14 countries (Guinea and three Western Pacific countries: 
China, Vietnam and the Philippines). In conclusion, there is no general decline in case 
detection to date, and several important countries still have high CDRs. Prevalence is an 
irrelevant indicator for monitoring epidemiological changes in leprosy. Trends in the 
transmission and incidence of leprosy are still completely unclear, necessitating further 
research. The target to eliminate leprosy as a public health problem, defined as a 
prevalence of less than 1 per 10,000, is therefore also an inadequate yardstick for decision 
making on leprosy control.  
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3.2 Introduction 
The annual number of leprosy cases detected globally each year has not declined since 
1985 (1, 2). Yet, in May 2001, it was announced that leprosy was ‘eliminated as a public 
health problem’ at a global level. The 44th World Health Assembly (WHA) in 1991 
defined the elimination target as a prevalence of less than one patient per 10,000 
population (3). At a national level, the World Health Organization (WHO) schedules the 
elimination target to be reached in all countries by the end of 2005 (4). The discrepancy 
between the trend in global case detection and proclaimed and expected elimination at 
global and national levels requires further explanation. 
The target indicator for elimination – prevalence per 10,000 population – is not univocal. 
Reported prevalence refers to numbers of patients in leprosy registers, and is sensitive for 
the treatment duration. This follows directly from the simple formula ‘number on 
treatment = case detection × average treatment duration’. The treatment duration became 
much shorter with the gradual replacement of dapsone monotherapy by multidrug 
therapy (MDT). In addition, there was no consistency in register keeping: following the 
introduction of MDT, many (ex-)patients not in need of treatment, but possibly with 
complications or disabilities due to leprosy, were removed from existing registers (5, 6). In 
fact, the 1991 WHA resolution did not state the exact meaning of prevalence; the 
definition of the seventh WHO Expert Committee on Leprosy only includes patients 
registered for chemotherapy (7). In any case, the reported prevalence figure fell 
dramatically, from over five million in 1985 to 750,000 in the year 2000, due to the 
shortening of the treatment duration and the change in register keeping. The achievement 
of the elimination target is based almost solely on these two factors, because global case 
detection did not decrease.  
Leprosy control has achieved a great deal since the introduction of MDT, mainly because 
millions of patients have been bacteriologically cured. However, WHO’s strict emphasis 
on the elimination target (as defined above) has been criticized (6). Successful leprosy 
control should bring about reductions in transmission and incidence (i.e. onset of 
disease), leading to true reductions in case detection. Previously, we conducted a literature 
review of published trends in leprosy case detection rates (CDRs) up to 1993 (8). In this 
review, the CDR was declining in most areas/countries, as opposed to the global trend 
since 1985. We could not demonstrate that the observed declines were due to leprosy 
control, and pointed out the possibility of publication bias in the sense of a tendency to 
publish on high-quality programs covering long periods of time or indicating successful 
control. 
Since the review, additional information has become available which allows for the 
construction of a time series of case detection at various levels of geographical 
aggregation. This information includes case detection data at country level from 1985 
onwards for 14 countries which together account for 94% of global case detection in 
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1998. This paper gives a description of trends in case detection and CDR since 1985. By 
doing so, we aim to improve the understanding of the global leprosy trend and the 
present day situation at regional and national levels, looking beyond the currently defined 
target to eliminate leprosy as a public health problem as the sole yardstick of success of 
leprosy control. 
3.3 Material and methods 
Data on case detection in five WHO Regions during 1994-2000 (Africa, Americas, 
Eastern Mediterranean, South-East Asia and Western Pacific) are taken from a 2002 issue 
of Weekly Epidemiological Record (2). The number of cases detected annually in the sixth 
WHO Region, Europe, is negligible compared to case detection in these five regions (in 
1998, less than 100 new cases were reported in Europe (9)). Therefore, ‘global’ case 
detection during 1994-2000 is calculated by summing the case detection figures for the 
first five WHO Regions. 
Cumulative data on case detection for the ‘top 32 endemic countries’ during 1985-1998 
are taken from two issues of Weekly Epidemiological Record (1, 10). The first issue reported 
that these countries provided consistent information over the last 13 years, and that they 
represented ‘93% of the current global leprosy burden and 85% of that of 1985’ (10). The 
exact meaning of this phrasing is unclear. Due to insufficient data, we could not extend 
the time series of cumulative case detection for the top 32 to the years 1999 and 2000. We 
extended the top 32 to a ‘top 33’ by adding case detection data for China for 1985-1998 
(see below). In alphabetical order, the 32 countries are Bangladesh, Benin, Brazil, Burkina 
Faso, Cambodia, Chad, Colombia, Congo, Democratic Republic of the Congo, Côte 
d’Ivoire, Egypt, Ethiopia, Guinea, India, Indonesia, Madagascar, Mali, Mexico, 
Mozambique, Myanmar, Nepal, Niger, Nigeria, Pakistan, Philippines, Senegal, Sudan, 
Thailand, Venezuela, Viet Nam, Yemen and Zambia.  
For 13 countries of the top 32 and China, complete case detection time series could be 
constructed for the period 1985-1998 using two sources of information. The first is a 
document prepared for the International Conference on the Elimination of Leprosy that 
was held in New Delhi, India in October 1996 (11). This report provides annual case 
detection figures for 1985-1995 for a large number of leprosy endemic countries. To 
extend the time series, the data are supplemented with national figures on case detection 
for the years 1996-1998 as reported by countries to WHO. WHO has provided these 
figures in subsequent issues of Weekly Epidemiological Record (1, 9, 12, 13). Using an 
additional issue (14), the resulting time series could be extended with case detection data 
for the years 1999 and 2000 for the majority of these 14 countries (top 14). For other 
countries, we briefly summarize information on 1998 case detection (9). In alphabetical 
order, the 14 countries are Bangladesh, Brazil, China, Ethiopia, Guinea, India, Indonesia, 
Madagascar, Mozambique, Myanmar, Nepal, Philippines, Sudan and Vietnam. 
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Time series of mid-year population sizes of individual countries required to calculate 
CDRs are obtained from the World Bank’s 2002 World Development Indicators CD 
ROM (15). Time series for the mid-year size of the world population for the years 1994-
2000 are based on data from the U.S. Bureau of the Census (16).  
The appendix to this paper provides the full time series of case detection and CDR of 
individual countries, combinations of countries, WHO Regions and the world that are the 
subject of this paper. 
3.4 Results 
WHO Regions 
Table 3.1 and Figure 3.1 give details on global case detection with distribution by WHO 
Region for the period 1994-2000. Just over 800,000 cases were detected globally in 1998, 
with South-East Asia accounting for 86% of the new caseload. India alone contributed 
almost 80% (Table 3.2), and Africa, the Americas and South-East Asia minus India each 
about 30% when the Indian figures are excluded. The contributions to case detection in 
1994-2000 as a whole are of the same order as for the year 1998. Decreasing tendencies in 
case detection are not observed in Africa, the Americas and South-East Asia. Case 
detection decreased in the last 3 years in the Western Pacific. A clear pattern is not 
observed in the remaining Eastern Mediterranean region. 
Top 33 endemic countries 
Table 3.2 and Figure 3.2 provide the cumulative case detection data for the top 33 
endemic countries for the period 1985-1998. The 33 countries contributed 99% to the 
global case detection and 96% to the global detection when India is excluded in 1994, and 
Table 3.1 Case detection by WHO Region, 1994-2000. 
 
Population 
in millions Cases detected
Case
detection ratio:
2000 over 1994
Percentage of global 
case detection 
(1998, %) 
WHO Region 1998 1994 1998 2000
corrected a:
no           yes
including 
India 
excluding
India
Africa 619 47,900 51,530 54,602 1.1 1.0 6% 30%
Americas 802 36,623 47,218 44,786 1.2 1.1 6% 28%
Eastern Mediterr. 453 6504 5923 5565 0.9 0.7 1% 3%
South-East Asia 1480 456,882 689,069 606,703 1.3 1.2 86% 32%
Western Pacific 1639 12,737 10,617 7563 0.6 0.6 1% 6%
World 5905 560,646 804,357 719,219 1.3 1.2 100% —
a Corrected for population growth (no/yes). 
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98% and 91% in 1998. We could not derive these percentages for earlier years. The 
cumulative CDR of the 33 countries was rather stable during 1985-1998. However, a 
gradual increase in cumulative CDR results after excluding India, which heavily dominates 
the cumulative case detection data (Figure 3.2). The annual number of new cases detected 
in the top 33 minus India about doubled between 1985 and 1998 (Table 3.2).  
The CDR level is also relevant: throughout 1985-1998, the Indian CDR is much higher 
than the CDR of the top 33 minus India (12 times higher in 1998). However, China is 
included in the top 33 minus India. It has a huge population but does not contribute 
much to total case detection. By consequence, the deviation from the Indian CDR 
decreases from 12 to a factor 6.5 when China is also excluded (Table 3.2). This indicates 
that the level of the CDR of combinations of countries should be interpreted with 
caution. This also holds for the global CDR which exceeded 1 per 10,000 per year during 
1997-2000: contributing 98% to global case detection, the top 33 countries constituted 
only 64% of the 1998 world population. For similar reasons, we refrained from 
calculating CDRs for the WHO Regions. 
Top 14 countries 
The contribution of the 14 countries for which case detection time series could be 
constructed to the total case detection in the top 33 countries hardly changed during 
1985-1998. In 1998, this contribution was 96%, and 81% when India is excluded 
(Table 3.2). Similarly, the contributions to the global case detection in 1998 were 94% and 
73%. The trend in cumulative case detection of the top 14 almost parallels the trend in 
1986 1988 1990 1992 1994 1996 1998 2000
1
10
100
1000
Case detection (thousands)
Africa
World
Americas
Eastern Mediterranean
Western Pacific
South-East Asia
Figure 3.1 Global case detection and detection by WHO Region, 1994-2000. 
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India, due to the numerical dominance of India. For the top 14 except India, cumulative 
new case detection increased between 1987 and 1992, and further increased between 1995 
Table 3.2 Case detection and case detection rate (CDR) for each of the top 14 countries, for the top 14 and 
top 33 endemic countries combined with and without India and China included, and global case detection and 
CDR, 1985-1998. 
 
Population 
in millions 
Cases
detected
CDR
/10,000/year
Ratio:
1998 over 1985
Contribution to 
case detection in 
top 33 except
India (%)
Area  1998 1985 1998 1985 1998 Cases CDR 1985 1998
      Africa   
Ethiopia 61 5113 4457 1.18 0.73 0.9 0.6 6.5% 2.9%
Guinea 7 200 3684 0.40 5.20 18.4 13.0 0.3% 2.4%
Madagascar 15 2016 8957 1.99 6.14 4.4 3.1 2.6% 5.8%
Mozambique 17 955 3764 0.71 2.22 3.9 3.1 1.2% 2.5%
      Americas   
Brazil 166 19,265 42,055 1.42 2.53 2.2 1.8 24.6% 27.4%
      Eastern Mediterranean   
Sudan 30 77 2077 0.03 0.69 27.0 20.2 0.1% 1.4%
      South-East Asia 
Bangladesh 127 4834 12,351 0.50 0.98 2.6 2.0 6.2% 8.0%
India 980 477,000 634,901 6.23 6.48 1.3 1.0 — —
Indonesia 204 8313 18,367 0.51 0.90 2.2 1.8 10.6% 12.0%
Myanmar 47 6600 14,357 1.78 3.08 2.2 1.7 8.4% 9.4%
Nepal 22 4999 6570 3.09 2.99 1.3 1.0 6.4% 4.3%
      Western Pacific   
China 1242 4964 2051 0.05 0.02 0.4 0.3 6.3% 1.3%
Philippines 73 1139 3490 0.21 0.48 3.1 2.3 1.5% 2.3%
Vietnam 77 2062 2162 0.35 0.28 1.0 0.8 2.6% 1.4%
      Country combinations   
Top 14 except China, India 844 55,573 122,291 0.85 1.45 2.2 1.7 71.1% 79.7%
Top 14 except India 2086 60,537 124,342 0.35 0.60 2.1 1.7 77.4% 81.0%
Top 14 3066 537,537 759,243 2.17 2.48 1.4 1.1 — —
Top 33 except China, India 1534 73,224 151,411 0.63 0.99 2.1 1.6 — —
Top 33 except India 2777 78,188 153,462 0.35 0.55 2.0 1.6 100.0% 100.0%
Top 33  3756 555,188 788,363 1.86 2.10 1.4 1.1 — —
World 5904 — 804,357 — 1.36 — — — —
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and 1998, with a ratio of 1998 to 1985 case detection of 2:1. 
Africa The four African countries of the top 14 contributed 40% to the total 1998 case 
detection in the region (Tables 3.1, 3.2). The 1998 CDR was above 5 per 10,000 for two 
countries (Guinea, Madagascar) and above 2 per 10,000 for a third (Mozambique). Over 
time, the CDR about tripled in Madagascar and Mozambique, with even larger increases 
in new case detection due to population growth (Table 3.2, Figure 3.3). The Ethiopian 
CDR initially decreased, but was stable in the 1990s. After an initial increase, the Guinean 
CDR shows a decreasing tendency from 1992 onwards, although it again peaked in 1997.  
Americas Brazil is ranked second after India in terms of country-wise annual case 
detection. In 1998, it accounted for 25% of global case detection except India (top 33: 
27%), and for 89% of case detection in the Americas. The annual Brazilian CDR 
gradually increased during 1985-1998, exceeding 2 per 10,000 from 1992 onwards. 
Additional information shows that the increase started around 1970 (8).  
Eastern Mediterranean In 1998, Sudan accounted for 35% of case detection in the region. 
Reported detection increased strongly between 1985-1989 (annually: less than 100 cases) 
and 1994 when it peaked (3070 cases), and fluctuated between 2000 and 2700 new cases 
per year afterwards. The annual CDR was always below 1 per 10,000, except for the year 
1994.  
South-East Asia In 1998, India contributed 79% to global case detection (top 33: 81%), 
 
1986 1988 1990 1992 1994 1996 1998 2000
0.01
0.10
1.00
10.00
Case detection rate /10 000 /year
Top 33 except India
Top 33
China
India
Top 33 except China, India
World
Figure 3.2 Case detection rate for India, China, and the top 33 endemic countries with and without India and
China included, and the global case detection rate, 1985-2000. 
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    (c) South East Asia
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    (b) Western Pacific and Americas
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Vietnam
China
Brazil
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    (a) Africa and Eastern Mediterranean
Sudan
Ethiopia
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Mozambique
Figure 3.3 Case detection rates for each of the top 14 endemic countries, 1985-2000. 
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and 92% to detection in the region. The Indian CDR decreased by 2.7% per year between 
1985 and 1996 (exponential curve fit; half-value time 25 years), and subsequently 
increased. The CDR always exceeded 5 per 10,000, except for 1994-1996. The Indian 
population increased by about 30% between 1985 and 2000. By result, cumulative case 
detection during 1997-2000 was higher than in any of the three other four-year periods 
(case detection = CDR × population size).  
Bangladesh, Indonesia, Myanmar and Nepal each detected more than 6000 cases in 1998, 
and together accounted for 30% of 1998 global case detection except India (top 33: 34%), 
and for 95% of case detection in South-East Asia except India. Overall, the CDRs did not 
decrease in the four countries. The country with the largest population, Indonesia, 
detected most cases in 1998, but also had the lowest CDR. It never exceeded 1 per 10,000 
per year. In Bangladesh, the annual CDR gradually increased, equalling about 1 per 10,000 
in the late 1990s. Case detection tripled, comparing 1997-2000 with 1985-1988. In 
Myanmar, the annual CDR always exceeded 1 per 10,000, and increased. The Nepali CDR 
was also always above 1 per 10,000 per year: a clear trend is not visible. The CDR peaked 
in 1999 in both Myanmar and Nepal, with values that were more than twice as high as 
those for both 1998 and 2000 (1999 CDRs: 6.5 and 8.3 per 10,000, respectively). 
Western Pacific In 1998, China, the Philippines and Vietnam contributed only 5% to global 
case detection except India (top 33: also 5%), and 73% to detection in the region. Annual 
CDRs were always below 1 per 10,000, except for the Philippines in 1991. The CDR 
attained its highest values in the early 1990s in the Philippines and Vietnam, and 
decreased thereafter. The Chinese CDR gradually decreased from 4.7 per 100,000 in 1985 
to 1.6 in 1995, and was stable during 1995-1998. Additional information shows that the 
Chinese CDR has been on the decrease during the last 4 decades (17). 
Additional information for the year 1998 (9)  
Africa Four countries accounted for an additional 30% of African case detection in 1998, 
each also detecting at least 2500 cases (Democratic Republic of Congo, Niger, Nigeria 
and Tanzania). After Madagascar, most cases were detected in Nigeria (7230 cases, 14% 
of African detection, CDR /10,000/yr: 0.6). Overall, twelve African countries had a 1998 
CDR of more than one per 10,000 (Angola, Benin, Cameroon, Central African Republic, 
Congo, Côte d’Ivoire, Guinea, Madagascar, Mali, Mozambique, Niger, Tanzania).  
Americas All American countries except Brazil detected fewer than 1000 patients in 1998, 
and had CDRs below 1 per 10,000. 
Eastern Mediterranean Three countries accounted for an additional 60% of 1998 case 
detection in the region (Egypt, Pakistan and Yemen). Only Egypt detected more than 
1000 cases. The CDR was below 1 per 10,000 for all countries in the region.  
South-East Asia In 1998, both Thailand and Sri Lanka detected in between 1000 and 1500 
cases. Their CDRs were below 1 per 10,000 per year. Information for other countries was 
not available, indicating prevalences of less than 100 registered cases (9).  
TRENDS IN CASE DETECTION SINCE 1985 
61 
Western Pacific With 1609 cases, Cambodia accounted for another 15% of 1998 case 
detection in the region. Its 1998 CDR was 1.45 per 10,000. All other countries reported 
less than 500 new cases. Still, three of these other countries also had 1998 CDRs of 1 per 
10,000 or more (Federated States of Micronesia, Papua New Guinea and Marshall Islands; 
the latter country had a 1998 CDR of over 20 per 10,000).  
3.5 Discussion 
This paper uses leprosy case detection data that are based on country statistics and 
aggregated information from WHO. Figures may sometimes be incomplete or involve 
inaccuracies due to difficulties in many countries in the collection, processing and 
reporting of data. Overdiagnosis and reregistration of previously treated cases may also 
have influenced the detection figures (9). Nevertheless, the presented case detection data 
are the best available and do allow for crude analyses comparing countries and regions. 
We have analysed these data at three levels: number of cases detected, level of the case 
detection rate (CDR), and trend in CDR and case detection. Time series for other 
indicators which may help to assess trends in leprosy transmission, in particular child 
proportion in new case detection, mean age at detection and age-specific case detection 
rates (18), could not be constructed and detailed information on how control 
programmes evolved over time is not available.  
Number of cases detected 
Case detection figures indicate the number of patients that health services need to treat, 
and provide information on the geographical distribution of new cases in the world. 
Throughout 1985-1998, by far most cases were detected in India (on average 490,000 
cases per year, 79% of global detection in 1998). Brazil always ranked second after India. 
With an average of 31,000 cases per year, it dominated case detection in the Americas. 
South-East Asia, which includes India, accounted for 86% of the 1998 global case 
detection of about 800,000 cases. The WHO Regions Africa, the Americas and South-
East Asia each contributed about 30% to the 1998 detection of 170,000 cases, which 
remains after India is excluded. Virtually all other cases are detected in the Eastern 
Mediterranean Region and the Western Pacific; detection in Europe is negligible 
compared to the other regions. Excluding India, 73% of global case detection in 1998 
(124,000 cases) is concentrated in the other 13 countries of the top 14 in this study.  
Case detection rate (CDR) 
The CDR is a crude indicator for comparisons between countries of the relative severity 
of leprosy as a public health problem. In 1998, half of the top 14 countries had CDRs 
above 2 per 10,000 (Table 3.2). The CDR did not exceed 1 per 10,000 for the other half. 
India, the country that dominates global case detection, also had the highest CDR in 
1998. For an additional four Western Pacific and 12 African countries, the CDR was also 
above 1 per 10,000.  
CHAPTER 3 
62 
CDR levels for combinations of countries should be interpreted with caution. Table 3.2 
shows that these levels strongly depend on whether certain countries, in particular India 
(many cases, huge population) and China (relatively few cases, huge population), are 
included in the calculations or not. Also in India itself, leprosy is not distributed evenly: 
according to recent figures, 70% of its new case detection is concentrated in five out of 
the 25 Indian states (1). Concerning the global CDR, it should be realized that 36% of the 
world population does not live in leprosy endemic countries, and that China contributes 
less than 1% to present global case detection, but another 20% to the world population. 
Therefore, we do not consider the level of the global CDR to be informative for 
combinations of countries. We did not calculate CDRs at the level of WHO Regions. 
Trend in case detection rate (CDR) and case detection  
Trends in CDRs reflect trends in incidence rates, provided that no significant changes 
occur in case detection efforts, self reporting behaviour, or diagnostic procedures and 
criteria. The sources of information from which we derived the time trends in case 
detection and CDR do not provide information on control programmes of countries and 
changes in them. However, it can be stated that the adoption of the elimination resolution 
by the World Health Assembly in 1991 led to intensification of leprosy control in many 
countries (19). Geographical coverages of control programmes improved, and many 
countries initiated Leprosy Elimination Campaigns (LECs) in the late 1990s. In view of 
this, it is not surprising that the 1998 CDR was lower than the 1985 CDR for only three 
countries of the top 14 (Table 3.2: China, Ethiopia and Vietnam). Decreasing tendencies 
in CDR, either for the whole period or in the 1990s, are only observed for four countries 
(Figure 3.3: Guinea and the three Western Pacific countries: China, Vietnam and the 
Philippines). Further findings are that the case detection figures for the three WHO 
Regions with most cases, Africa, the Americas and South-East Asia, increased between 
1994 and 2000 (Figure 3.1), and that the cumulative CDR for the top 33 except India 
gradually increased between 1985 and 1998, overall almost doubling (Figure 3.2). The 
Indian CDR very slowly decreased up to 1996 and subsequently increased. These 
observations lead to the overall conclusion that so far, there is no general decline in case 
detection. Underlying trends in incidence and transmission of leprosy remain completely 
unclear. 
The CDR is more informative than case detection for comparing time trends by country, 
because the CDR also indicates endemicity levels. It should however be realized that in 
growing populations, annual case detection may increase substantially with time when the 
CDR is stable. This follows directly from the simple formula ‘case detection 
= CDR × population size’. During 1985-1998, all top 14 endemic countries experienced 
population growth, with growth rates ranging from 1.3% and 2.9% per year. By 
consequence, case detection would have increased by 18% to 45% under constant CDRs 
during this period. The effect of population growth is also illustrated by the Indian figures 
in Table 3.2: case detection increased by about 30%, but the CDR hardly changed. 
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Finally, the time series for the global CDR from 1994 onwards illustrates that the global 
target for ‘elimination of leprosy as a public health problem’ has no epidemiological 
significance: the elimination target would already have been attained by the end of 1994 if 
all patients had received MDT treatment according to the current guidelines (7), and 
registers had been confined only to those on treatment. This follows directly from the 
global CDR and the percentage MB in case detection in 1994 (1.01 per 10,000 and 35% 
of all cases (2, 10, 16)) in combination with the formula ‘number on treatment = case 
detection × average treatment duration’. With half a year of MDT treatment for the 65% 
PB patients and 1 year for the 35% MB patients, the ‘on-treatment prevalence’ equals 0.65 
× 1.01 × 0.5 + 0.35 × 1.01 × 1 = 0.68 per 10,000, which is well below the elimination 
target of 1 per 10,000. This calculation illustrates that the elimination target, proclaimed to 
be reached in 2001, was indeed achieved by rigorous implementation of treatment 
guidelines. Any changes in the epidemiological situation of leprosy are not reflected in 
this target indicator.  
Conclusion 
The main conclusion is that to date, there is no general decline in case detection. Several 
countries with many new cases, including India, still have CDRs exceeding 2 per 10,000 
per year. Endemicity levels for combinations of countries should not be summarized in 
one cumulative indicator, such as the overall CDR. Prevalence is an irrelevant indicator 
for monitoring epidemiological changes in leprosy. Trends in the transmission and 
incidence of leprosy are still completely unclear, necessitating further research. The target 
to eliminate leprosy as a public health problem, defined as a prevalence of less than 1 per 
10,000, is therefore also an inadequate yardstick for decision making on leprosy control.  
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4.1 Summary 
SIMLEP is a computer program for modeling the transmission and control of leprosy 
which can be used to project epidemiologic trends over time, producing output on 
indicators such as prevalence, incidence and case detection rates of leprosy. In SIMLEP, 
health states have been defined that represent immunologic conditions and stages of 
leprosy infection and disease. Three types of interventions are incorporated: vaccination, 
case detection and chemotherapy treatment. Uncertainties about leprosy have led to a 
flexible design in which the user chooses which of many aspects should be included in the 
model. These aspects include natural immunity, asymptomatic infection, type distribution 
of new cases, delay between onset of disease and start of chemotherapy, and mechanisms 
for leprosy transmission. An example run illustrates input and output of the program. The 
output produced by SIMLEP can be readily compared with observed data, which allows 
for validation studies. The support that SIMLEP can give to health policy research and 
actual decision making will depend upon the extent of validation that has been achieved. 
SIMLEP can be used to improve the understanding of observed leprosy trends, for 
example, in relation to early detection campaigns and the use of multidrug therapy, by 
exploring which combinations of assumptions can explain these trends. In addition, 
SIMLEP allows for scenario analyses, in which the effects of control strategies combining 
different interventions can be simulated and evaluated. 
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4.2 Introduction 
Estimates of the short- and long-term effects of leprosy control strategies are required for 
decision making, for target setting, and for prediction of the moments at which targets are 
likely to be reached. However, limited knowledge of leprosy epidemiology and of the 
effects of population-based interventions make it difficult to explain observed trends in 
leprosy incidence and morbidity and to predict the future of leprosy. 
There is ample evidence that socioeconomic development might affect leprosy 
transmission, and that secular trends can occur (1, 2). BCG vaccination has a protective 
effect, but its efficacy is highly variable (3). The introduction of multidrug therapy (MDT) 
in the 1980s, with its relatively short duration of treatment, resulted worldwide in rapid 
declines in the prevalence as defined by the number of cases registered for treatment, and 
MDT has become the mainstay for leprosy control (4). However, convincing evidence for 
a persistent favorable effect of MDT on new case detection rates has so far not been 
observed (5, 6) and, therefore, the long-term impact of MDT-based programs is not clear. 
In this situation, simulation models can help to organize knowledge and assumptions on 
leprosy and to structure discussions on its control. These types of models enable 
exploration of the behavior of a disease in populations over time under specified 
assumptions about processes involved (7). The present paper introduces an 
epidemiological simulation model for leprosy, SIMLEP, which provides a framework for 
the quantitative description of the dynamics of leprosy transmission, the course of 
infection and disease, and the impact of interventions. Simulation results on trends in case 
detection rates and in the prevalence of cases registered for treatment can be compared 
with observed data. SIMLEP can be used to explore the possible effects of interventions 
such as MDT-based control on leprosy transmission under assumptions or scenarios on 
unknown aspects of leprosy epidemiology which can be varied by the user. 
In the 1970s and 1980s, Lechat, et al. were the first to develop a comprehensive model for 
leprosy (8-12). Their simulations concentrated on the comparison of the long-term impact 
of alternative control strategies, and helped considerably to clarify the thinking about 
leprosy control. SIMLEP builds on the approach which is followed in the Lechat model 
and in several conceptually similar tuberculosis models (e.g. (13-17)). Shortly after the 
introduction of MDT-based control, Lechat, et al. made a courageous attempt to explore 
its consequences (10, 11). However, their predicted rapid and persisting decline in 
incidence has not been observed in reality. In its conclusions and recommendations, the 
1991 International Meeting on Epidemiology of Leprosy in Relation to Control recognized a need 
for making predictions for future trends, and recommended that simulation models 
should be developed (18). This has initiated the development of the present SIMLEP 
model. SIMLEP allows for variation of many model assumptions, for example, with 
respect to natural immunity, the incubation period and asymptomatic infection. Delays 
for becoming aware of disease and for start of treatment are incorporated, and SIMLEP 
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also provides different mechanisms for describing leprosy transmission. SIMLEP includes 
detailed output facilities for comparison of simulation results with observed trends, and 
for the prediction of future trends. 
This paper describes the structure of the SIMLEP model, gives an example of a SIMLEP 
simulation experiment, and discusses quantification of the model, potential applications 
and known limitations. Background information on simulation modeling for tropical 
diseases, and for leprosy in particular, can be found elsewhere (7, 12, 19, 20). The 
Appendix gives a mathematical description of SIMLEP.  
4.3 The model 
The SIMLEP model describes the process of leprosy transmission, disease and control in 
a population which is followed over time. SIMLEP has a pre-defined structure of 
compartments (representing health conditions with respect to leprosy) and flows between 
compartments (Figure 4.1). Within this framework, the SIMLEP user can specify 
assumptions about demography, leprosy and interventions by giving birth and death rates 
and numerical specifications for the flows between the compartments. The arrows with 
solid shafts and points in Figure 4.1 represent birth, death and the flows (transitions) 
between the compartments (boxes in the flowchart). The dashed arrows with open heads 
– or influence arrows – and the “force of infection circle” represent leprosy transmission. 
The arrows with solid shafts and spearheads indicate flows related to the SIMLEP 
interventions: vaccination, case detection and chemotherapy. By not using boxes – 0% 
flows – the user can simplify the model actually used. SIMLEP performs all calculations 
for each age separately, and represents the epidemiological situation at the end of a 
simulation time step by the age-specific distribution of the population over the various 
compartments. The maximum value for the time step in SIMLEP simulations is two 
months. Flows from compartments are calculated according to (Markov) transition rates 
if not indicated otherwise. A flow between two compartments, say k and l, is indicated by 
fkl (both k and l run from a to j, Figure 4.1). The three flows f0a, f0b and f0c represent births, 
and death from a compartment, say m, is denoted by fmz (m runs from a to j).  
Background situation 
The history of leprosy control influences future trends of leprosy in an area and is, 
therefore, simulated in SIMLEP. SIMLEP runs always start from a stable situation, i.e. an 
age-specific distribution of the population over the various compartments in which no 
changes over time occur, with all control measures switched off. This stable situation is 
derived from the numerical specifications for the model parameters and from a user-
specified background incidence rate for the first years of interest for the simulation run 
(incidence being defined as the first appearance of any specific signs or symptoms of 
leprosy). SIMLEP will automatically fit this background incidence rate at the start of a 
simulation experiment by tuning the transmission parameter β (is defined later). 
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 f-z 
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Figure 4.1 SIMLEP: The health states (compartments), the flows between them (arrows), the process of leprosy
transmission (dashed arrows and "force of infection" circle) and two interventions: vaccination and diagnosis
plus chemotherapy ("intervention" flows and shaded compartments). All transitions are age-specific and the age
structure of all compartments is updated at the end of each simulation time step. 
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Demography 
Birth is simulated according to a crude birth rate. A life table governs death in SIMLEP: 
at the end of each time step, age-specific death rates which correspond to the life table are 
applied (flows faz, fbz, .., fjz) and the age structure of the population is updated. SIMLEP 
does not consider migration and possible excess mortality in leprosy patients, and does 
not distinguish between males and females. 
Susceptibles and nonsusceptibles 
In order to evaluate the potential impact of natural immunity against leprosy, SIMLEP 
has the option to specify a fraction of newborns to enter the compartment of life-long 
NATURAL IMMUNITY (flow f0a). The other newborns all enter the compartment 
SUSCEPTIBLE (flow f0b). The compartment SUSCEPTIBLE can also contain individuals who 
were cured after treatment without acquiring immunity against new leprosy infections. 
Upon acquiring a leprosy infection, people from the SUSCEPTIBLE compartment move to 
the compartment ASYMPTOMATIC INFECTION (flow fbd). 
Course of infection and disease 
In SIMLEP, infected individuals are assumed to pass first through an episode without 
manifestation of specific signs or symptoms of leprosy, which is represented by the 
compartment ASYMPTOMATIC INFECTION. The user can specify time distributions for the 
length of this episode (see the Appendix). SIMLEP offers the possibility of spontaneous 
healing of asymptomatic infections without manifestation of symptomatic leprosy (flows 
fdb and fdh). Flows fde, fdf and fdg denote the first appearance of any sign or symptom of 
leprosy (e.g. skin lesion or nerve function impairment) irrespective of recognition by the 
patient or diagnosis by a medical worker. SIMLEP distinguishes three expression types of 
symptomatic leprosy: 
1. symptomatic leprosy from which all individuals will self-heal when left untreated (via a 
self-healing rate; flows feb and feh): SELF-HEALING SYMPTOMATIC LEPROSY; 
2. symptomatic leprosy that is not strongly contagious, but from which individuals will 
downgrade to strongly contagious symptomatic leprosy at a later stage when left 
untreated (via a downgrading rate; flow ffg): DOWNGRADING SYMPTOMATIC LEPROSY; 
and 
3. symptomatic leprosy that is strongly contagious directly upon manifestation of the 
first signs or symptoms of leprosy: STRONGLY CONTAGIOUS SYMPTOMATIC LEPROSY. 
Note that preventing downgrading will enhance the impact of early detection and 
chemotherapy on transmission. For evidence of downgrading see Scott, et al. (21). After 
self-healing from asymptomatic infection or symptomatic leprosy, people either are 
susceptible for a new infection and move to SUSCEPTIBLE (flows fdb and feb), or become 
immune and move to SELF-HEALED & IMMUNE FOR NEW INFECTIONS (flows fdh and feh). 
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Possible endogenous reactivation of leprosy in self-healed individuals is neglected. People 
with symptomatic leprosy move to the compartment DIAGNOSED + ON CHEMOTHERAPY 
TREATMENT as soon as they are detected and are put on treatment. 
Transmission 
New infections (flows fbd and fcd) are assumed to be caused by contagious individuals in 
the population. Knowledge on who are responsible for leprosy transmission, and to what 
extent, is limited. It cannot be excluded, for example, that most transmission occurs in the 
episode of asymptomatic infection. In SIMLEP, contagiousness is therefore modeled in a 
flexible way: it can be switched on and off separately for: 
1. each of the four groups in compartment ASYMPTOMATIC INFECTION, namely, the ones 
who self-heal without becoming symptomatic, and the people later becoming 
symptomatic of, respectively, the self-healing, downgrading and strongly contagious 
types 
2. people in compartment SELF-HEALING SYMPTOMATIC LEPROSY 
3. people in compartment downgrading symptomatic leprosy. 
A person with STRONGLY CONTAGIOUS SYMPTOMATIC LEPROSY is assumed always to be 
contagious, but he might rapidly infect people living close to him. After some time, this 
person will therefore have transmitted Mycobacterium leprae to most of his susceptible 
contacts. To account for this, the capability to transmit M. leprae gradually decreases over 
time (it follows a negative exponential function) for all persons who enter the 
compartment STRONGLY CONTAGIOUS SYMPTOMATIC LEPROSY. This loss of 
contagiousness can be quantified by the average contagiousness – closs – of all people in 
the compartment STRONGLY CONTAGIOUS SYMPTOMATIC LEPROSY relative to the level of 
contagiousness at entry in this compartment. 
For the compartments for which contagiousness is optional (ASYMPTOMATIC INFECTION, 
SELF-HEALING SYMPTOMATIC LEPROSY, DOWNGRADING SYMPTOMATIC LEPROSY), the 
user should specify a second (lower) level of contagiousness relative to the initial level in 
the compartment STRONGLY CONTAGIOUS SYMPTOMATIC LEPROSY. Because of this lower 
level, SIMLEP does not postulate loss of contagiousness for the compartments SELF-
HEALING SYMPTOMATIC LEPROSY and DOWNGRADING SYMPTOMATIC LEPROSY. Presently, 
the symplifying assumption has been made that the duration of the episode of 
asymptomatic infection is following the same time distribution for those who self-heal 
without development of symptoms and those who proceed to symptomatic leprosy of 
either the self-healing or the downgrading type. A different time distribution can be 
specified for those who proceed to STRONGLY CONTAGIOUS SYMPTOMATIC LEPROSY. The 
contagiousness in compartment ASYMPTOMATIC INFECTION is assumed to build up 
gradually to the level of strong contagiousness for those who move to STRONGLY 
CONTAGIOUS SYMPTOMATIC LEPROSY, and to the second (lower) level of contagiousness 
for those who do not. 
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SIMLEP translates the (weighted) contagiousness of all contagious people together into 
the force of infection (circle in Figure 4.1) which is the rate at which individuals who are 
still susceptible acquire M. leprae infection (flow fbd). For example, if only people in the 
compartment DOWNGRADING SYMPTOMATIC LEPROSY are contagious in addition to the 
people from the compartment STRONGLY CONTAGIOUS SYMPTOMATIC LEPROSY, then the 
force of infection FOI is equal to  
( )
N
Gc+FwFOI  =  lossweak ββ  
with closs as in above text and 
β = measure for contagiousness of people who just entered the compartment 
STRONGLY CONTAGIOUS SYMPTOMATIC LEPROSY 
wweak = weighting factor: the level of contagiousness in the compartments SELF-
HEALING SYMPTOMATIC LEPROSY and DOWNGRADING SYMPTOMATIC LEPROSY is 
given by wweak · β 
F = number of people in the compartment DOWNGRADING SYMPTOMATIC LEPROSY 
G = number of people in the compartment STRONGLY CONTAGIOUS SYMPTOMATIC 
LEPROSY 
N = total population size. 
The fraction among the susceptible people that acquires M. leprae infection during a 
simulation time step (∆t) is calculated from this force of infection and equals FOI · ∆t. If 
other compartments are also (weakly) contagious, the people in these compartments are 
added to the FOI term. The gradual buildup of contagiousness in the compartment 
ASYMPTOMATIC INFECTION is described in more detail in the Appendix. Secular declines 
in leprosy can be taken into account by an annual reduction factor for the transmission 
parameter β. 
Leprosy control 
Vaccination 
BCG vaccination is often given in early childhood. It only offers protection to a certain 
degree (3). In SIMLEP, vaccination is assumed to take place at birth with a user-defined 
coverage. Vaccinated newborns without natural immunity enter the compartment 
VACCINATED (REDUCED SUSCEPTIBILITY) (flow foc). People in this compartment can still 
be infected but at a lower rate (flow fcd). In a study in South India, the protective efficacy 
of BCG for younger ages decreased from 58% to 18% over a period of 15 years (22). The 
protective efficacy can therefore be specified to depend on the time since vaccination. 
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Diagnosis 
Early case detection reduces the delay between onset of symptomatic leprosy and start of 
chemotherapy. In SIMLEP, this delay consists of two consecutive parts: cases must first 
become aware of their disease (“awareness delay”), before they can look for care after a 
certain “reporting delay”. The user specifies case detection by choosing two rates which 
are associated with the awareness delay and the reporting delay, respectively. A reporting 
delay which is infinitely long corresponds with absence of treatment. 
Chemotherapy 
Chemotherapy shortens the average duration of contagiousness of patients. It is believed 
that with rifampin bacterial kill is achieved almost instantaneously at the first dose, and 
that dapsone monotherapy can achieve this effect in about 3 months. However, for 
simplification, both dapsone monotherapy and multidrug therapy are in SIMLEP 
assumed to start at the moment of diagnosis and to immediately stop the contagiousness 
of patients.  
Upon starting treatment, patients move to the noncontagious compartment DIAGNOSED 
+ ON CHEMOTHERAPY TREATMENT (flows fei, ffi and fgi). The duration of leprosy treatment 
depends on the type of leprosy at presentation. In SIMLEP, one average treatment 
duration must be specified per treatment regimen, reflecting the mean treatment duration 
over the different types of symptomatic leprosy. This duration is converted into a 
treatment cessation rate; treatment cessation thus does not depend on the bacteriological 
status of patients. Fixed durations of treatment were not implemented in SIMLEP 
because of computational complexities. In view of the possibility of endogenous 
reactivation after cessation of treatment, provision is made for relapses. A new infection 
can also cause a new episode of symptomatic leprosy after cessation of treatment. In 
SIMLEP, both options are offered: after cessation of treatment, a fraction can return to 
the compartment SUSCEPTIBLE (flow fib), and a fraction can move to the compartment 
TREATMENT CURED & IMMUNE FOR NEW INFECTIONS (flow fij) from which they can 
experience a relapse to the compartments for symptomatic leprosy (flows fje, fjf, fjg). 
A chemotherapy-based control strategy in SIMLEP is characterized by the awareness 
delay, the reporting delay, the duration of treatment, and relapse rates (if relapses are 
specified to occur) which are specific for the type of treatment used (dapsone 
monotherapy or multidrug therapy). Note that since both dapsone and multidrug therapy 
are assumed to immediately stop the contagiousness of patients, only shorter associated 
delays in diagnosis and lower relapse rates can render multidrug therapy-based control to 
be more powerful in reducing transmission than dapsone-based control. Upon cure, 
individuals either become immune or susceptible for new infections. The corresponding 
fractions are in SIMLEP independent of the type of treatment. Thus, they are identical 
for dapsone monotherapy and multidrug therapy. Up to six chemotherapy control 
strategies can be applied consecutively in one simulation run. 
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4.4 Example 
An example of a simulation run is discussed below in order to show how SIMLEP can be 
used. As an illustration, a model structure and a set of parameter quantifications have 
been chosen that in our judgment are not implausible. A simplified model with no 
NATURAL IMMUNITY (no f0a) and with self-healing and treatment cure always being 
followed by immunity (no fdb, feb, and fib) is used (Figure 4.2). The parameter 
quantifications for demography, transmission, course of infection and disease and control 
strategies are listed in Tables 4.1 and 4.2. In the text below, figures in parentheses denote 
choices for parameter quantifications. 
Input specifications 
The stable epidemiological situation at the start of the simulation (1950) has an incidence 
rate of 2 per 1000 population per year. Demographic data for India for 1976 were used 
for the birth rate (34.4 per 1000 population) and the life table (Health Monitor, Pune, 
India: The Foundation for Research in Health Systems, 1993, pages 10, 21). In SIMLEP, 
the birth rate and life table simulate populations with a constant growth rate and age 
structure. 
By excluding natural immunity, it is assumed that everyone can develop leprosy. The 
duration of asymptomatic infection is, on average, shorter for those who will not directly 
develop STRONGLY CONTAGIOUS SYMPTOMATIC LEPROSY than for those who will 
(Figure 4.3). The average durations are 6.8 and 13.4 years, and the probabilities for this 
episode to be shorter than 5 years are 73% and 37%, respectively. 
Of newly infected individuals, a fraction will self-heal without developing symptomatic 
leprosy (30%), while the others (70%) will develop symptomatic leprosy. Recovery from 
an asymptomatic infection, self-healing from symptomatic leprosy, and cure by treatment 
are assumed to lead to immunity for new leprosy infections (exclusion of flows fdb, feb, and 
fib). The proportion among new symptomatic cases developing strong contagiousness de 
novo is relatively small (10%), and cases downgrading at a later stage (30%) will make an 
important contribution to the pool of strongly contagious individuals. The average 
duration until self-healing from symptomatic leprosy of 3 years implies that 33% per year 
will self-heal. Similarly, the annual downgrading rate is 20% per year (or 5 years on 
average). 
All individuals in the compartment ASYMPTOMATIC INFECTION are building up 
contagiousness, and all untreated symptomatic leprosy cases who are not of the 
STRONGLY CONTAGIOUS SYMPTOMATIC LEPROSY type are weakly contagious. Their 
relative degree of contagiousness (9%) was calculated in such a way that STRONGLY 
CONTAGIOUS SYMPTOMATIC LEPROSY cases in total infect four times as many individuals 
as self-healing cases. In SIMLEP, the strongly contagious cases become gradually less 
effective in transmitting M. leprae (the effectiveness reduces by 50% every 9 months). A 
“natural” decline in the trend of leprosy incidence is not assumed in the simulation. 
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Figure 4.2 Example: Model structure (all ages combined) and parameter specifications. 
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The assumptions on leprosy control are summarized in Table 4.2. BCG, which is 
administered at birth, has a protective efficacy which by assumption decreases from 60% 
at age 0 to 0% at age 50 and over. Vaccination starts in 1980, and the coverage increases 
from 25% in the period 1980-1989 to 75% in 1990 and further to 90% from 1995 
onward.  
Table 4.1 Input specifications for the SIMLEP simulation example (see Table 4.2 for control related input). 
Input parameter Flows Value 
Background incidence rate   
Pre-control incidence rate per 1000 total population per year fde, fdf, fdg 2.0 
Demographic data   
Birth rate per 1000 total population per year f0a, f0b, foc 34.4 
Life table f-z see text 
Natural immunity   
Proportion of newborns who enter NATURAL IMMUNITY f0a 0% 
Asymptomatic infection   
Proportion among newly infected individuals not developing symptomatic 
leprosy 
fdb, fdh 
 
30% 
 
Duration of asymptomatic infection 
 
fdb, fde, fdf, fdg, fdh 
 
see text 
and Figure 3 
Untreated symptomatic leprosy   
Proportion of new cases who (first) to go to 
–   SELF-HEALING SYMPTOMATIC LEPROSY 
–   DOWNGRADING SYMPTOMATIC LEPROSY 
–   STRONGLY CONTAGIOUS SYMPTOMATIC LEPROSY 
fde 
fdf 
fdg 
60% 
30% 
10% 
Self-healing rate from SELF-HEALING SYMPTOMATIC LEPROSY per year feb, feh 33% 
Downgrading rate from DOWNGRADING SYMPTOMATIC LEPROSY per year ffg 20% 
Immunity for new infections upon self-healing fdh, feh 100% 
Awareness and reporting delays 
 
fei, ffi, fgi 
 
see Table 2 
and Figure 4 
Transmission  
Average duration until the transmission of M. leprae per unit of time by a 
strongly contagiousness individual is reduced by 50% 
fbd, fcd 
 
0.75 years 
 
Contagiousness for the compartments 
–   ASYMPTOMATIC INFECTION 
–   SELF-HEALING SYMPTOMATIC LEPROSY 
–   DOWNGRADING SYMPTOMATIC LEPROSY 
–   STRONGLY CONTAGIOUS SYMPTOMATIC LEPROSY 
fbd, fcd 
buildup 
weak 
weak 
strong 
Weighting factor wweak: relative degree of contagiousness (in %) for contagious 
persons not belonging to STRONGLY CONTAGIOUS SYMPTOMATIC LEPROSY 
fbd, fcd 
 
9% 
 
Annual secular reduction in the transmission parameter fbd, fcd 0% 
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Case detection plus chemotherapy start in 1955. A buildup phase of 5 years is assumed 
for case detection. The program remains unchanged in the period 1960-1990. The years 
1990-1993 reflect a transition phase from dapsone to multidrug therapy during which 
both the awareness delay and the reporting delay are reduced. The delays again remain 
unchanged from 1993 onward; see Figure 4.4 for the probability distribution of the total 
Table 4.2 Input specifications for the SIMLEP simulation example: control related input. 
(a) BCG vaccination at birth (flows: fob, foc, fcd). 
 Period 
 1980-1989 1990 1991-1995 1995-2020 
BCG coverage 25% 75% increases to 90% 90% 
Protective efficacy 
 
60% at age 0, decreasing linearly to 50% at age 5, to 25% at age 15, 
and to 0% for ages 50 and over 
(b) CHEMOTHERAPY: delay until diagnosis (i.e. start of treatment) for SYMPTOMATIC LEPROSY (flows fei, ffi, fgi). 
 Period 
 1955-1960 1960-1990 1990-1993 1993-2020 
Average awareness delay (years) 1.25 1.25 decreases to 1 1 
Average reporting delay (years) 
 
decreases from 
"infinity" to 3.25 
3.25 
 
decreases to 2 
 
2 
 
Average total delay before starting 
treatment (years) 
decreases from 
"infinity" to 4.5 
4.5 
 
decreases to 3 
 
3 
 
(c) CHEMOTHERAPY: duration of treatment (flows: fib, fij). 
 Period 
 1955-1990 1990-1998 1998-2020 
Average treatment duration (years) 5 0.8 0.2 
(d) CHEMOTHERAPY: after cure by treatment. 
Input parameter Flows Value 
Immunity for new infections upon cure by treatment fij 100% 
Relapse rate after monotherapy cure per year fje, fjf, fjg 1.5% 
Relapse rate after multidrug therapy cure per year fje, fjf, fjg 0.1% 
Proportion of relapsing cases who relapse to (either therapy): 
–   SELF-HEALING SYMPTOMATIC LEPROSY 
–   DOWNGRADING SYMPTOMATIC LEPROSY 
–   STRONGLY CONTAGIOUS SYMPTOMATIC LEPROSY 
 
fje 
fjf 
fjg 
 
10% 
50% 
40% 
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delay. It has a high variability, with probabilities of 17%, 43%, 86% and 99% that the 
delay is smaller than 1, 2, 5 and 10 years, respectively. These values apply to all three types 
of symptomatic leprosy.  
The average durations of dapsone treatment, of multidrug therapy, and of the shortened 
duration of MDT treatment which is postulated from 1998 onward are based on the mix 
of the different types of symptomatic leprosy considered (the average durations are 
associated with negative exponential time functions that correspond with treatment 
completion rates). As mentioned above, cure by treatment in this example implies 
immunity for new infections (exclusion of flow fib). Relapse rates after dapsone 
monotherapy (1.5% per year) are much higher than after multidrug therapy (0.1% per 
year). The distribution of relapses over the three types of symptomatic leprosy 
(10%,50%,40%) is in SIMLEP independent of the administered therapy (dapsone 
monotherapy or multidrug therapy).  
Simulation results 
The user interface of SIMLEP enables on screen inspection and printing of the output of 
simulations in both tabular form and through a large number of pre-defined graphs. The 
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34
0.00
0.05
0.10
0.15
0.20
0.25
0.30
Probability density
Newly infected individuals who will proceed
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Figure 4.3 Example: Probability density functions for the duration of ASYMPTOMATIC INFECTION for those who after
this episode directly will proceed to STRONGLY CONTAGIOUS SYMPTOMATIC LEPROSY (the probabilities for this
episode to be shorter than 5, 10 and 20 years are, respectively, 37%, 47% and 75%) and those who either will
self-heal without showing any sign or symptom of leprosy or will proceed to another expression type of
symptomatic leprosy (the corresponding probabilities are 73%, 82% and 92%, respectively). 
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pre-defined graphs include both type- and age-specific graphs for the rates of onset of 
symptomatic leprosy (incidence rate) and of starting chemotherapy treatment of 
symptomatic leprosy, and for the point prevalences of untreated symptomatic cases and 
of symptomatic cases on treatment. 
Figure 4.5 shows, for the example run, a slow but persistent decrease in the incidence rate 
from the gradual introduction of dapsone-based control in 1955-1960 onward. The rate 
of decline increases shortly after 1990 because of the introduction of multidrug therapy 
and the rise in BCG coverage. The introduction of multidrug therapy is associated with 
less opportunities for transmission of M. leprae due to a (somewhat) earlier detection and 
its lower relapse rate (relapsed cases contribute to transmission until they again start 
treatment). The number of cases relapsing after treatment is small as compared to the 
number of incidence cases. In SIMLEP, case detection only counts when a chemotherapy 
treatment is started. The early peak in treatment starting rates reflects a clearance of a 
backlog of untreated cases from the pre-control era. The increase in the treatment starting 
rate in the transition phase toward multidrug-based control (1990-1993) is explained by 
earlier detection due to an assumed shortening of the awareness and reporting delays. As 
a consequence, the gap between the treatment starting rate and the incidence rate 
becomes smaller (Figure 4.5), and the prevalence of untreated cases declines (Figure 4.6). 
Figure 4.4 Example: Probability density function for the total delay between onset of the first sign or symptom of
leprosy and start of chemotherapy during the chemotherapy control strategy over the years 1993-2020 in the
example. 
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Figure 4.5 Example: Simulated incidence rate of symptomatic leprosy, rate of starting treatment and relapse
rate (all expression types of symptomatic leprosy combined). 
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Figure 4.6 Example: Simulated point prevalences of untreated symptomatic leprosy, of cases on treatment, and
"total" (all types of symptomatic leprosy combined). 
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In the pre-control period, STRONGLY CONTAGIOUS SYMPTOMATIC LEPROSY is life-long. 
Excess mortality due to leprosy is in addition not (yet) included in SIMLEP. The resulting 
accumulation is the cause of the high prevalence of over 23 per 1000 total population in 
the pre-dapsone era (Figure 4.6). The clearance of the prevalence pool after the 
introduction of dapsone gives a rapid fall in the prevalence of untreated cases in the 
period 1955-1965. Further falls in the total prevalence and in the prevalence of cases on 
treatment in 1989-1990 and again in 1997-1998 are explained by sudden decreases in the 
duration of treatment. These reductions lead to less resource requirements and workload 
in the control program. In the example, the incidence rate (Figure 4.5) and the prevalence 
of untreated cases (Figure 4.6) are not decreasing very fast, especially because individuals 
in the compartment ASYMPTOMATIC INFECTION build up contagiousness before diagnosis 
takes place. 
4.5 Discussion 
In developing the SIMLEP simulation model we made choices regarding aspects to be 
included and their level of detail, keeping in mind the objectives of SIMLEP: to be a 
useful tool in analyzing leprosy data and, in particular, to be valuable in predicting the 
effects of existing and potential control policies.  
Both objectives require characterization of processes underlying leprosy transmission. 
Several aspects relating to susceptibility and transmission are included: natural immunity, 
asymptomatic infections, differences in contagiousness between asymptomatic and 
symptomatic stages, and the decline in effective contagiousness over time. This decline 
reflects that household and other frequent contacts of highly contagious cases are 
probably already infected during the period shortly after the index case became 
contagious. 
A central issue is the impact of control on transmission. Control options can be described 
while taking into account limitations in their effectiveness. When specifying a SIMLEP 
vaccination program, one may account for incomplete coverage, less than 100% 
protective efficacy, and waning of protection over time. The influence of a control 
program on case detection can be simulated by its impact on two consecutive delays. The 
delays can be thought to represent becoming aware of leprosy symptoms and reporting 
the disease, respectively. The delays may, for example, decrease when short-term 
chemotherapy is introduced. Provisions for relapse and for susceptibility to new 
infections following cure limit the effectiveness of chemotherapy control. SIMLEP 
produces output on trends in age-specific prevalence, incidence and case detection rates 
in order to study the impact of the interventions vaccination, case detection and 
chemotherapy treatment. 
SIMLEP can assist in clarifying basic mechanisms that govern transmission and the 
natural history of leprosy as well as the impact of control. One could argue that the 
present structure of SIMLEP is too complex for this type of application. However, the 
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user may simplify the model structure within the SIMLEP framework according to his or 
her requirements. By selectively inactivating flows and compartments from the full 
SIMLEP structure, much simpler models can be simulated. For example, it is possible to 
simulate chemotherapy control strategies using a model with only the five compartments 
SUSCEPTIBLE, ASYMPTOMATIC INFECTION, SELF-HEALING SYMPTOMATIC LEPROSY, 
STRONGLY CONTAGIOUS SYMPTOMATIC LEPROSY and DIAGNOSED + ON CHEMOTHERAPY 
TREATMENT of Figure 4.1. 
On the other hand, SIMLEP may not be sufficiently comprehensive. Model extensions 
that are required when specific questions are addressed may often be incorporated in 
SIMLEP. Examples are excess mortality, separate contagiousness of self-healing 
infections, drug resistance and prolonged contagiousness after initiation of chemotherapy. 
The same applies to the distinction between males and females which is not yet included. 
But increasing the number of aspects covered in a compartment model such as SIMLEP 
quickly leads to an explosion of the number of states in the computer program, leading to 
unrealistic requirements regarding computer power. The population-based simulation of 
compartments also prohibits incorporation of certain aspects. This particularly applies to 
provisions for explicit and detailed modeling of high transmission risks in small groups 
such as households, or detailed modeling of individual (genetic / hereditary) differences 
in susceptibility, which require individual-based simulation. Note that these kinds of 
heterogeneity can substantially influence the age distribution of prevalence, incidence and 
case detection rates, and the impact of interventions on transmission. 
Quantification and validation 
Proper validation of a model is crucial for its usefulness as a tool for prediction, 
evaluation, and planning. Uncertainty about the validity of SIMLEP refers to both the 
structure of the model and to the quantification of the individual parameters, and reflects 
the state of knowledge on leprosy. This uncertainty is shared with any other approach to 
produce statements on leprosy epidemiology and its control. Levels of uncertainty about 
model parameters vary with the amount and quality of pertinent data that can be used for 
testing and quantifying assumptions. The age structure and life table can be obtained 
from demographic data which are available for most regions. Program registries give 
information on the type distribution of new symptomatic cases according to type of 
leprosy at the time of detection. Relapse rates after cure by dapsone monotherapy and 
multidrug therapy have been documented (23). Some data are also available on self-
healing and downgrading rates (21, 24). Crude estimates on delays between onset of 
disease and start of chemotherapy have been obtained in several control programs by 
interviewing patients (e.g. (25-28)). Vaccine trials give information on the extent to which 
vaccines can prevent new cases of leprosy (3) . 
There are also parameters for which it is much more difficult, if not impossible, to collect 
data. Due to a lack of diagnostic tools to establish M. leprae infection, knowledge is in 
particular limited on the incubation period, on the occurrence of asymptomatic infections 
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and natural immunity, and on leprosy transmission. The flexibility in SIMLEP can be 
used to explore and test a broad range of assumptions about transmission. The example 
can be used to illustrate that different combinations of assumptions may describe trend 
data equally well. We assumed that natural immunity does not occur, and that all 
individuals who have asymptomatic or symptomatic leprosy infections are contagious. 
However, the incidence rates in the pre-control period and in 1990, as shown in 
Figure 4.5, can also be obtained when 80% natural immunity is assumed among newborns 
or when contagiousness is assumed to be restricted to strongly contagious leprosy cases 
only, with simultaneous adaptation of transmission parameters, such as the level of weak 
contagiousness, the half-life time of the effectiveness in transmitting M. Leprae for 
strongly contagious individuals, and the contagiousness of a strongly contagious 
individual as expressed by SIMLEP’s internal transmission parameter β. 
Further confidence in the model is to be gained from extensive validation studies in 
which detailed data sets are being used. At present, SIMLEP is being validated on the 
long-term data describing the decline of leprosy in Norway between 1850 and 1920 (29). 
Model assumptions will be checked against age-specific information on trends in 
prevalence, incidence and case detection of leprosy by calendar year and birth cohort, 
using available information on the reporting delay and on changes in proportions of 
patients being isolated. Trends will be analyzed for areas with different initial endemicity 
levels in 1850. 
The mid-term and long-term impact of intensified case finding plus MDT treatment on 
leprosy transmission is still unclear. The transition phase from dapsone-based to MDT-
based programs often goes hand in hand with intensification of case detection efforts, 
which may lead to increasing new case detection rates, even if incidence rates are 
declining. Benefits of this change in policy in terms of reductions in leprosy transmission 
may also not directly be visible due to the long incubation period of leprosy. Further 
validation studies will be targeted at describing the impact of leprosy control (including 
BCG vaccination). The uncertainty about model assumptions, especially relating to 
leprosy transmission, can potentially be narrowed down by comparing SIMLEP results 
with data from recent intervention studies (e.g. (3, 30, 31)). These further validation 
studies are essential in making SIMLEP a useful tool for prospectively evaluating 
alternative intervention policies. 
Contribution to policy discussion 
Policy makers and epidemiologists face large gaps in knowledge about leprosy. Still, policy 
makers have to make decisions about leprosy control, and epidemiologists and leprosy 
experts are sometimes tempted to make quite forthright forecasts on future incidence and 
prevalence of leprosy (4). The SIMLEP example tried by us suggests that it may not be 
easy to achieve rapid declines in leprosy transmission through intensified case finding plus 
MDT. In situations like this that are fraught with uncertainties, a simulation model like 
the present SIMLEP can be a useful, independent input in rational reasoning about 
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leprosy. When experts and decision makers specify their knowledge and uncertainties 
about aspects of leprosy, the model can be used to predict the range of possible effects of 
these options. In future, we will analyze how sensitive predictions of trends and effects of 
control policies are for variations in the input parameters, and will identify those 
uncertain parameters that affect the predictions most. 
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4A Mathematical appendix 
This appendix gives a complete description of the SIMLEP model. Compartment names in this 
appendix refer to the flowchart (Figure 4.1) and are given in capital. Some compartments have 
been split up in sub-compartments in order to allow sojourn time distributions other than negative 
exponential and in order to allow the effectiveness of contagiousness to reduce over time. A 
complete set of equations describing the model is given at the end of this appendix. 
The sub-compartments Di,j (i=1,2,j=1,..5), E1, E2, F1, F2, G1, G2, G3, G4, J1 and J2 
Upon infection, individuals enter the compartment D which represents the asymptomatic period. 
This compartment is divided into two parallel chains of five successive stages (sub-compartments) 
with equal transition rates within each chain. This results in ten sub-compartments Di,j 
(i = 1,2,,j = 1,..5) with two transition rates λi (i = 1,2). 
The compartments SELF-HEALING SYMPTOMATIC LEPROSY (E) and DOWNGRADING SYMPTOMATIC 
LEPROSY (F) have been split up in E1 and F1 for individuals who are not (yet) aware of their 
disease, and E2 and F2 for individuals who have become aware of their disease. The 
compartment STRONGLY CONTAGIOUS SYMPTOMATIC LEPROSY (G) is also subdivided to allow for 
individuals who are and who are not aware of their disease. In addition, G is further subdivided 
into a category in which contagiousness is still fully effective, and a category for individuals with 
zero effectivity in transmitting M. leprae. Thus, G consists in fact of the following four sub-
compartments: 
G1 not aware of disease, full effectivity of contagiousness 
G2 not aware of disease, zero effectivity of contagiousness 
G3 aware of disease, full effectivity of contagiousness 
G4 aware of disease, zero effectivity of contagiousness. 
Individuals shift from full to zero effectivity of contagiousness with a transition rate λfoi loss. The 
average contagiousness closs of all people in G (see main text) is the weighted average of the 
effectivity of contagiousness of individuals in the compartments G1 and G3 (full effectivity), and G2 
and G4 (zero effectivity). Formulae for the force of infection are given elsewhere in this appendix. 
SIMLEP distinguishes two relapse rates, one for monotherapy, and one for multidrug therapy. The 
compartment J for individuals who are cured by treatment, and who are immune for new 
infections, but who can relapse, is split up accordingly: J1 comprises individuals who have been 
cured by monotherapy (corresponding relapse rate λrelapse,1), and J
2 reflects cure by multidrug 
therapy (corresponding relapse rate λrelapse,2). 
Transition rates and probabilities for transitions from compartments 
Transitions from most compartments are governed by transitions rates. SIMLEP applies the 
following transition rates: 
SIMLEP: MATHEMATICAL APPENDIX 
89 
)fromoccurs(relapsecuretherapy multidrugafterraterelapseλ
)fromoccurs(relapsecureymonotherapdapsoneafterraterelapseλ
timeatstrategycontrolunderusedregimendrugforratecureλ
),,,(timeatstrategy
controltheunderdiseaseofawarebeingwhentreatmentforreportingofrateλ
),,,(
timeatstrategycontroltheunderdiseaseofawarebecomingofrateλ
andinsindividualfortransmittocapabilitylosingofrateλ
toandfromgdowngradinofrateλ
and fromhealing-selfofrateλ
1,2)(infectionicasymptomatoftcompartmen-subpresenttheleavingofrateλ
2
J,relapse
1
J,relapse
t,cure
4322
t,X,chemo
2111
aware,X,t
31
lossfoi
321
downgr
21
heal
i
J
J
t
GGFEXt
GGFEX
t
GGlepraeM.
GFF
EE
i
2
1
=
=
=
=
=
=
=
=
=
=
==
 
SIMLEP is a discrete time simulation model in which people can only make one transition per time 
step, and in fact calculates transitions according to transition probabilities. For some 
compartments people can only move to one subsequent compartment. The probability p for 
occurrence of such a transition during a time step ∆t and the corresponding transition rate λ are 
interrelated through the negative exponential distribution via tp ∆λe1 ⋅−−= . The corresponding 
average sojourn time d (in years) in such a compartment is given by ptd /∆= . 
For a number of compartments, transitions to different destinations are possible because several 
events can occur. For these compartments, transition probabilities are derived by combining the 
negative exponential distribution functions that correspond with the transition rates. The exact 
formulae for each compartment are given at the end of this appendix. Three combination rules are 
possible:  
• the event that takes place first may determine the destination, e.g. self-healing or starting 
chemotherapy: see the equations for t,E,heal 2p  and t,E,chemo 2p   
• some events rule out others, e.g. becoming aware of disease is irrelevant if self-healing occurs 
in the same time step: see the equations for t,E,heal 1p  and t,E,chemo 1p  
• events can occur independently of each other in the same time step without excluding each 
other, e.g. becoming aware of disease and losing effectiveness of contagiousness: see the 
equations for t,G,lossfoi 1p , t,G,aware 1p  and t,G,both 1p . 
The average sojourn time in compartments from which multiple transitions are possible follows 
from the sums of the probabilities for these transitions to take place. 
Probabilities for determining the destination of transitions which do not depend on 
transition rates 
At birth, people can move to one of several compartments. Similarly, relapses can take place to 
each of the three types of symptomatic leprosy. The user can specify probabilities that determine 
the destination of such transitions.  
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The two chains of subcompartments D1,j and D2,j represent the slow and fast asymptomatic 
stages, respectively. The user specified probabilities q≠G and qG denote the probability of having a 
“short” asymptomatic period, i.e. of entering D1,1 upon infection. Probability q≠G applies to 
individuals who would eventually move to the compartment G1 and probability qG applies to 
individuals who would move to one of the other compartments (B,E1,F1 or H). The user also 
specifies the transition probabilities qDX which denote the probability that newly infected 
individuals who enter compartment D would eventually transfer to compartment X 
(X=B,E1,F1,G1,H). These individuals may however die during their stay in compartment D. 
SIMLEP therefore derives probabilities 5,1 XDq  and 
5,2
XDq  for transfering to compartment X 
(X=B,E1,F1,G1,H) upon having passed through (and having survived) the five stages of either 
chain. SIMLEP calculates these probabilities 5,1 XDq  and 
5,2
XDq  from the probabilities qDX , q≠G and 
qG (X=B,E
1,F1,G1,H).  
Summarizing, the probabilities which directly determine transition destinations and which do not 
depend on the transition rates are: 
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The force of infection 
G1 and G3 are by definition contagious, and G2 and G4 are not. Indicator functions indicate which 
of the compartments E1, E2, F1 and F2 have been specified to be (weakly) contagious, and for 
which destinations (E1,F1,G1, and B or H) buildup of contagiousness during the asymptomatic 
period D has been specified. An initial number of the sub-compartments D1,j and D2,j can still be 
specified to be non-contagious when buildup of contagiousness is assumed. The contagiousness 
is assumed to increase step-wise over the remainder of the five sub-compartments. This is taken 
care of through the function wbuildup. The force of infection FOIt at time t involves the transmission 
parameter β, weights for the relative contagiousness of individuals, numbers of individuals in the 
compartments that are contagious, and the total population size Nt at time t. In formula: 
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The order of calculations for birth, death, ageing and transitions between compartments 
At each time step, the compartments are first updated for the transitions that take place between 
them. Next, the updated compartments are corrected for deaths that occur during the time step. 
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Then, the age of the remaining (surviving) individuals is increased by one time step, and the 
newborns enter into the system with initial age 0. The number of newborns is calculated by 
multiplying the model parameter b (number of births per head of population per year) with the 
average of the population sizes before and after death, and with the length of the simulation time 
step ∆t. In the set of difference equations given below a simplified notation is used which does 
neither express this order of calculations nor the averaging of the population size before and after 
death for calculating the number of births in the time step. 
The set of difference equations for SIMLEP 
The following notations are used in the set of difference equations: 
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Transition probabilities and transition rates are inter-related as follows: 
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The resulting set of difference equations for SIMLEP is as follows (the superscript 1 of the 
compartments E1,F1 and G1 is omitted in destination probabilities q of transitions to these 
compartments): 
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5.1 Summary 
Background By the middle of the 19th century, leprosy was a serious public health problem 
in Norway. By 1920, new cases only rarely occurred. This study aims to explain the 
disappearance of leprosy from Norway. 
Methods Data from the National Leprosy Registry of Norway and population censuses 
were used. The patient data include year of birth, onset of disease, registration, hospital 
admission, death, and emigration. The Norwegian data were analysed using 
epidemiological models of disease transmission and control.  
Results The time trend in leprosy new case detection in Norway can be reproduced 
adequately. The shift in new case detection towards older ages which occurred over time 
is accounted for by assuming that infected individuals may have a very long incubation 
period. The decline cannot be explained fully by the Norwegian policy of isolation of 
patients: an autonomous decrease in transmission, reflecting improvements in for 
instance living conditions, must also be assumed. The estimated contribution of the 
isolation policy to the decline in new case detection very much depends on assumptions 
made on build-up of contagiousness during the incubation period and waning of 
transmission opportunities due to rapid transmission to close contacts. 
Conclusion The impact of isolation on interruption of transmission remains uncertain. This 
uncertainty also applies to contemporary leprosy control that mainly relies on 
chemotherapy treatment. Further research is needed to establish the impact of leprosy 
interventions on transmission.  
5.2 Keywords 
computer simulation, epidemiology, history, leprosy, Norway, patient isolation 
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5.3 Introduction 
Founded in 1856, the National Leprosy Registry of Norway documents the fall of leprosy 
in Norway. By 1920, new cases were only rarely detected. On the basis of the registry, 
Irgens analysed the disappearance of leprosy from Norway (1). Between 1856 and 1920, 
the new case detection rate steadily declined, whereas the ages of newly detected cases 
gradually but distinctly increased. The decline of leprosy coincided with changes in a 
number of factors which may influence the occurrence of leprosy and it has been shown 
to be associated with the policy of isolation of patients in hospitals which was 
implemented in Norway (1). The decline took place long before effective anti-leprosy 
treatment became available. 
Leprosy epidemiology is fraught with many uncertainties. In particular, knowledge on the 
relative contagiousness of different stages of leprosy is lacking. The uncertainties make it 
difficult to assess the impact of interventions on time trends in leprosy, especially when 
other factors influencing leprosy change simultaneously. Simulation models can help to 
organize knowledge and assumptions on diseases, and enable exploration of the 
occurrence of diseases in populations over time. This study uses a series of simulation 
models of leprosy transmission and control with the objective of further clarifying 
mechanisms underlying the Norwegian time trend data. The following questions are 
addressed:  
• Can the decline in leprosy be simulated? 
• Can the age-shift in new case detection over time be explained? 
• Can the contribution of isolation to the declining trend be assessed? 
First, a statistical model is used, which does not include assumptions about leprosy or the 
fact that an infectious disease is addressed (curve fitting). Next, a simple standard 
infectious disease transmission model is applied which does not yet include age. These 
models only allow for exploration of the overall trend in new case detection. As a third 
step, models are introduced with an explicit age dimension in order to explain the shift in 
new case detection to older ages over time, as observed in Norway (2). Differences in 
contagiousness before and after onset of clinical symptoms of leprosy influence the 
degree to which isolation can prevent leprosy transmission. Various model variants are 
therefore considered which make different assumptions on the transmission of 
Mycobacterium leprae in successive stages of leprosy. The age-specific models are 
implemented in the SIMLEP framework for modelling the transmission and control of 
leprosy (3).  
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5.4 Material 
History of leprosy and its control in Norway 
A historical overview of leprosy research and control in Norway indicates that leprosy 
was not regarded as a serious health problem by the Norwegian authorities prior to the 
1820s (4). Censuses of leprosy sufferers in 1836, 1845 and 1852 each time reported more 
new patients. Control measures were initiated following the 1852 census which reported 
1782 patients. A Chief Medical Officer for Leprosy was appointed, and local measures 
were entrusted to District Health Officers. By Royal Decree in 1856, the National 
Leprosy Registry of Norway was founded. The first leprosy hospital in Norway, St. 
George’s in Bergen, probably dates back to the 15th century. In 1849, a leprosy research 
hospital was completed. Three additional hospitals were built in the period 1854-1861. 
The total capacity in 1861 was 930 beds. In 1873, the leprosy bacillus M. leprae was 
discovered at the research hospital, and it became recognized that leprosy is an infectious 
disease. It was suggested that transmission could be reduced by isolation of contagious 
individuals from the general community. The admission to hospitals was voluntary up to 
1875. By legislation acts of 1877 and 1885, leprosy patients either had to be isolated in 
separate rooms in their homes, or had to be admitted to a hospital, if necessary with the 
help of the police. 
The National Leprosy Registry of Norway: patient data 
The National Leprosy Registry was computerized in the 1970s, and consists of a district 
register and a hospital register. A detailed description of the database is available (1). The 
database includes information on birth, onset of disease as recalled by the patient, 
registration, admission to hospital, death, and emigration. Years of birth and onset of 
disease are available for 98% and 94% of patients, respectively. The year of detection 
refers to the first entry in either the district register or the hospital register. It is known for 
all registry patients. Nearly 60% of registry patients had at least one hospital admission 
recorded, and 72% of these admissions were permanent. We will use the term isolation to 
refer to the first hospital admission of a patient. For 96% of registry patients, the year of 
either death or emigration is available.  
Trends in case detection 
The registry contains information on 8231 patients, including 213 patients who were 
admitted to a hospital before the founding of the registry in 1856. The secular trend 
before 1856 is uncertain. Annual numbers of patients detected during 1856-1920 and 
corresponding case detection rates are given in Table 5.1. In 1856, many patients were 
detected (1796). This reflects the registration of a backlog of prevalent leprosy cases. The 
declining trend in new case detection rate accelerated over time and was on average about 
7% per year during 1861-1920. Only 27 patients were detected after 1920.  
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The age distribution of cases detected during the period 1856-1920 is given in Table 5.2. 
The proportion of children is low. A shift towards older ages is observed after 1876: the 
percentage of newly detected cases of ages ≥ 35 increased steadily from 49% for 
1876-1885 to 66% for 1901-1920. Demographic data show that the age structure of the 
Norwegian population hardly changed between 1856 and 1920 (5).  
Times between onset, detection, isolation and emigration or death 
Table 5.3 gives the mean times between onset and detection, between onset and isolation, 
emigration or death, and between onset and emigration or death (intervals 1-3). The 
longer intervals for patients with onset of disease before 1856 are due to length bias in 
Table 5.1 New leprosy case detection in Norway, 1856-1920. 
Period 
Population 
(personyears) Number detected a 
Detection rate 
per 100,000 personyears 
1856-1860 7,671,135 2,833b 36.9 
1861-1865 8,199,131 1,146 14.0 
1866-1870 8,597,373 1,034 12.0 
1871-1875 8,828,299 797 9.0 
1876-1880 9,326,248 692 7.4 
1881-1885 9,620,933 428 4.4 
1886-1890 9,859,632 358 3.6 
1891-1900 20,958,385 411 2.0 
1901-1910 23,095,413 220 1.0 
1911-1920 24,997,694 72 0.3 
Total 7,991  
a Out of the 8,231 registry patients, 213 were detected before 1856, and 27 after 1920. 
b 1,796 cases were detected in the first year of the National Leprosy Registry, 1856. 
Table 5.2 Age distribution of newly detected leprosy cases in Norway, 1856-1920. 
Period Contribution of age groups to total new case detection (%) 
 0-14 15-24  25-34  35-44  45-59  60+ 
Total 
number 
detected 
1856-1860 5% 18% 26% 25% 12% 14% 2833 
1861-1865 8% 21% 24% 20% 15% 13% 1146 
1866-1875 8% 23% 24% 18% 16% 12% 1831 
1876-1885 5% 21% 24% 18% 18% 13% 1120 
1886-1900 6% 18% 20% 16% 18% 21% 769 
1901-1920 3% 13% 18% 17% 19% 30% 292 
Total 6% 20% 24% 21% 15% 15% 7991 
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registration: apart from the 213 early hospital admissions, the registry only includes those 
patients that survived up to the founding of the registry in 1856. The delay in case 
detection (interval 1) was somewhat shorter in the first 15 years of the registry as 
compared to later years. Interval 2 gives an indication of the period during which 
symptomatic leprosy cases can transmit M. leprae under the assumptions that the first 
isolation is permanent, and that isolated patients stop contributing to transmission. The 
mean length of this period decreased initially due to an increase in the proportion of 
patients who were isolated, and was rather stable during 1876-1920. Since only 1% of the 
patients emigrated, the time between onset and emigration or death (interval 3) reflects 
the life expectancy at onset of leprosy. A clear trend is not visible. The additional time 
during which leprosy cases could transmit M. leprae when isolation would not affect 
transmission is reflected in the difference between the intervals 2 and 3, which is smaller 
in early as compared to later years (about 3.5 to 5 years between 1851-1870 versus about 6 
years for 1876-1920). 
5.5 Methods 
Models 
Three modelling approaches are used: statistical curve fitting, a transmission model 
without age-dimension and age-specific transmission models. 
Table 5.3 Time from onset to events for leprosy patients, according to year of onset of disease, Norway, 
1800-1920. 
year of onset number a mean time (in years) 
  
onset 
to 
detection 
(1) 
onset 
to 
isolation, death or migration
(2) 
onset 
to 
death or emigration 
(3) 
< 1851 b 1088    12.2 18.6  22.0 
1851-1855 b 1201    3.8 9.4  12.9 
1856-1860 1154    2.8 8.0  12.7 
1861-1865 1009    2.7 7.3  11.8 
1866-1870 996    2.8 7.0  11.7 
1871-1875 716    3.2 6.9  12.3 
1876-1885 865    3.2 6.4  12.1 
1886-1900 551    3.5 6.1  11.9 
1901-1920 160    3.2 6.2  13.0 
a Concerns 7740 of the 8231 registry patients. For the remaining 491 patients, the year of onset was after 1920 
for 14 patients, and not available for 477 patients.  
b High values for mean times between events due to founding of registry in 1856, see text. 
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Statistical curve fitting 
To fit the observed trend in case detection, a regression model that does not involve any 
assumptions about leprosy is used. Inspired by visual inspection, the log-transforms of 
the new case detection rates D(t) with time t, ln(D(t)), are fitted by a quadratic regression 
model, ln(D(t)) = ln(D0) – a ( t  – t0 )
 2, with three free parameters time t0 (year in which 
the quadratic function starts to decline), D0 (the detection rate at time t0) and a (the 
strength of the quadratic decline in the log-transformed rates). This model is implemented 
in Excel. 
Simple transmission model without age-dimension 
The transmission model without age-dimension, shown in Figure 5.1, is also implemented 
in Excel. The in-flux of newborns in the SUSCEPTIBLE compartment is determined by a 
crude birth rate. Upon becoming infected, susceptible individuals move to 
ASYMPTOMATIC infection. A rate reflecting the length of the incubation period governs 
the transition from ASYMPTOMATIC infection to SYMPTOMATIC leprosy, i.e. the onset of 
clinical symptoms. The transition from SYMPTOMATIC to DETECTED reflects detection of 
leprosy. Detected patients who emigrate, die from leprosy or are isolated move to 
WITHDRAWN. The rates that describe the transitions to DETECTED and WITHDRAWN are 
referred to as ‘registration rate’ and ‘withdrawal rate’ respectively. All compartments are 
subject to death from other causes. Emigration rates as reported for the general 
population in Norway (5) are applied to the compartments SUSCEPTIBLE and 
ASYMPTOMATIC infection, which will contain most individuals.  
Transmission is caused by individuals in the compartments SYMPTOMATIC and 
DETECTED. A transmission parameter represents the level of their contagiousness. 
Downward trends in leprosy can be the consequence of leprosy control, but may also 
have other causes, such as improvement of general living conditions. These autonomous 
factors are accounted for by assuming that the initial transmission parameter β0 decreases 
by a constant annual reduction factor ∆β from a certain time t0 onwards. The resulting 
transmission parameter β(t) at time t beyond t0 thus equals 0)1(0 tt −− β∆β . The fraction 
of individuals in the SUSCEPTIBLE compartment that becomes infected in a time step ∆t is 
calculated as FOI × ∆t, with force of infection FOI equal to β(t) ( SYM + DET ) / N 
 (SYM, DET  = number of individuals in SYMPTOMATIC and DETECTED respectively; N = 
population size).  
A policy of isolation causes detected individuals to move faster from DETECTED to 
WITHDRAWN. This results in lower forces of infection. Anti-leprosy treatment of patients 
is not considered because it only became available long after the end of the study period.  
Age-specific models 
An age-specific version of the simple transmission model with age-specific death rates 
and emigration rates is considered first (Model I). Starting from this model, a series of 
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models is explored. These models are implemented in the SIMLEP framework for 
modelling the transmission and control of leprosy, which was adapted to allow for 
emigration. SIMLEP uses a different time distribution for the duration of the incubation 
period to the simple transmission model (see below). A detailed description and 
discussion of the SIMLEP modelling framework has been provided before (3). 
Directly estimated model parameters 
Parameters of the simple transmission model and of the corresponding age-specific 
Model I are estimated as follows.  
                          
SUSCEPTIBLE
birth rate
force
of
infection
                          
ASYMPTOMATIC
                          
SYMPTOMATIC
                          
DETECTED
                          
WITHDRAWN
rate
(reflects mean length
of incubation period)
registration rate
(reflects detection
of leprosy)
withdrawal rate
(reflects isolation,
emigration or death
with leprosy)
All compartments:
- death rate for all causes but leprosy
Compartments
SUSCEPTIBLE and ASYMPTOMATIC:
- emigration rate
Figure 5.1 The transmission model. 
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Birth, death and emigration 
The birth rate and the crude and age-specific death rates for the middle decade 1881-1890 
of the period 1851-1920 (5) are used in all simulations. The birth rate and crude death rate 
are 30.8 and 17.1 per 1000 population, respectively. The total and age-specific emigration 
rates vary over time and were derived from data that are available from 1836 onwards 
(5, 6).  
Incubation period 
The simple transmission model uses a constant transition rate based on a mean length of 
the incubation period of 11.0 years. The age-specific models use a time distribution with a 
mean duration of 8.6 years and less variation (five phase Erlang distribution (3)). The 
mean durations of the incubation period have been estimated from war veteran data (7).  
Registration rates 
These rates are derived from the observed mean times between onset of clinical 
symptoms and detection (Table 5.3: column 2), adjusted for death from all causes. The 
corresponding mean sojourn times in SYMPTOMATIC from the year 1857 onwards are 
given in Table 5.4 (the period before 1857 is addressed under ‘Fitting the Norwegian 
leprosy trend data’). 
Withdrawal rates 
The withdrawal rate w is based on the sojourn time distribution which minimizes the 
difference (using the Kolmogorov-Smirnov criterion) between: 
(1) the distribution of the recorded times between onset and isolation, emigration or 
death, and 
(2) the distribution of the total time in SYMPTOMATIC and DETECTED that results from 
subsequent application of the registration rate and this withdrawal rate w itself. 
To investigate the impact of isolation, withdrawal rates are also estimated from the 
recorded times between onset and emigration or death only. All withdrawal rates are 
corrected for death from other causes. The corresponding sojourn times in DETECTED 
are given in Table 5.4.  
Table 5.4 Mean sojourn times in the SYMPTOMATIC and DETECTED disease stages, according to year of onset of 
disease. 
year of onset mean sojourn time (in years) 
 in SYMPTOMATIC 
in DETECTED: 
with isolation policy 
in DETECTED: 
without isolation policy 
1857-1860 2.9  3.8 10.1  
1861-1870 2.9  2.9 10.2  
1871-1875 from 2.9 to 3.5 from 2.9 to 1.7 from 10.2 to 9.0 
1876-1920 3.5  1.7 9.0  
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Age-specific model: variants 
Starting from Model I, variants involving assumptions about the following six aspects of 
transmission and of course of infection and disease (A1-A6) are explored.  
A1 Geographic heterogeneity in exposure 
In Norway, 98% of leprosy cases with onset between 1851 and 1920 originated from the 
counties in West and North Norway. The percentage of the Norwegian population living 
in these counties was stable at about 47% (1). Model I assumes homogeneous exposure 
of the susceptible population. The alternative assumption is that 53% of newborns will 
never be exposed to M. leprae. 
A2 Genetic heterogeneity 
Leprosy infection has been considered to be far more common than clinical leprosy (7, 8). 
The extent to which genetic factors influence the outcome of infection with M. leprae is as 
yet unknown (9). Model I assumes that every infection leads to clinical disease. The 
alternative assumptions are that 45% and 90% of individuals self-heal from infection 
without developing clinical disease. It is assumed that individuals who self-heal after 
becoming infected will not be re-infected and have immunity from ever developing 
clinical leprosy disease.  
A3 Waning of transmission opportunities 
Close contact to a leprosy patient, in their own household or through neighbours and 
social contacts, may be important for leprosy transmission. Since a contagious individual 
may infect close contacts rapidly, opportunities to transmit M. leprae may decrease with 
longer duration of disease. Model I neglects this possibility. In three alternative 
assumptions, it is assumed that the contribution of individuals with SYMPTOMATIC leprosy 
to transmission gradually decreases after onset of clinical symptoms, being halved every 2, 
4 and 8 years, respectively.  
A4 Build-up of contagiousness during ASYMPTOMATIC infection 
Model I assumes that contagiousness of leprosy requires the presence of clinical 
symptoms, but this may not necessarily be true (10). The alternative assumption is that 
contagiousness builds up gradually from zero immediately after infection to the maximum 
level at onset of clinical symptoms.  
A5 Age at maximum exposure 
In Model I, exposure to M. leprae is assumed to be independent of age. SIMLEP offers 
the provision to specifying that exposure gradually increases from zero at birth to a 
maximum level from a certain age onwards. The alternative assumptions are that 
maximum exposure is reached at the ages of 1, 2,..., 10 years.  
A6 Tail of the incubation period 
The war veteran data on incubation periods involve small numbers of patients and only 
relate to adults becoming infected (7). The maximum time span available for diagnosis 
after leaving for service abroad was about 25 years for the vast majority of the veterans 
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(11-13). It has been suggested that manifestation of disease can be due to a mechanism 
similar to endogenous reactivation in tuberculosis (i.e. the manifestation is due to bacilli 
that were acquired earlier in life, and which persisted as dormant bacilli within the body) 
(8). This is not considered in Model I. The alternative assumption is that the distribution 
of the incubation period is a mix of a distribution with a mean of 8.5 years (as in Model I) 
and an essentially lifelong distribution (mean of 50 years) that expresses endogenous 
reactivation (two five-phase Erlang distributions).  
Fitting the Norwegian leprosy trend data 
All models are fitted to the Norwegian trend data. For each model, the values for the 
‘free’ parameters are determined that minimize the difference between the observed and 
the estimated numbers of newly detected cases in successive time periods. The three free 
parameters for the quadratic model are a, D0 and t0. The three free parameters for the 
transmission models are: 
• β0: the initial value of transmission parameter β, 
• ∆β: the annual proportional decrease in the transmission parameter which reflects 
‘autonomous decline’ (i.e. secular decline due to factors other than isolation), 
• t0: the year in which the autonomous decline starts. 
Age-specific models that involve assumption A6 have a fourth free parameter: 
• the fraction of newly infected individuals with a mean of 50 years for the time 
distribution of the incubation period. 
Simulations with the transmission models start in the year 1830 from a stable 
epidemiological situation, which is calculated on the basis of the model parameters 
(including the free parameter β0). The decline in the simulated new case detection rates 
over time depends on changes in both registration and withdrawal rates (Table 5.4), and 
on the strength of the autonomous decline. 
We quantify the free parameters of the quadratic model and the simple transmission 
model by fitting these models to the data on total new case detection from the period 
1856-1920, using Excel’s solver utility. The observed numbers of new cases Oi are given 
in Table 5.1. The model-generated new case detection rates are combined with the sizes 
of the Norwegian population for deriving the estimated numbers of newly detected cases 
Ei. The fit is evaluated as the weighted sum of the squared differences between observed 
and estimated numbers of cases for the nine time periods from 1861 onwards, 
(Table 5.1): 
i
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The age-specific Model I and variants with assumptions from A1 to A6 are quantified 
using the Nelder & Mead Simplex optimization method (14). Observed numbers Oi,j of 
cases detected in time period i and age group j follow from Table 5.2 (five time periods, 
CHAPTER 5 
106 
six age groups). Estimated numbers Ei,j again follow from simulated new case detection 
rates and Norwegian population data, and the weighted sum of the squared differences 
for evaluating age-specific models is calculated as: 
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First, Model I is fitted to the age-specific Norwegian trend data. Subsequently, a forward 
stepwise procedure is applied which with each step adds a new assumption from A1 to 
A6 to Model I. In each step, the assumption that is added is the one that gives the largest 
improvement in the goodness-of-fit score D2. The stop criterion is a less than 10% 
improvement in D2. The resulting model will be referred to as Model II.  
The period before 1856 
Case detection data before 1856 are very incomplete. The completeness of detection 
efforts in 1856 is not exactly known. Therefore, data from 1860 onwards are used to fit 
the models. We only marginally considered the early years, as follows. We assumed a 
detection delay of 12 years before 1856, and 90% detection of SYMPTOMATIC cases in 
1856. Model quantifications are only rejected when the estimated and observed number 
of newly detected cases in 1856-1860 differ by more than 10%.  
Impact of isolation 
The impact of isolation is estimated using Model II by comparing the average annual 
decline dtot as calculated from the simulated new case detection rates for 1861 and 1920, 
with results of a simulation which ignores the isolation policy by only using withdrawal 
rates that refer to emigration and death (Table 5.4). The average annual decline over 
1861-1920 for this simulation, dsec, is due to other factors than isolation (autonomous 
decline). The simulated contribution of isolation to the decline is estimated as 
( dtot –  dsec ) / dtot . 
In a sensitivity analysis of the impact of isolation, extensions to Model II are considered 
with assumptions from A1 to A6 that were not yet included due to the stop criterion in 
the forward stepwise procedure. Only those assumptions are selected for which the 
goodness-of-fit score D2 of Model II does not decrease by more than 10%. The impact of 
isolation is also determined for these variants.  
5.6 Results 
Trend in total new case detection 
The new case detection data of Table 5.1 are more or less equally well fitted by the 
quadratic model, the simple transmission model and the corresponding age-specific 
version (Model I). The goodness-of-fit scores equal 17, 17 and 22, respectively 
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(Table 5.5). Statistically significant differences (p < 0.05) between data and model results 
are observed for the consecutive periods 1876-1880 (estimates lower than data) and 
1881-1885 (estimates higher than data). The less good fit for Model I is entirely 
attributable to these two periods. For the decade 1876-1885 as a whole, estimated total 
new case detection deviates by less than 1% from the Norwegian data for all three 
models. 
The decline in new case detection rate in Norway accelerated over time. The quadratic 
model estimates an increase in decline from 4.5% during 1861-1880 to 9.2% during 1901-
1920 (Figure 5.2). The simple transmission model and the age-specific Model I estimate 
that both the overall decline and the autonomous decline in transmission started in the 
1860s. The fit of the age-specific Model I worsens considerably when the start of the 
autonomous decline is postulated to occur before 1855.  
Age-specific trend in new case detection 
The fit of Model I to the age-specific Norwegian trend data from Table 5.2 is poor. Too 
many child cases are estimated for all time periods considered, and also too few cases of 
ages ≥ 60 for 1896-1900 and 1901-1920. The reason for the latter finding is that Model I 
fails to reproduce the observed shift in new case detection towards older ages: the 
estimated percentage of new cases of ages ≥ 35 only increases by 2% between 1876-1885 
and 1901-1920 (Model I: 48% versus 50%; data: 49% versus 66%). The child case group 
Table 5.5 Start of autonomous decline and goodness-of-fit score for the fit of different model variants against 
Norwegian leprosy new case detection data, 1856-1920. 
Model a 
Start of autonomous  
decline 
Goodness  
of fit score 
evaluation: trend in total new case detection  
Quadratic regression model n.a.  17  
Simple transmission model 1863  17  
Model I 1868  22  
evaluation: age-specific trend in new case detection  
Model I 1861  204  
Model I + A5 b 1866  104  
Model I + A5 + A6  1867  79  
Model I + A2 + A5 + A6 c 1866  66  
Model II = Model I + A1 + A2 + A5 + A6 1865  60  
a A1: Geographic heterogeneity in exposure; A2: Genetic heterogeneity; A5: Age at maximum exposure; 
A6: Tail of the incubation period. 
b With age at which maximum exposure is reached: 4 years (A5). 
c With percentage of new infections that self-heal without manifestation of clinical disease: 90% (A2). 
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and the failure to reproduce the age shift together account for more than 60% of the 
goodness-of-fit score of Model I, which equals 204 (Table 5.5). 
The largest improvement of the fit is obtained by extending Model I with assumption A5: 
the goodness-of-fit score halves by assuming that maximum exposure is reached at age 4, 
due to much better estimates for the child case group (Model I + A5). First adding 
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Figure 5.2 Trend in total new case detection rate: comparison between observed data and estimates by the
quadratic regression model for log-transformed new case detection and by the first age-specific transmission
model (Model I), Norway, 1856-1920. 
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assumption A6 also leads to a major improvement: assuming a long tail for the 
distribution of the incubation period results in a satisfactory reproduction of the age shift 
and a goodness-of-fit score of 145 (Model I + A6).  
Table 5.5 shows that stepwise extension of Model I with A5 and A6 reduces the 
goodness-of-fit score to 79. By adding the assumptions A2 (genetic heterogeneity with 
90% self-healing infections) and A1 (geographic heterogeneity in exposure) in the next 
two steps, the score further improves to 60. The resulting model is denoted as Model II 
(= Model I + A1 + A2 + A5 + A6). The fitting results for Model II are as follows: the 
autonomous decline in transmission starts in 1865, and 9.7% of newly infected individuals 
have a long incubation period (mean duration of 50 years) which causes ages at detection 
to increase with time. No substantial further improvement is achieved by adding the 
remaining assumptions A3 and A4. 
Table 5.6 and Figure 5.3 compare age-specific new case detection as simulated by Model 
II with the observed Norwegian data. No important systematic under- or overestimation 
of child cases (ages 0-14) occurs. The shift in new case detection towards older ages over 
time is reproduced well: the estimated percentage of new cases of ages ≥ 35 increases 
from 50% for 1876-1885 to 65% for 1901-1920 (data: 49% to 66%). Statistically 
significant differences between estimated and observed numbers of newly detected cases 
are observed in 4 out of the 30 cells of Table 5.6. These differences are largely due to 
fluctuations in observed new case detection rates with age which are not well understood: 
from 1861 to 1885, the rates were highest for the age group 25-34, and lower for the age 
group 45-59 than for those of ages ≥ 60 (Figure 5.3). These fluctuations are also largely 
responsible for the difference in the age-specific fits of Model II itself and the earlier 
Model I + A5 + A6 which includes the two assumptions that influence the goodness-of-
fit most. The importance of this difference is not clear, and some caution in the 
comparative judgement of these two models is indicated. 
 
Table 5.6 Age-specific new case detection: comparison between estimates by the age-specific Model II and 
observed data, Norway, 1861-1920. 
Period New case detection: difference (%) between estimated (E) and observed (O) numbers by age a 
   0-14 15-24 25-34 35-44 45-59 60+ 
1861-1865 17%  11% -11% -13% 4%  -8%  
1866-1875 2%  8%   -13%b -4% 15%c 0%  
1876-1885 13%  7% -13%b -14% 12%  7%  
1886-1900 -34% b 1% 0% 4% 12%  -11%  
1901-1920 27%  18% -9% -14% 16%  -9%  
a Differences calculated as (E-O) / E. 
b p < 0.05. 
c p < 0.01. 
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Role of isolation 
The contribution of isolation to the simulated decline in new case detection rate over 
1861-1920 is 60% for Model II, and 68% for the earlier Model I + A5 + A6 which 
excludes geographic and genetic heterogeneity. Seven new models result from extending 
Model II with the remaining assumptions regarding waning of transmission opportunities 
(A3) and build-up of contagiousness during the incubation period (A4) (Table 5.7). Since 
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Figure 5.3 Trend in age-specific new case detection rate: comparison between observed data and estimates by
the age-specific Model II. 
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the fits do not worsen by more than 10%, these new models are all included in the 
sensitivity analysis for investigating the role of isolation. Table 5.7 shows that the 
contribution of isolation strongly depends on the precise assumptions made: it varies 
between almost no impact (3%) and 39% (Model II: 60%). The contribution decreases 
with more rapid waning of transmission opportunities (A3) and/or with build-up of 
contagiousness during the incubation period (A4). This is not surprising because less 
transmission can be prevented through isolation under these assumptions, which 
necessitates a stronger autonomous decline that starts earlier in order to arrive at good fits 
of the data. The start of the autonomous decline varies from 1846 to 1857 for the seven 
new models (Model II: 1865). 
5.7 Discussion 
The disappearance of leprosy in Norway has been analysed by epidemiological models 
that explain both the time trend in total new case detection and the shift towards older 
ages. Various model variants are capable of explaining the data, but the estimated impact 
of isolation varies widely between these variants. 
Reproduction of the Norwegian trend data 
The quadratic regression model fits the accelerating decline in total new case detection 
well but it does not provide insight into the mechanisms (including the isolation policy) 
which may have governed the declining leprosy trend. A simple transmission model also 
produces this acceleration. Its age-specific version has two problems: too many child 
cases are predicted, and the shift in new case detection towards older age groups is 
missed.  
Table 5.7 Sensitivity analysis: estimated contribution of isolation to the total decline in new case detection rate 
for Model II and variants of Model II, Norway, 1861-1920. 
Contribution of isolation to decline Half-value time  
for transmission 
opportunities a Build-up b: no   Build-up b: yes 
infinite c 60%d 36%  
8 years 39%  17%  
4 years 27%  9%  
2 years 14%  3%  
a Reflects waning of transmission opportunities due to rapid transmission to close contacts (A3). 
b Build-up of contagiousness during ASYMPTOMATIC infection: yes or no (A4). 
c No waning of transmission opportunities. 
d Estimated contribution of isolation for Model II. 
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The problem with detection rates in children is solved by letting the exposure to M. leprae 
gradually increase from zero at birth to a maximum level that is reached in young 
childhood. We are aware that this assumption is rather arbitrary. International data on 
age-specific new case detection rates vary. Peaks in the age group 10-20 have been 
observed several times (7). A study from Bangladesh shows a peak in the new case 
detection rate for ages 10-14 in females, while rates continue to rise in males until age 25 
(15). In Norway, new case detection rates are highest for the age group 25-34 during the 
first few decades of the study period (Figure 5.3). Causes that may underlie this variation 
include the role of intra-household transmission and the duration of the incubation 
period which appears to be related to the type of leprosy (7) (the frequency of 
lepromatous leprosy was always high in Norway (1)). In addition, the extent of natural 
immunity, factors related to gender, endemicity levels of leprosy, and operational factors 
(case detection methods) may be relevant. 
Different explanations are possible for the observed shift in new case detection towards 
older age groups. Firstly, detection may have been delayed longer, however, no important 
increase in the detection delay was found in the registry data. Secondly, case detection at 
older ages is limited by the decreasing number of remaining susceptibles when 
transmission is high. A decrease in transmission will lead to an increase in the number of 
susceptibles at older ages, and thus to an increase in infection rate at older ages. However, 
leprosy transmission was quite low even at the start of the study period, and the 
susceptibles constitute the largest part of the population throughout the study period.  
The third explanation relates to the incubation period. The fraction of new cases with 
long incubation periods will increase over time with decreasing transmission levels, which 
will cause ages at detection to go up. The variance in the time distribution of the 
incubation period should be sufficiently large to reproduce the observed age shift. We 
reproduce this age shift by adding a long tail to the baseline incubation time distribution 
(Figure 5.3). According to this distribution, 7% of all incubating individuals has an 
incubation period of at least 25 years. This percentage is still compatible with further 
analyses of the war veteran study which showed that the follow-up period did not exceed 
25 years for the vast majority of the war veterans (7, 11-13). The long incubation periods 
are consistent with the suggestion that reactivation of bacilli that were acquired earlier in 
life, and which persisted as dormant bacilli within the body (endogenous reactivation) 
may play a role in the manifestation of leprosy disease (8).  
Due to the transmission cycle, detected numbers of cases in subsequent time periods are 
interdependent. In addition, sizeable fluctuations in observed numbers of detected cases 
occur over time and with age which are difficult to explain. Therefore, we considered a 
formal χ2 test overkill, and restricted ourselves to comparative analysis of the various 
models and their fits. The SIMLEP model framework which has been used for the age-
specific models is limited in possibilities for varying model assumptions. More freedom to 
vary model parameters could potentially result in much lower values of the age-specific 
goodness-of-fit score.  
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Role of the isolation policy 
The isolation regime in Norway was relatively mild: hospital patients had full freedom of 
movement, but had to spend the night in hospital (4). An earlier epidemiological analysis 
showed that the degree of isolation, a measure reflecting how often and long patients were 
hospitalized, was associated with relative falls in leprosy incidence rates between 
subsequent decades in different counties (1). Both the degree of isolation and the decline 
in incidence rate increased over time.  
Our study shows that the model variants that are compatible with the observed age-
specific trend data lead to a broad range of estimates for the contribution of isolation to 
the decline (from 3% to 60%). The impossibility of measuring contagiousness is an 
important cause of this broad range. The estimated contribution of isolation to the 
decline was lower when much of the transmission was assumed to occur before the onset 
of symptoms. Discussions are ongoing on who is responsible for leprosy transmission. 
Cree et al (10) suggest that infection from ‘subclinical sources’ may be more important 
than infection from symptomatic cases. There is even evidence from Norway and from 
other countries suggesting existence of environmental sources of infection in addition to 
human sources (16, 17). 
The estimate for the role of isolation also became lower when transmission opportunities 
were assumed to wane during the infectious period. Whether and to what extent waning 
really occurs is not known. It is more likely to occur if close contact to a patient is 
important for the transmission of leprosy. Family clustering of patients was observed in 
Norway despite of incomplete information (1). By also considering neighbour and social 
contacts, a recent study of an Indonesian village showed that close contact may be more 
important for transmission than is commonly believed: out of 101 cases newly detected 
over a period of 25 years, 78% could be associated to other patients (household contact: 
28%, neighbours and neighbours of neighbours: 36%, social contacts: 15%) (18). The 
suggestion that many individuals who become infected with leprosy do not develop 
clinical leprosy disease (7, 8) further supports hypothesising waning of transmission 
opportunities. 
The model from which the sensitivity analysis for the role of isolation started, Model II, 
assumes geographic and genetic heterogeneity. The estimated contribution of isolation to 
the decline was somewhat higher when these heterogeneities were ignored (68% versus 
60%). In endemic areas, individuals not developing leprosy through endogenous 
reactivation may well have shorter incubation periods than the war veteran data (7) 
suggest. Shorter incubation periods reduce the turnaround time of the transmission cycle, 
thus increasing the estimated impact of isolation on reported trends. The estimated  
contribution of isolation indeed increases from 60% to 67%, when a mean duration of 6 
instead of 8.5 years is used for the incubation period in Model II (a similar fit is realized, 
and the long tail is maintained). Smaller means resulted in too rapid declines in new case 
detection rate in the first few decades of the study period.  
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More complex models could be considered. For instance, we do not distinguish between 
different types of leprosy disease. Also, we do not take gender differences into account. 
Undoubtedly, adding complexity would lead to other estimates of the contribution of 
isolation to the decline. However, such additions would not tackle the problem of 
measuring contagiousness, and the uncertainty regarding the role of isolation will remain. 
Therefore, further complexity would not add to the insights gained through the present 
analysis.  
Other contributing factors 
We represented the way transmission may be influenced over time by factors other than 
isolation simply by a constant annual reduction factor. The earlier epidemiological study 
identifies several such factors (1). These include nutritional conditions, a rise in 
tuberculosis, and selective emigration to overseas countries. At farm level, the occurrence 
of leprosy is shown to be associated with a low production of oats and milk. No doubt, 
nutritional conditions greatly improved during the second half of the 19th century (1). 
This is in line with a historical analysis of the Norwegian economy by Bergh et al which 
shows growth in the production per capita from 1830 onwards after centuries of 
economic stagnation (19). This growth continued virtually without interruption for the 
next 150 years. Thus, the Norwegian population may, due to improved nutritional 
conditions, have been rendered more resistant to infections with M. leprae (1), which may 
have originated from environmental sources (16). Morbidity rates of tuberculosis, which 
may protect against leprosy (7), either by immunization or by competing risk, increased in 
Norway until beyond the turn of the 19th century (1). The increase was relatively high in 
the coastal counties (leprosy was particularly frequent in the coastal counties). Emigration 
heavily influenced the Norwegian demography (20). It was particularly frequent in areas, 
and in age and sex groups, with high leprosy incidence rates. The assumptions made on 
emigration in this study hardly affect estimated impacts of isolation. We could, however, 
not exclude whether selective emigration would affect estimates on the impact of isolation.  
Relevance for contemporary leprosy control  
The estimated impact of isolation strongly depends on assumptions made about leprosy 
transmission. The results also have a modern interpretation, because both isolation and 
anti-leprosy treatment of patients, which became available long after leprosy had 
disappeared from Norway, prevent leprosy transmission. Nowadays, early case detection 
followed by chemotherapy treatment (multidrug therapy: MDT) forms the mainstay of 
leprosy control. It is unclear to what extent present-day control influences leprosy trends 
in populations. Currently, we are performing a model-based scenario analysis to predict 
plausible leprosy trends up to 2020 and the influence of present day control. The scenario 
predictions are complicated by the same factors that we encountered in the evaluation of 
the decline of leprosy in Norway. A logical next step in our approach would be a model-
based analysis of long-term trends in geographical areas with comparable general 
conditions, but with different well-documented leprosy control policies. Such data would 
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enable further clarification of the forces driving leprosy trends, but are unfortunately not 
readily available. Epidemiological studies which apply modern diagnostics and address 
different hypotheses on leprosy transmission (e.g. (10, 17, 18)) may improve knowledge 
on leprosy transmission. Further development, testing and application of various 
diagnostic tools is required, including serological tests and tests using skin reagents for 
detection of subclinical and early clinical leprosy, DNA amplification for detection of 
carriage of M. leprae in nasal swabs, and DNA fingerprinting to distinguish between 
different strains of M. leprae. Improved knowledge about the contagiousness of 
individuals and the process of leprosy transmission would greatly improve the conditions 
for evaluation of the impact of interventions such as early case finding in combination 
with chemotherapy treatment, vaccination strategies, and chemoprophylaxis of close 
contacts of leprosy patients. 
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6.1 Summary 
Objective To investigate the impact of the current strategy for the elimination of leprosy on 
its incidence and to assess the consequences of failure to sustain this strategy.  
Methods Scenarios for assessing the impact of the elimination strategy were implemented 
in a computer simulation program. The scenarios reflected the assumptions made 
regarding contagiousness, transmission and bacille Calmette-Guèrin (BCG) vaccination. 
The trend in case detection rate for the main countries in which leprosy was endemic 
during 1985-1998 was fitted, and incidence up to 2020 was projected. 
Findings Owing to the gradual shortening of delays in detection up to 1998, and because 
of the low relapse rate that occurs with multi-drug treatment (MDT), incidence is 
predicted to decrease beyond 2000 in all scenarios. The annual decline was a few per cent 
higher when favourable assumptions were made about protection and coverage of BCG 
vaccination. Overall, the predicted annual decline in incidence rates ranged from 2% to 
12%.  
Conclusion The elimination strategy reduces transmission, but the decline may be slow. 
Relaxation of control after 2005 is unjustified given the uncertainty about the rate of 
decline and the adverse effects of longer delays in detection. A long-term strategy for 
leprosy control should be adopted. 
6.2 Keywords  
Leprosy / Elimination; Early detection; Chemotherapy; BCG vaccination; Computer 
simulation 
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6.3 Introduction 
The mainstay of current leprosy control is early detection and treatment with MDT. The 
number of patients receiving treatment declined after implementation of MDT because 
the period of treatment for MDT is shorter than that for dapsone monotherapy. At the 
same time, the annual number of new leprosy cases increased (1). These contrasting 
trends result from changes in control programmes, and the impact of MDT-based control 
on transmission is unknown.  
MDT was introduced in 1982 because of the emergence of resistance to dapsone 
monotherapy (2). Relapse rates are low (3). MDT has improved the image of leprosy as a 
curable disease and has led to increases in the commitment of national health services to 
finding and treating leprosy patients (4, 5). In 1991 optimism about the impact of MDT 
led the World Health Assembly (WHA) to pass a resolution to “eliminate leprosy as a 
public health problem” by the year 2000. This elimination target led to intensive case-
finding campaigns, called “leprosy elimination campaigns” in the late 1990s. The WHA 
resolution has therefore indirectly caused the increase in global case detection. 
The elimination target was defined as a prevalence of less than one person per 10 000 
population registered for treatment by the year 2000 (6-8). During this year, the number 
of patients registered for treatment worldwide fell below the target level (9). This 
achievement was largely the result of two operational factors: the duration of treatment 
was shortened, and patients not in need of treatment, but possibly with disabilities, were 
removed from registries (10, 11). This elimination target differs from the concept of 
“elimination of an infectious disease”, which is defined as the absence of incident cases in 
a defined geographic area (12).  
In order to reach the elimination target in all countries by the end of 2005, the World 
Health Organization (WHO) formulated a strategy based on early case detection and 
MDT, called “the Final Push” (13). This strategy is intended to “reduce the leprosy 
burden to very low levels, and therefore liberate resources to address other health 
priorities in the community”. In response, the editor of Leprosy Review pointed out that 
there is no evidence that reaching the target will reduce transmission, and expressed 
serious concerns regarding the fulfilment of future demands to control leprosy (11).  
An assumption underlying the elimination strategy is that MDT will reduce transmission 
through reduction of the number of contagious individuals in the community, but 
evidence to support this assumption is lacking (14-16). Data to evaluate the impact of 
MDT are not readily available, for several reasons. Because leprosy has a long and 
variable incubation period (17), decreases in transmission only gradually become evident. 
Also, declines in case detection may have other causes, such as BCG vaccination. BCG 
vaccination is used against tuberculosis, but appears to afford greater protection against 
leprosy (18). Variability in control efforts further complicates the interpretation of trend 
data.  
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How much transmission a control strategy can prevent depends on two unresolved issues. 
Is the incubation period contagious, and, are close contacts of a patient infected rapidly? 
In this article, we describe scenarios based on certain assumptions regarding earliness of 
case detection, the above-mentioned unresolved issues and BCG vaccination. These 
scenarios were explored using the epidemiological modelling framework known as 
SIMLEP which was designed for assessing and predicting trends in leprosy (19). For each 
scenario, the trends in incidence and case detection up to 2020 were projected. By 
comparing the projections, the impact of the current MDT-based elimination strategy 
could be explored. An analysis of the sensitivity of the projections for uncertainties in 
leprosy epidemiology was undertaken. Finally, the consequences of relaxation of the 
elimination strategy beyond 2005 were predicted. 
6.4 Methods  
SIMLEP distinguishes states to describe the course of leprosy infection and disease. 
Changes in these states are determined by epidemiological parameters. The parameter 
values and a set of mathematical equations determine how an epidemiological situation, 
i.e. the proportions of the total population within the various states, evolves over time. 
Different models can be specified within SIMLEP. The essential features of the model 
used in this study are as follows. The number of births is based on a birth rate applied to 
the general population. Newborns are susceptible to leprosy and susceptible individuals 
can become infected as a result of transmission. New infections self-heal, or progress 
either to contagious disease which does not self-heal, or to non-contagious disease which 
self-heals, i.e. the patient becomes free from bacteria. Self-healing is a well-recognized 
phenomenon (17, 20, 21). The appearance of the first clinical symptom denotes the onset 
of disease, or incidence. A transmission parameter reflects the contagiousness of 
individuals with contagious disease. SIMLEP considers two interventions: (early) case 
detection followed by chemotherapy, and BCG vaccination, with the associated states “on 
treatment” and “vaccinated”, respectively. The time between onset of disease and case 
detection, or detection delay, reflects the length of time for which an individual with 
contagious disease can transmit Mycobacterium leprae, and can be varied in SIMLEP. 
Further assumptions regarding transmission and interventions are varied in the scenario 
analysis, see below. SIMLEP is age-specific. A life table governs mortality. 
The appendix gives more details on the model used including a graphical representation, 
and provides the quantification of the parameters. A detailed description of SIMLEP is 
provided elsewhere (19). SIMLEP is conceptually similar to models for tuberculosis 
(22, 23). 
Transmission of leprosy  
Two gaps in knowledge were found to be critical in a SIMLEP-based investigation of the 
role of control in the disappearance of leprosy from Norway (24). 
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Does contagiousness build up during the incubation period of leprosy? Contagiousness does not 
necessarily require the presence of clinical symptoms. We consider two possibilities; the 
first is that there is no contagiousness during the incubation period, and the second, that 
there is gradual build-up of contagiousness during the incubation period. The level of 
contagiousness is assumed to be constant after onset of disease.  
Do opportunities to transmit M. leprae decrease over time? Because close contacts, who are the 
people most at risk, may be infected rapidly, the opportunities to transmit M. leprae may 
decrease over time. In addition to no decrease, we considered half-value times for 
transmission opportunities of 2, 4 and 8 years. The decrease starts at onset of disease. 
Leprosy control 
The value assigned to the detection delay reflects earliness of case detection. In SIMLEP, 
chemotherapy is considered to start immediately following case detection, and to stop 
contagiousness instantaneously, because both dapsone and MDT render patients non-
contagious quickly (25). In the scenario analysis, dapsone is used from the start of the 
simulations in 1960, and MDT from 1990 onwards. The main differences between 
dapsone and MDT are the duration of treatment and the risk of relapse after treatment.  
Trends in the detection delay were based on information recalled by patients from areas 
with good control (26-31). Our assumptions are as follows. The average detection delay 
gradually decreased from an initial period of 12 years (no control) to 6 years in 1990, 
reflecting the gradual establishment of control programmes. Subsequently, the average 
delay decreased to a constant 4 years for 1992-1996, corresponding to intensified control 
after the 1991 WHA resolution (32). Next, following the initiation of leprosy elimination 
campaigns (33), the average delay decreased further to 2 years in 1998. For the future, we 
considered two possibilities. The first is that the delay remains constant until 2020. The 
second is that the average delay gradually increases from 2 to 4 years between 2006 and 
2009, and remains constant thereafter reflecting failure to sustain early case detection. 
The protective efficacy of BCG against leprosy is well established, although the reported 
efficacy varies widely (18). The policy in most developing countries is to vaccinate only 
very young children (34). Country data on immunization coverage are disseminated by 
WHO (35). We consider two policies: no vaccination at all, and, vaccination of infants 
starting in 1975 with an initial coverage of 5%, increasing to 80% in 1990, and to 95% in 
1999 and later years. In SIMLEP, BCG reduces the chance of an individual becoming 
infected. A non-waning protective efficacy of 50% was assumed. 
Scenarios: procedure 
The alternative assumptions regarding contagiousness during incubation of disease, 
waning of transmission opportunities and BCG vaccination resulted in 16 (2×4×2) 
scenarios: eight without BCG and eight with BCG. Each scenario was fitted to a 
reference case detection rate (CDR) during 1985-1998. The CDR trends since 1985 are 
described elsewhere (1) using reported information (36-42). Reference CDRs are 
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calculated as the average of the CDRs of the countries that satisfied two criteria, namely 
that at least 2000 cases were detected in 1998, and that figures on the number of cases 
detected had been reported throughout 1985-1995. Fourteen countries satisfied these 
criteria: Bangladesh, Brazil, China, Ethiopia, Guinea, India, Indonesia, Madagascar, 
Mozambique, Myanmar, Nepal, Philippines, Sudan and Viet Nam. The reference CDR 
increased from 1.3 per 10 000 total population per year in 1985 to 2.3 per 10 000 in 1998, 
which corresponds to an average annual increase of 4.6% (Figure 6.1). The increase was 
the result of the intensification of control following the WHA elimination resolution, and 
of leprosy elimination campaigns.  
In the scenario simulations, the postulated reductions in the detection delay may first 
induce increases in CDR (see Results). On the other hand, these reductions imply that 
contagious cases are detected earlier and earlier. This may bring about reductions in 
transmission, and after a time lag due to the incubation period and detection delay, also to 
reductions in incidence and CDR. 
The reference trend is fitted by varying SIMLEP’s transmission parameter for the level of 
contagiousness of individuals with contagious disease (19). The best fit of a scenario is 
obtained by minimizing the sum of the squared differences between the simulated CDR 
and reference CDR between 1985 and 1998. After fitting, projections of the incidence 
rate and CDR until 2020 were made (see above).  
Sensitivity analysis: procedure  
Leprosy epidemiology is fraught with uncertainty, and a sensitivity analysis was carried out 
to account for this. The following seven parameters are varied one by one: percentage of 
infected individuals who do not develop disease, duration of the incubation period, 
percentage of new cases who develop contagious disease, self-healing rate for non-
contagious self-healing disease, trend in detection delay, duration of dapsone 
monotherapy and relapse rate after dapsone. 
For each new parameter value, the eight scenarios with BCG were again fitted to the 
CDR reference trend. Projections are made under the assumption that early case-finding 
and treatment are sustained until 2020 (i.e. a constant detection delay of 2 years is used). 
Results were compared with those obtained with the baseline assumptions. Tables 6A.2 
and 6A.3 in the appendix specify the parameter values used in the sensitivity analysis. 
6.5 Results 
Scenarios without BCG vaccination 
Figure 6.1a shows the simulated CDR and the incidence rate for the scenario in which 
leprosy is most difficult to control; i.e. the disease is contagious during the incubation 
period and opportunities for transmission wane fast. The simulated CDR roughly follows 
the reference data, suggesting that the trend in the observed seemingly capricious CDR 
  
 
Figure 6.1 Trends in incidence rate and case detection rate. The circles display the case detection reference
data, and the solid lines give projected case detection rates. The dashed lines give the projected incidence
rates. Figures 6.1a and 6.1c differ from Figures 6.1b and 6.1d in the assumptions made about contagiousness of
leprosy and waning of transmission opportunities. Results are given both with (6.1c, 6.1d) and without (6.1a,
6.1b) BCG vaccination. 
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can be explained by reductions in detection delays. These reductions were associated with 
the removal of backlogs in case detection and ceased in 1998, which explains the peak 
and subsequent drop in simulated CDR. The simulated CDR then started to follow the 
trend in the incidence rate because the detection delay was not reduced further. Relative 
to the incidence rate, the simulated CDR beyond 2000 was higher than in the 1980s 
because fewer patients with non-contagious leprosy self-healed before detection. The 
incidence rate was constant until 1995, and the average decrease in incidence rate 
predicted between 2000 and 2020 is 1.6% per year.  
Figure 6.1b depicts a scenario in which leprosy is easier to control; i.e. there is no 
transmission during the incubation period and transmission opportunities wane slowly. 
Before 1990, the incidence had already decreased. Nevertheless, the simulated CDR again 
increased in the 1990s due to the reductions in detection delays. The trend in the 
incidence rate determines the trend in simulated CDR beyond 2000, as in the previous 
scenario. The projected average annual decline in incidence rate during 2000-2020 is 
8.3%. 
In six of the eight scenarios without BCG, the CDR increased during 1985-1998, with a 
difference from the 4.6% annual increase in the reference trend of less than 50% 
(Table 6.1). These increases coincided with incidence rates in the same period which were 
either stable, or decreased by up to 3.6% annually. As expected, the decline in incidence 
rate beyond 2000 is faster when the incubation period is not contagious, and when the 
transmission opportunities wane more slowly. The projected decline in incidence rate 
accelerates after 2000 in all scenarios because detection delays became shorter in the 
1990s, but also because few relapses occur after MDT. For the six scenarios, the average 
annual decline in incidence rate projected for 2000-2020 ranges from 1.6% to 8.3% 
(corresponding range for the time needed to halve the incidence rate: from 8 to 43 years). 
The two remaining scenarios assumed that transmission opportunities do not wane over 
time and show a stable CDR (annual changes: between –1% and 1%), which conflicts 
with the reference trend.  
Scenarios with BCG vaccination 
The addition of BCG vaccination had a small impact up to 2000, because only infants are 
vaccinated and coverages were initially low. Therefore, no important changes were noted 
in the fit of the reference trend and in the decline in incidence rate during the reference 
period 1985-1998 (Table 6.1). BCG vaccination is projected to enhance the annual decline 
in incidence rate during 2000-2020 by a few per cent, with a resulting range for the annual 
decline in incidence rate from 4.9% to 10.0% for the six scenarios with a good fit. The 
time required to halve the incidence rate varies from 7 to 14 years. The scenarios with the 
least and most favourable projections (see Figures 6.1c and 6.1d), have 57% and 39% 
lower incidence rates in 2020 than in the corresponding scenarios without BCG.  
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Scenarios without sustained early case detection and treatment  
The consequences of an increase in the detection delay after 2005 are shown in Figures 
6.2a and 6.2b. Initially, the CDR decreases considerably because detection is postponed 
and more self-healing cases will go undetected. However, the prolonged delay also implies 
increased transmission which, after some delay due to the incubation period, results in a 
slower decrease of the incidence rate. The consequences of failure to sustain early case 
detection are similar for the other scenarios.  
Sensitivity analysis 
Of the seven parameters varied in the sensitivity analysis (see appendix: Table 6A.3), only 
two – the length of the incubation period and the trend in detection delay – led to a 
substantial change in the annual decline in incidence rate beyond 2000. In all other cases, 
the annual declines are very close to the baseline value (maximum difference, 1%).  
Halving the length of the incubation period leads to a faster decrease in the incidence rate 
because shorter incubation periods imply shorter transmission cycles. The effect is greater 
for the unfavourable scenarios; the decline in incidence rate beyond 2000 is up to 4% 
higher. Of the four scenarios with a good fit to the reference trend, the highest annual 
Table 6.1 Trend in case detection rate (CDR) and in incidence rate for the 16 scenarios. The scenarios with 
trends indicated in bold are the subject of Figure 6.1. a 
Incubation period contagious? Yes No
Half-value time of transmission opportunities 
(years): No b 8 4 2 No b 8 4 2
Without BCG 
vaccination 
Fit of trend in 
case detection rate: 1985-1998 Poor Good Good Good Poor Good Good Good
 
Annual decrease in  
incidence rate: 1985-1998 5.5% 2.4% 1.1% 0.1% 6.4% 3.6% 2.0% 0.5%
 
Annual decrease in 
incidence rate: 2000-2020 8.9% 5.2% 3.3% 1.6% 10.6% 8.3% 6.6% 4.3%
With BCG 
vaccination 
Fit of trend in 
case detection rate: 1985-1998 Poor Good Good Good Poor Good Good Good
 
Annual decrease in 
incidence rate: 1985-1998 6.5% 3.5% 2.3% 1.4% 7.2% 4.4% 3.0% 1.5%
 
Annual decrease in 
incidence rate: 2000-2020 10.9% 7.9% 6.3% 4.9% 11.9% 10.0% 8.5% 6.5%
a A trend in CDR between 1985 and 1998 is scored as Good when the scenario has a CDR increase that differs 
at most by 50% from the 4.6% annual increase in the CDR reference data (i.e. between 2.3% and 6.9%), and 
is otherwise scored as Poor. The four scenarios in which no waning of transmission opportunities occurs show 
either no increase in CDR or an average annual increase below 2.3%. 
b Transmission opportunities do not decrease over time. 
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decline in incidence rate beyond 2000 is 10.4% (baseline, 10.0%). Doubling the 
incubation period has the reverse effect of slowing the declines in incidence rate.  
Two alternative trends for detection delay up to 1998 were considered: one with 
decreases in delay that were greater than in the baseline delay trend, and the other with 
smaller decreases. Of the scenarios with larger decreases in delay, three give a good fit to 
the reference trend, whereas six of the scenarios with the baseline delay trend had a good 
fit. This is because with larger decreases, initial delays in detection are longer and 
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Figure 6.2 Effect of failure to sustain early case detection beyond 2005 on leprosy incidence and case
detection. The impact on incidence rate and case detection rate of an increase in the detection delay from 2 to 4
years between 2006 and 2009 is shown for the scenarios from Figures 6.1b and 6.1d. These scenarios assume
no transmission during the incubation period and a half-value time for transmission opportunities of 8 years. 
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detection backlogs larger, which led to greater increases in simulated CDR during the 
reference period 1985-1998. When compared to the baseline, the decrease in incidence 
rate beyond 2000 – when the detection delay has ceased to be longer – is predicted to be 
somewhat faster (maximum increase, 1.6%). The greatest annual decline was 11.8% 
(half-value time, 6 years) for the three “good” scenarios, which is the highest decline 
among all scenarios with a good fit. The maximum annual decline is a little higher (13.5%; 
half-value time, 5 years), when the five scenarios with a poor fit are also considered. 
Faster declines were not obtained in this study. The scenarios in which smaller decreases 
in detection delay were assumed before 1998 had a slower decline in incidence rate 
beyond 2000 compared to the baseline. 
6.6 Discussion  
This study addressed two questions: what is the impact of early case detection and MDT 
treatment on the transmission and incidence of leprosy, and what are the consequences of 
failing to sustain early case detection?  
Early case detection and treatment led to a reduced incidence of leprosy in all scenarios. 
The time required to halve the incidence rate was 7 years in the most optimistic scenario 
with BCG vaccination. Slightly faster declines were obtained in the sensitivity analysis. 
However, much slower declines were found to be possible; half-value times of 14 years 
with BCG and 43 years without BCG cannot be excluded. A detailed analysis of the 
predictions indicates that ensuring early detection of contagious patients is the key factor 
in reducing transmission. Treatment with MDT instead of dapsone monotherapy is also 
beneficial, because of the lower relapse rates after MDT. 
Consequences of not sustaining early case detection 
Sustained early case detection is essential for maintaining decreases in transmission and 
incidence: the predicted decrease slows down when the detection delay increases after 
2005. Keeping detection delays short will be more difficult when leprosy incidence 
decreases, because both the general population and health workers will become less 
experienced in recognizing symptoms of leprosy.  
Leprosy is a public health problem because of the impairments it causes. There may be 
three million people worldwide with impairments caused by leprosy (43). It has been 
argued that early detection could prevent the development of impairments in more than 
three-quarters of patients (44). Early case detection is therefore also important for 
prevention of leprosy morbidity. 
Trend in detection delay 
For most scenarios, the shortening of the detection delay after 1990 resulted in a good fit 
of the historical trend for the average case detection rate in countries for which data were 
available throughout 1985-1998. The incidence rate of leprosy in the “good” scenarios 
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decreased by at most 4.4% per year in this period (Table 6.1: half-value time 15 years). 
The simulations show that where such declines occur, intensified control may induce a 
temporary increase in case detection (Figures 6.1b and 6.1d). In recognition of the limited 
empirical basis for quantifying the detection delay, two additional delay trends were 
considered in the sensitivity analysis. The impact on incidence predictions was found to 
be small: detection delays before 2000 did not influence incidence trends far beyond 2000. 
It could be argued that the 2-year delay used from 1998 onwards is somewhat optimistic 
(28, 30, 45, 46); longer delays would lead to less optimistic predictions about future 
declines in incidence.  
Historical case-detection data  
The simulated CDRs increased for more than a decade until 1998, after which control 
activities were not intensified further. The increase was possible because the simulated 
CDRs were substantially lower than the incidence rates in 1985 (Figure 6.1). The increase 
in the historical CDR also lasted more than a decade. Cumulative new cases detected in 
1992-1998 exceeded those detected in 1985-1991 by at least 50% in eight of the 14 
countries for which historical data on CDRs were available (1). This indicates that the 
differences between case detection and incidence rates must indeed have been substantial. 
Information on detection of new cases worldwide is incomplete. Aggregate information is 
available from 1985 onwards for a group of 33 countries in which leprosy is endemic. 
Throughout 1994-1998, at least 97% of cases detected globally were detected in these 33 
countries (global figures are not available before 1994) (1). India detected at least 75% of 
the cases in this group throughout 1985-1998. The other 13 countries in this study 
accounted for at least 75% of the remaining cases detected. Thus, the majority of the 
world leprosy problem was concentrated in the 14 countries that detected at least 2000 
cases in 1998 and for which historical CDR data were available throughout 1985-1998.  
The figures reported from some countries may be incomplete or contain inaccuracies, and 
may have been influenced by overdiagnosis and re-registration of previously treated 
patients (39). Nevertheless, the data used in this analysis were the best available. To 
compensate for limitations in the quality of the data, the CDR increase was allowed to 
deviate by 50% from the increase in the historical CDR over 1985-1998 while scoring 
simulated trends as “good”. The historical trend in CDR reflects an average pattern of 
case detection trends, and only in some cases is it representative of the trend in individual 
countries. However, the robustness of the predicted declines in incidence beyond 2000 
has already been indicated. Given the historical trend towards an increase in CDR, 
autonomous decreases in transmission (e.g. due to socioeconomic improvement) were 
not considered. 
India was counted as one country in the construction of the historical trend. The CDR in 
India was quite stable over 1985-1998. For each of the three trends in detection delay, we 
also fitted the scenarios to India alone for the baseline assumptions: this resulted in 
slower declines in incidence beyond 2000.  
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Impact of BCG vaccination 
The scenario analysis suggests that BCG vaccination is important in reducing the 
incidence of leprosy, yet for various reasons its impact remains uncertain. BCG 
vaccination is ignored in half of the scenarios, which is equivalent to making the 
pessimistic assumption that BCG does not protect against leprosy. The remaining 
scenarios incorporated optimistic assumptions about the efficacy and coverage of BCG 
vaccination. Fifty per cent lifelong protective efficacy was assumed. In randomized trials, 
the protection afforded ranged from 20% to 80%, with low values reported in India (18, 
47). The assumed trend in coverage is optimistic when compared with data disseminated 
by WHO (35). Thus, the impact of BCG vaccination may have been overestimated in this 
analysis.  
Reasons for variability in predicted incidence trends  
The scenarios differ in their assumptions regarding two important unknowns, namely, 
transmission during the incubation period and waning of transmission opportunities due 
to rapid transmission to close contacts. These unknowns have led to great uncertainty as 
to the part played by the policy of isolating patients in the disappearance of leprosy from 
Norway (24). Basic and epidemiological research on transmission is required to improve 
our understanding of the impact of any strategy for controlling leprosy. 
Extrapolation to global case detection 
In the year 2000, 720 000 new cases of leprosy were detected worldwide (1). In an 
intermediate scenario with BCG vaccination, it would take about 10 years to halve the 
incidence rate. If population growth is ignored, extrapolation of this rate of reduction to 
case detection would imply that 360 000 cases would be detected worldwide in 2010, and 
180 000 in 2020. The cumulative number of new patients who will be detected up to 2010 
and 2020 is 5 million and 7.5 million, respectively. In the most optimistic prediction, 
obtained with larger decreases in the detection delay than in the baseline trend (11.8% 
annual decline in incidence rate), the number of cases detected would be 4 million in 2010 
and 5 million in 2020. 
Conclusion 
The scenario analysis demonstrates that the present leprosy elimination strategy will 
reduce transmission, although the decline may be slow. Early case detection is the key 
factor in the success of the strategy. The uncertainties about the rate of decline and the 
adverse effects of longer detection delays imply that relaxation of leprosy control 
following the end of the “Final Push” period in 2005, when the target of elimination of 
leprosy as a public health problem is set to be achieved in all countries, is unjustified. A 
long-term strategy for leprosy control should be adopted.  
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6A Appendix 
This appendix details the quantification of the SIMLEP model and provides the values 
for the parameters used in the sensitivity analysis. A detailed description of the SIMLEP 
modelling framework has appeared elsewhere (1). The information underlying the 
reference trend for the case detection rate (CDR) that is used in the scenario analysis is 
also summarized.  
6A.1 Model and parameter quantifications  
Figure 6A.1 shows the structure of the SIMLEP model. The transitions between 
compartments are governed by transition rates, i.e. by exponential probability 
distributions, unless otherwise indicated (see also (1)). Tables 6A.1 and 6A.2 list the 
quantification of the model parameters. Additional information and its sources are given 
below.  
Demographic data 
Demographic data for India for 1987, which is close to the middle year of the simulation 
period, 1960-2020, are used for the birth rate and age-specific death rates (2).  
Asymptomatic infection 
A high percentage (90%) of newly infected individuals are assumed to self-heal without 
developing any clinical symptoms of leprosy, because leprosy infection is considered to be 
far more common than leprosy disease (3, 4). 
The episode of asymptomatic infection represents the time until self-healing for infected 
individuals who do not develop disease, and the incubation period for those who develop 
non-contagious self-healing disease or contagious disease which does not self-heal. These 
forms of disease are referred to in this appendix as PB leprosy (paucibacillary leprosy) and 
MB leprosy (multibacillary leprosy). The median values of the duration of the incubation 
periods of PB leprosy (3.5 years) and MB leprosy (10 years) are based on data collected 
from studies on veterans from non-endemic areas who contracted leprosy after serving in 
endemic areas (reported minimum and maximum estimates for the median incubation 
period for veterans with PB leprosy: 2 and 5 years, respectively, and for MB leprosy 8 and 
12 years, respectively) (3). For those people who did not develop the disease, the length 
of time until self-healing is equal to the duration of the incubation period for PB leprosy.  
Untreated disease and transmission 
The incidence of leprosy is based on a ratio of PB to MB disease of 4:1. For PB disease, a 
self-healing rate of 22.4% per year is assumed in accordance with Sirumban et al. (5). The 
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Figure 6.A1 Structure of the SIMLEP model as used in the scenario analysis. 
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Table 6A.1 Parameter values used in the scenario analysis. a 
Input parameter Flows Value(s) 
Demographic data   
Birth rate per 1000 total population per year f1, f2 32.2 
Age specific death rates (based on Indian lifetable) f14 see text 
Asymptomatic infection   
Percentage among newly infected individuals not developing leprosy 
disease 
f5 
 
90% 
 
Median duration of asymptomatic infection (Erlang distribution; years) 
–   for those not developing leprosy disease 
–   for those developing paucibacillary disease 
–   for those developing multibacillary disease 
f5 
f6 
f7 
3.5 
3.5 
10 
Disease and transmission   
Percentage of new cases who develop 
–   paucibacillary disease 
–   multibacillary disease 
f6 
f7 
80% 
20% 
Self-healing rate for PB disease per year b f8 22.4% 
Build-up of contagiousness while incubating for MB disease b f3, f4 no, yes 
Half-value times for waning of transmission opportunities (years) f3, f4 none 
c, 2, 4, 8 
BCG vaccination at birth: different scenarios   
Application f1, f2 no, yes 
Coverage f1, f2 see text 
Protective efficacy f4 50% lifelong 
Case detection and chemotherapy treatment   
Mean delay in case detection f9, f10 see text, Table 6A.2 
Mean duration of treatment (years) and drug regimen 
–   1960-1989: dapsone monotherapy 
–   1990-1999: multidrug treatment 
–   2000-2020: multidrug treatment 
f11 
f11 
f11 
9 
0.8 
0.6 
Relapse rate per year 
–   after dapsone monotherapy cure 
–   after multidrug therapy cure 
f12, f13 
f12, f13 
1.5% 
0.1% 
Proportion of relapsing cases who relapse to (either therapy) 
–   paucibacillary disease 
–   multibacillary disease 
f12, f13 
f12, f13 
10% 
90% 
 
a Flows refer to Figure 6A.1. Underlined values refer to assumptions that have been varied in the 16 scenarios. 
b PB = paucibacillary, MB = multibacillary. 
c Transmission opportunities do not decrease over time. 
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ratio of PB leprosy to MB leprosy in new case detection depends on the PB to MB ratio 
for incidence, on the self-healing rate of PB leprosy, and on delays in detection and 
diagnosis. The reported ratios vary widely between the different regions of the world (see 
e.g. (3)). 
Knowledge on the extent of contagiousness and transmission of leprosy is limited. In the 
scenario analysis, MB leprosy is assumed to be contagious, and in half of the scenarios 
considered, individuals incubating MB disease are assumed to gradually build up 
contagiousness. The possibility that patients with PB leprosy and those incubating it are 
also contagious was not explored. This is because the issue of contagiousness of patients 
with PB leprosy was considered to be much less important in assessing the possible 
impact of interventions on transmission than the question of when (which may also be 
before the onset of disease) transmission takes place. 
It is unknown whether the opportunities for an individual to transmit Mycobacterium leprae 
decrease over time. Such a decrease is plausible because close contacts, who are at a high 
risk of contracting leprosy (6), may be infected rapidly. In the scenario analysis, in 
addition to no decrease, half-value times for transmission opportunities for diseased 
individuals of 2, 4 and 8 years were considered. 
BCG vaccination at birth 
In most developing countries, bacille Calmette-Guèrin (BCG) vaccination is given in very 
young childhood (7). BCG vaccination was ignored in half of the scenarios (“no 
vaccination at all”), which is equivalent to the pessimistic assumption that BCG does not 
protect against leprosy. In the other half of the scenarios, optimistic assumptions about 
BCG were made. A policy of vaccination of infants was assumed, starting in 1975 with an 
initial coverage of 5%, increasing to 80% in 1990, and to 95% in 1999 and all subsequent 
years. These figures are optimistic when compared to coverages reported by member 
states to WHO (8). Randomized controlled trials have shown that the protective efficacy 
of BCG against leprosy ranges from 20% to 80% (9). The protective efficacy was quite 
low in Asia, particularly in India where most patients with leprosy are detected (10-12), 
and it is unknown whether the protective efficacy decreases with age. The optimistic 
assumption of a lifelong 50% efficacy was made.  
Case detection and chemotherapy 
The delay in detection has a skewed distribution (13). Therefore, SIMLEP uses a 
convolution of two exponential probability distributions for the length of the detection 
delay (13). A trend in mean detection delay was defined using historical information based 
on recall by patients from areas in which leprosy control is well organized (13-18). 
The historical trend is summarized in Table 6A.2 (baseline trend in delay). The mean 
detection delay gradually decreases from an initial 12 years (“no control”) to 6 years in 
1990, reflecting the gradual establishment of leprosy control programmes. Subsequently, 
the mean delay decreases to a constant 4 years for 1992-1996, corresponding to the 
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intensification of control after the 1991 WHA resolution regarding leprosy elimination 
(19). The mean delay then decreases to 2 years in 1998, following the initiation of 
“leprosy elimination campaigns” (20). 
In the predictions for the future, two possibilities were considered. The first was that the 
detection delay remains constant at 2 years until 2020. The second possibility was that the 
mean detection delay gradually increases from 2 to 4 years between 2006 and 2009, 
remaining constant thereafter, which reflects possible failure to sustain early case 
detection and treatment beyond 2005. 
The duration of treatment is governed by a single exponential probability distribution for 
all patients. In the scenario analysis, treatment between 1960 and 1989 was by dapsone 
monotherapy and, from 1990 onwards, by multidrug therapy (MDT). The choice of a 
mean duration of dapsone treatment of 9 years was somewhat arbitrary: dapsone was 
usually prescribed for 5 years for patients with tuberculoid leprosy and for 20 years or for 
life for patients with lepromatous leprosy (21). The prescribed duration of MDT 
treatment has changed several times, but has always been much shorter than dapsone 
treatment (22-24). The assumed mean duration of MDT treatment (all patients) was less 
than 1 year (Table 6A.1). 
In SIMLEP, the relapse rates after treatment cure are equal for PB and MB leprosy, and 
are constant over time. A relapse rate after dapsone monotherapy of 1.5% per year was 
chosen, based on the data of Becx-Bleumink who reported a relapse rate of 0.7% for PB 
leprosy and 2.5% for MB leprosy (under the assumption that equal numbers of new cases 
of PB and MB leprosy are detected, the 1.5% rate for all patients and the separate 0.7% 
and 2.5% rates for PB leprosy and MB leprosy give the same cumulative proportion of 
relapsed cases after 25 years) (25). The reported rates of relapse after dapsone 
monotherapy vary widely (see e.g. (25-32)). Programmes conducted in the field have 
reported much lower relapse rates after MDT (6). A relapse rate for PB and MB patients 
of 0.1% per year following MDT was used. Using the data of Smith et al. (33), 10% of 
patients with relapses present with PB leprosy, and the remaining 90% with MB leprosy.  
Table 6A.2 Time trends over 1960-2020 for the mean detection delay. 
 Mean detection delay (years) 
 1960-1990 1990-1992 1992-1996 1996-1998 1998-2020 
 Decrease Decrease Constant Decrease Constant 
Trend with small decreases in delay from 8 to 4 from 4 to 3 3 from 3 to 2 2 
Baseline trend in delay from 12 to 6 from 6 to 4 4 from 4 to 2 2 
Trend with large decreases in delay from 16 to 8 from 8 to 5 5 from 5 to 2 2 
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6A.2 Sensitivity analysis 
Tables 6A.2 and 6A.3 list the different values of the parameters that were used in the 
sensitivity analysis. Birth rate and age-specific death rates were not varied in the sensitivity 
analysis. Also, no variation was made in the mean duration of MDT (changes will not 
affect simulation results), the relapse rate after cure with MDT (this rate is too low to 
affect simulation results), or in the proportion of those patients who relapse to MB 
disease (baseline value: 90%; the vast majority of patients who relapse would be expected 
to have leprosy of the MB type). 
Values of parameters that are varied  
The values of the baseline parameters are given in Tables 6A.1 and 6A.2. For most of the 
parameters, the baseline values were halved and doubled for the scenario analysis 
(Table 6A.3). The exceptions were the percentage of newly detected cases who do not 
develop leprosy disease (Table 6A.3) and the trend in detection delay (Table 6A.2). The 
baseline assumption is that 90% of newly infected individuals self-heal without ever 
displaying any clinical symptom of leprosy. The contrasting assumption is that all newly 
infected individuals will develop leprosy disease. In the baseline trend in detection delay, 
the mean delay decreases by 2 years between 1990 and 1992, and by a further 2 years 
between 1996 and 1998 (Table 6A.2). By contrast, for the trend with small decreases in 
the delay, the mean delay decreases twice by 1 year and, in the trend with large decreases, 
Table 6A.3 Alternative quantifications in the sensitivity analysis. a 
Parameter changes Flows Value(s) 
Percentage among newly infected individuals not developing disease f5 0% 
Median duration of incubation period (years) b 
 
f6, f7 
 
halved: PB 1.75, MB 5 
doubled: PB 7, MB 20 
Percentage of new cases who develop MB disease 
 
f6, f7 
 
halved: 10% 
doubled: 40% 
Self-healing rate for PB disease per year 
 
f8 
 
halved: 11.2% 
doubled: 44.8% 
Trend in mean delay in case detection 
 
f9, f10 
 
small decreases in delay 
large decreases in delay 
Mean duration of dapsone monotherapy (years) 
 
f11 
 
halved: 4.5 
doubled: 18 
Relapse rate per year after dapsone monotherapy cure 
 
f12, f13 
 
halved: 0.75% 
doubled: 3.0% 
a PB = paucibacillary, MB = multibacillary. 
b Median durations of 1.75 and 7 years were also used for the period of asymptomatic infection for subjects who 
did not develop disease (flow f5). The duration of this period had no effect on the scenario predictions. 
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twice by 3 years. The mean delay of 2 years from 1998 onwards, which corresponds to a 
median delay of 1.5 years, was used in all three trends for the detection delay.  
6A.3 Reference data for case detection rate 
The reference CDR during 1985-1995 is calculated as the average of the CDRs of the 14 
countries in which at least 2000 cases were detected in 1998, and for which detection 
figures at country level were reported throughout 1985-1995. The trends in CDR since 
1985 are described elsewhere (34) on the basis of the reported information (35-41). The 
CDRs per 10 000 total population for the year 1998 and the average annual increases in 
CDR between 1985 and 1998, derived from the CDRs for these 2 years for the 14 
countries are as follows: Bangladesh (1.0; +5.3%), Brazil (2.5; +4.5%), China (0.02; 
–7.8%), Ethiopia (0.7; –3.6%), Guinea (5.2; +21.8%), India (6.5; +0.3%), Indonesia (0.9; 
+4.5%), Madagascar (6.1; +9.0%), Mozambique (2.2; +9.2%), Myanmar (3.1; +4.3%), 
Nepal (3.0; –0.2%), Philippines (0.5; +6.6%), Sudan (0.7; +26.0%) and Viet Nam (0.3; 
–1.6%). The reference CDR increased from 1.3 per 10 000 total population per year in 
1985 to 2.3 in 1998 (average annual increase, 4.6%). 
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7.1 Summary 
Data on the importance of the delay between onset of symptoms and registration as a risk 
factor for impairment are sparse. This study investigates the quantitative relationship 
between this delay, other risk factors and the impairment status in new leprosy patients. It 
reports on 592 new leprosy patients enrolled in 1988-1992 in the prospective ALERT 
MDT Field Evaluation Study in central Ethiopia (AMFES). The influence of the risk 
factors sex, age, delay, PB/MB classification in relation to BI, and prior dapsone 
treatment on the impairment status at intake is analysed. Estimates for the delay are based 
on patient recall. For the risk factors, odds ratios on impairment and on severity of 
impairment were calculated using both univariate and multivariate logistic regression. The 
registration delay was 2 years or more for 44% of new patients. The prevalence of 
impairment (WHO impairment grades 1 and 2 combined) increased continuously from 
36% for new patients with a delay of 0-1 year to 81% for new patients with delays of 4 
years or more. This prevalence also increased continuously with age; it rose from 26% in 
children to 80% for the age group 60 and over. In the multivariate regression, the odds 
ratios for new patients to be impaired were statistically significant for all delay categories 
(baseline 1-2 years) and age groups (baseline 15-29 years). No statistically significant 
differences in odds ratios were observed with respect to sex and PB/MB classification in 
relation to BI. Overall, 31% of new patients presented with WHO impairment grade 1 
and 23% with grade 2. The risk on grade 2 also increased with the registration delay 
amongst the impaired new patients. Relatively few impaired males and relatively few 
impaired MB patients with a BI value of 3 or higher had grade 2 impairment. Registration 
delay and age are the main risk factors for presentation with impairment. Reduction of 
delay in central Ethiopia requires re-thinking of control methodologies. The search for 
ways to reduce delays in diagnosis and treatment should receive high priority in leprosy 
research and in leprosy control programmes. 
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7.2 Introduction 
The implementation of effective antibacterial treatment for leprosy has shifted the focus 
in leprosy programmes to prevention of disability. However, many new cases already have 
impairments and disabilities. Amongst major endemic countries, the proportion of new 
cases presenting with WHO disability grade 2 was reported in 1995 to range from 6% to 
21% (1). Several studies showed that the majority of patients who were impaired at release 
from MDT already had nerve function impairment at the time of registration (2-4). This 
paper documents risk factors for impairment in new cases, which may contribute to the 
improvement of prevention of disability activities in leprosy control programmes. 
Various factors might be associated with the presence of impairment at registration. For 
example, differences in impairment status at registration have been observed with respect 
to gender, age at registration, and leprosy type according to clinical classification systems 
or the WHO paucibacillary / multibacillary (PB/MB) classification (2-9). At the same 
time, higher proportions of MB cases amongst male patients have been documented 
(2, 7-10), and different age distributions for new PB and MB cases have been reported 
(9, 11-14). This implies that interrelations must be taken into account when analysing 
which factors are associated with the impairment status at registration.  
In addition, it is generally believed that a longer delay between onset of disease and 
registration, here called registration delay, is associated with more impairment. The 
proportion of new cases with impairments at registration is, for instance, much higher in 
passively, as compared to actively, detected cases in Malawi (2). Richardus et al concluded 
that early diagnosis (and subsequent activities for prevention of disability) could prevent 
impairments in more than 30% of all patients in a control programme in Bangladesh (3), 
more than any intervention at a later stage could achieve.  
Registration delay has been documented in several studies (7, 8, 10, 15-22). A study on 
long term leprosy trends in Thailand showed that important declines in the registration 
delay coincided with a declining trend in the proportion of cases presenting with grade 2 
disability (17). A recent study from another area in Thailand revealed a highly significant 
linear trend in the proportion of new cases with grade 2 disability in relation to the 
registration delay (4). Bekri et al concluded that the median registration delay was more 
than twice as high in disabled as compared with non-disabled patients from Ethiopia (22). 
Wittenhorst et al found a highly significant association between registration delay and 
presence of impairments in new leprosy patients from Zimbabwe (7). It is beyond doubt 
that the presence and severity of impairments are associated with duration of disease (e.g. 
(23-27)). Surprisingly, knowledge on the quantitative relationship between the registration 
delay and the impairment status at registration in new leprosy patients - while 
simultaneously considering the impact of other, interrelated factors - is very limited. 
This paper therefore examines the impairment status at registration as a function of 
several potential risk factors and their interaction for patients who were enrolled in a 
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long-term prospective study of the effectiveness of the WHO-recommended MDT 
regimens under routine leprosy control service conditions. This study, the ALERT MDT 
Field Evaluation Study (AMFES), is carried out in a selected area within ALERT’s leprosy 
control programme in central Ethiopia. Details of the design of the AMFES study and 
preliminary results for the new patients who were registered in the first 3 years have been 
reported upon before (28, 29).  
7.3 Materials and methods 
Case-finding in ALERT’s control programme was almost exclusively passive. All new 
cases from the selected area were eligible for AMFES, but not all patients presenting 
during the intake period were enrolled, mainly because of limitations in the accessibility of 
leprosy clinics. The AMFES intake period was April 1988 to March 1993. 
Cases who were relapses from previous chemotherapy treatment and newly detected 
cases with errors in diagnosis or in enrolment procedures were excluded from the present 
study. The present study involves all remaining newly detected cases who were enrolled in 
the AMFES study. Patient characteristics included are age, sex, classification, 
bacteriological index (BI), duration of prior dapsone treatment, impairment status and 
registration delay. PB and MB patients who received no more than 4 weeks and no more 
than 16 weeks of dapsone, respectively, were regarded as ‘new, untreated’, and were 
included in the study. Impairments are in this paper expressed in terms of the “WHO 
disability grades” and are, following Reed et al (30), referred to as “WHO impairment 
grades”. 
The type of treatment (PB or MB) was chosen on the basis of clinical classification and 
skin smears. Skin smears were routinely taken from both earlobes and from at least two 
skin lesions for all patients, and were repeated after 4 or 8 weeks in case of doubt. For 
some patients the smear was either not done, or the result was not available for logistic 
reasons. For clinical classification, the simplified system for field workers recommended 
by Jopling (which adds BB to the BL group) was used (31). Tuberculoid (TT) and 
borderline-tuberculoid (BT) patients with a negative smear at all sites were normally given 
PB treatment. Until July 1989, BT patients with BI not exceeding 1 were included in the 
PB group. Borderline-lepromatous (BL) and lepromatous (LL) patients and those with a 
positive smear at one or more sites were given MB treatment. For patients with nerve 
involvement only, lacking skin lesions and whose skin smears were (repeatedly) negative 
(neural leprosy, NL), assignment of treatment regimen was based on the extent of nerve 
involvement or on the finding of acid-fast bacilli in a nerve biopsy. In case of any 
controversy, patients were referred to the AMFES medical officer. In practical terms, 
many patients correctly classified as PB within this study, would be classified as MB if 
now used criteria focussing on number of skin lesions or number of body areas affected 
had been applied (32). The assignment of treatment regimen was straightforward for most 
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patients. More detailed information on procedures for diagnosis, classification and 
treatment is given by de Rijk et al (29). 
The registration delay is based on patient recall. Health workers first asked what the 
patient’s complaint is, and then tried to find out when any symptoms (e.g. skin lesions, 
neurological problems, weakness or numbness in hands and feet) were first noticed, 
relating them to known events if necessary. The health worker recorded the calendar year 
of the first notice of symptoms, and the registration delay is calculated from the mid-year 
of this calendar year and the date of registration. For example, a patient who registered on 
March 5, 1992 and who recalled having first noticed symptoms in 1990 was assigned a 
registration delay of 1 year and 8 months. In the Results, we will denote this as 1-2 years; 
this category includes all calculated delays between 1.0 and 2.0 years. If this patient had 
registered on September 5, 1992, he would have been assigned a delay of 2-3 years. 
Individuals registering in the same year as or before July 1 of the year following the year 
in which symptoms were first noticed, are assigned a delay of 0-1 year (i.e. less than 
1 year). 
The factors associated with increased risk for impairments at the time of registration were 
analysed both separately and in combination. In the data analysis, odds ratios for risk 
factors for presentation with impairments at the time of registration were calculated using 
univariate and multivariate logistic regression. Statistical significance refers to the 5% 
level. The data analysis was carried out in SPSS. 
7.4 Results 
A total of 603 new cases were enrolled in the AMFES project. Out of these, four 
individuals were wrongly diagnosed as having leprosy, and seven had improper enrolment 
procedures. Thus, 11 new cases had to be excluded from the present data analysis. This 
paper reports on the resulting 592 newly detected patients.  
Profile of AMFES and ALERT patients 
The 592 included patients and the new cases detected in the same period by ALERT’s 
routine control programme (33) were compared for age, sex, classification and WHO 
impairment status. Important discrepancies were not observed, and the patients involved 
in this study are thus considered to be sufficiently representative for new case detection 
by ALERT in the same period. 
Out of the patients involved in this study, 92% reported voluntarily. This confirms the 
passive nature of case finding by ALERT’s control programme in the late 1980s and early 
1990s. Table 7.1 shows that the number of males in the study population was almost 
twice as high as the number of females (male:female ratio: 1.8). The child proportion was 
14%, and for approximately half of the patients the age at registration was between 15 
and 34 years. The most common clinical classifications were BT and BL. TT and NL 
cases were rarely seen. Skin smears were taken from all but 14 (13 BT and 1 BL) patients. 
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None of the TT, and 13 BT patients had positive smears (10 with BI 1 and 3 with BI 2). 
Forty BL patients had a BI of 1 or 2, and 132 had a BI of 3 or more. The BI was 3 or 
more for all 84 LL patients but two. Overall, almost half of the patients were smear 
positive, and more than one third of the patients had high bacterial loads (BI ≥ 3). The 
group of patients who received MB treatment consisted of 2 NL patients, 12 BT patients 
Table 7.1 Characteristics of new patients at intake. Percentages are given in proportion to the numbers of 
patients for which information is available. Numbers of patients for which information is available are given in 
brackets if information is not available for all newly detected patients. 
Total patients     
592     
Gender     
Male Female    
377 (64%) 215 (36%)    
Age at registration in years    
0-14 15-29 30-44 45-59 60+ 
83 (14%) 240 (41%) 127 (21%) 97 (16%) 45 (8%) 
Ridley-Jopling classification    
TT BT BL LL NL 
6 (1%) 297 (50%) 202 (34%) 84 (14%) 3 (1%) 
Bacteriological index (BI) (n=578)    
0 1+2 3+4 5+6  
311 (54%) 53 (9%) 97 (17%) 117 (20%)  
PB / MB classification    
PB MB    
292 (49%) 300 (51%)    
Subdivision of PB and MB    
PB MB: BI=0 MB: BI=1+2 MB: BI=3-6  
292 (49%) 37 (6%) 49 (8%) 214 (36%)  
Registration delay in years (n=586)    
0-1 1-2 2-4 4+  
156 (27%) 174 (30%) 168 (29%) 88 (15%)  
Duration of prior dapsone treatment in weeks   
0 1-4 5-16   
499 (84%) 70 (12%) 23 (3.9%)   
WHO impairment grading    
0 1 2   
268 (45%) 185 (31%) 139 (23%)   
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(including nine smear-positives with two with BI 2), and all BL and LL patients. Overall, 
almost equal numbers of patients received PB and MB treatment. For data analysis, 
patients were re-classified according to a composite classification with four categories 
(PB; MB: BI=0; MB: BI=1+2; and MB: BI=3+4+5+6). At intake, about 16% of patients 
had received dapsone treatment (39 PB for at most 4 weeks and 54 MB for at most 16 
weeks). The registration delay was above 2 years for 44% of the patients. The mean 
registration delays for males and females were 2.4 and 2.3 years. Figure 7.1 presents a 
frequency distribution of the registration delay. Leprosy induced impairments are very 
common in the study population: 31% of new patients presented with grade 1 
impairment and 23% with grade 2.  
Univariate analysis of risk factors for presentation with impairment 
Table 7.2 gives details on risk factors for presentation with any impairment (either grade 1 
or grade 2). The six cases without information on the registration delay were excluded 
from the analysis. The univariate results indicate that the risk for presentation with 
impairment strongly increased with both age and registration delay. The proportion with 
impairment was much smaller for delays below 2 years than for longer delays (42 versus 
72%). The overall associations between presence of impairment and age and between 
presence of impairment and delay were both highly significant (p<0.001). A strong 
association was also found between risk for any impairment and classification in relation 
to BI (p=0.002); the risk was highest for MB patients presenting with BI 0, 1 or 2. Males 
more often presented with impairments than females, but the association was not 
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Figure 7.1 Frequency distribution of the registration delay. Numbers of patients for the respective registration
delays are given on top of the bars. Years are truncated, e.g. 2 years means between 2.0 and 3.0 years. 
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significant (p=0.07). Short term prior dapsone treatment is associated with a higher but 
non-significant risk of being impaired at the start of MDT treatment (p=0.17). The higher 
risk is even not significant when comparing no prior dapsone treatment with prior 
dapsone treatment up to a maximum of 16 weeks (i.e. prior durations of treatment of 1-4 
weeks and of 5-16 weeks are combined, p=0.09).  
Multivariate analysis of risk factors for presentation with impairment 
Figure 7.2 illustrates the simultaneous impact of registration delay and other risk factors 
on impairment. With increasing delay the proportion presenting with impairment 
 
Table 7.2 Impairment at intake according to various risk factors with odds ratios for presentation with impairment 
obtained by univariate and multivariate regression for the 586 new cases with known registration delay. 
Risk factor 
No. impaired 
(% of all cases) 
Univariate odds ratio 
(95% confidence interval) 
Multivariate odds ratio 
(95% confidence interval) 
Gender    
  Male 215 / 372 (58%) Baseline Baseline 
  Female 107 / 214 (50%) 0.7 (0.5-1.0) 0.8 (0.6-1.2) 
Classification i.r.t. BI     
  PB 150 / 286 (52%) Baseline Baseline 
  MB: BI=0 28 / 37 (76%) 2.8 (1.3-6.2) 2.2 (0.9-5.3) 
  MB: BI=1+2 35 / 49 (71%) 2.3 (1.2-4.4) 1.6 (0.8-3.2) 
  MB: BI=3-6 109 / 214 (51%) 0.9 (0.7-1.3) 0.8 (0.5-1.2) 
Age (in years)      
  0-14 21 / 81 (26%) 0.4 (0.2-0.7) 0.4 (0.2-0.7) 
  15-29 112 / 238 (47%) Baseline Baseline 
  30-44 85 / 127 (67%) 2.3 (1.5-3.6) 1.9 (1.2-3.0) 
  45-59 69 / 96 (72%) 2.9 (1.7-4.8) 2.6 (1.5-4.5) 
  60+ 35 / 44 (80%) 4.4 (2.0-9.5) 4.2 (1.8-9.6) 
Registration delay (years)    
  0-1 56 / 156 (36%) 0.6 (0.4-1.0) 0.6 (0.4-1.0) 
  1-2 82 / 174 (47%) Baseline Baseline 
  2-4 113 / 168 (67%) 2.3 (1.5-3.6) 2.1 (1.3-3.4) 
  4+ 71 / 88 (81%) 4.7 (2.6-8.6) 4.5 (2.3-8.5) 
Prior dapsone treatment (weeks)   
  None 264 / 494 (53%) Baseline Baseline 
  1-4 42 / 69 (61%) 1.4 (0.8-2.3) 1.0 (0.6-1.9) 
  5-16 16 / 23 (70%) 2.0 (0.8-4.9) 2.5 (0.9-6.9) 
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Figure 7.2 Proportions of new patients presenting with impairment according to registration delay in relation to
respectively gender, age, and classification in relation to BI. 
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increases in both males and females, in each age group, and in PB and MB patients 
irrespective of BI. Only 15% (four out of 27) MB patients with BI 0 and with a delay of 1 
year or more presented without impairment. Age influences impairment independently of 
the registration delay: the proportion with impairment increases with age for all 
registration delays. An effect of MB in relation to BI on impairment which is independent 
of the registration delay does not come out clearly.  
Table 7.2 gives the results of multivariate logistic regression for a model with all risk 
factors included. The odds ratios for the significant risk factors in the univariate analysis 
are pulled towards the no influence value of 1 in the multivariate logistic regression. 
Details below refer to the multivariate logistic regression. A statistically significant 
increase in odds ratios is found both for delay and for age. None of the odds ratios for 
the other risk factors is significant. In particular, the odds ratios for BI 0 and for BI 1+2 
have lost their category-wise statistical significance in the multivariate regression; however 
the differences in risk for the factor classification in relation to BI, with relatively higher 
risks for MB with BI 0 and MB with BI 1 or 2, are overall significant (p=0.04). The model 
which includes all risk factors was compared with a multivariate model that was obtained 
by backward selection of risk factors on the basis of the Wald statistic. Little difference 
was observed: the odds ratios and confidence intervals for the risk factors included in the 
model obtained by backward selection (age, registration delay and classification in relation 
to BI) are very close to those presented in Table 7.2. 
Level of impairment 
Table 7.3 gives the results of univariate analysis for the risk for impaired new cases to 
have grade 2 impairment. The multivariate results are not given, because they hardly 
differed from the univariate results. The risk is higher for long registration delays, but 
odds ratios for the longer delays are only just significant. The proportion with grade 2 
impairment among impaired cases was 31% for delays below, and 52% for delays above 2 
years. Figure 7.3 shows that longer registration delays are particularly associated with a 
higher proportion of grade 2 impairment. The apparent limited influence of longer delays 
on the proportion with grade 1 impairment must partially be due to an increase in grade 2 
resulting from worsening of grade 1, which is largely ‘compensated’ by individuals who 
were free from impairment but who develop grade 1 with increasing delay.  
Other factors show differences with respect to their influence on the risk of any 
impairment and on the severity of impairment in impaired cases. Firstly, MB with BI 3 or 
more gives a significantly lower risk for grade 2 impairment (baseline: PB leprosy). 
Secondly, there is no increase in the risk of grade 2 impairment with age. In fact, the risk 
appears to be highest for children and lowest for individuals of age 45 and older. No 
decrease was found in the mean registration delay with age in impaired new cases. Finally, 
while overall having less impairments, females with impairment more often had grade 2 
than impaired males (53% versus 38%). Figure 7.4 shows that the excess in grade 2 
impairment in impaired females as compared with impaired males exists for registration 
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delays above 1 year and for all age groups. Gender, age, registration delay and 
classification in relation to BI were all statistically significant risk factors, but prior 
dapsone treatment was not. 
7.5 Discussion 
The objective of this study was to examine the impairment status at registration as a 
function of registration delay, age, classification in relation to BI, gender and prior short 
term dapsone treatment. 
Table 7.3 Grade 2 versus grade 1 impairment at intake according to various risk factors with odds ratios for 
presentation with grade 2 impairment obtained by univariate regression for the 322 impaired new cases with 
known registration delay. 
Risk factor 
No. with grade 2 impairment 
(% of all impaired cases) 
Univariate odds ratio 
(95% confidence interval) 
Gender   
    Male 82 / 215 (38%) Baseline 
    Female 57 / 107 (53%) 1.8 (1.2-3.0) 
Classification i.r.t. BI   
    PB 72 / 150 (48%) Baseline 
    MB: BI=0 14 / 28 (50%) 1.1 (0.5-2.4) 
    MB: BI=1+2 19 / 35 (54%) 1.3 (0.6-2.7) 
    MB: BI=3-6 34 / 109 (31%) 0.5 (0.3-0.8) 
Age (in years)   
    0-14 15 / 21 (71%) 3.5 (1.2-9.6) 
    15-29 47 / 112 (42%) Baseline 
    30-44 46 / 85 (54%) 1.6 (0.9-2.9) 
    45-59 19 / 69 (28%) 0.5 (0.3-1.0) 
    60+ 12 / 35 (34%) 0.7 (0.3-1.6) 
Registration delay (years)   
    0-1 16 / 56 (29%) 0.8 (0.4-1.7) 
    1-2 27 / 82 (33%) Baseline 
    2-4 58 / 113 (51%) 2.1 (1.2-3.9) 
    4+ 38 / 71 (54%) 2.3 (1.2-4.5) 
Prior dapsone treatment (weeks)   
    None 116 / 264 (44%) Baseline 
    1-4 17 / 42 (40%) 0.9 (0.4-1.7) 
    5-16 6 / 16 (38%) 0.8 (0.3-2.2) 
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Risk factor: delay in registration 
This study clearly shows a heavy impact of long registration delay on the impairment 
status of new leprosy patients from central Ethiopia. Patients with delays below two years 
had a much smaller chance (42%) of being impaired than patients with longer delays 
(72%). Among the impaired, similar differences were observed: their chance of grade 2 
impairment was 31% for delays below and 52% for delays above 2 years. 
The role of registration delay was also addressed in recent studies from Zimbabwe and 
Thailand. A strong association between delay and grade 2 impairment was shown in the 
study from Zimbabwe (7). Further analysis of the dataset underlying that study revealed 
that 41% of patients with a registration delay below 2 years presented with impairment 
against 60% of patients with longer delays. The proportion with grade 2 impairment 
among the impaired new patients from Zimbabwe increased from 60% for delays below 
2 years to 73% for delays above 2 years. 
For Thailand also a significant association with delay was found: 17% of patients with a 
delay below 2 years had impairments against 23% of patients with longer delays (4). The 
association between delay and the proportion grade 2 impairment amongst the impaired 
was particularly strong: 30% for delays below 2 years and 58% for longer delays had 
grade 2. Biological differences between populations and differences in case detection and 
assessment methods, methods of interviewing patients and calculation procedures may all 
underlie differences in results from studies on the importance of the registration delay as 
a risk factor for impairment. Nevertheless, all the above results are remarkably consistent. 
0-1 1-2 2-4 4+
Registration delay in years (n=586)
0
10
20
30
40
50
60
70
80
90
Pe
rc
en
ta
ge
Grade 0
Grade 1
Grade 2
Figure 7.3 Impairment status of new leprosy patients according to registration delay. 
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Risk factor: age 
Several studies have reported that the risk of impairment in new cases increases with age 
(2, 5, 7, 8). However, such a univariate association does not occur in the study from 
Thailand (4), and observed univariate associations between age and impairment may be 
confounded by the registration delay. In the present study, the multivariate analysis shows 
that the risk of impairment increases with age independently of other risk factors 
including registration delay. Interestingly, a different effect of age was shown for the risk 
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Figure 7.4 Proportion of impaired new leprosy patients presenting with grade 2 impairment according to gender
in relation to both registration delay and age. 
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of grade 2 impairment amongst impaired new cases: this study showed this risk to be 
lowest among the individuals of ages 45 and above. We do not have a straightforward 
explanation for these age effects. Additional examination of the data presented in the 
Thailand study (4) and of the datasets underlying the Zimbabwe study (7) and another 
recent study from Bangladesh (9) did not give further evidence for the finding of a lower 
risk of grade 2 impairment in impaired new cases of older ages. 
Risk factor: classification in relation to BI 
MB patients with BI 0, 1 or 2 had the highest risks of impairment. The lower odds ratios 
in the multivariate analysis are largely explained by the relatively high age of these MB 
patients. MB patients with high bacterial loads (BI≥3) had relatively few impairments, and 
had a significantly lower risk of grade 2 once being impaired. Further investigation 
showed that this risk was significantly lower only for LL patients with BI≥3 in univariate 
analysis, and for both BL and LL patients with BI≥3 in multivariate analysis. In the 
present study, all LL patients but two had a BI of 3 or more. Gilbody stated that 
borderline leprosy is “potentially the most widespread and crippling form of leprosy” 
(34). This is in line with our observation that the risk of grade 2 impairment is lower for 
LL patients with BI 3 or more, but does not explain our finding that the risk is also lower 
for the BL patients with BI 3 or more than for the PB patients (all but 7 are BT) and the 
other MB patients (12 BT, 70 BL, 2 LL and 2 NL). This finding, however, may not be too 
surprising if one realizes that BL leprosy with BI 3 or more is very close to true LL 
leprosy in the leprosy spectrum. 
Risk factor: gender 
Males had impairments more often than females, but this finding was neither significant 
in the univariate nor in the multivariate analysis. The mean registration delays for males 
and females were almost identical (2.4 versus 2.3 years). The finding as such that 
impairments are more common in males than females (although with a non-significant 
difference) is in line with many reports in literature (e.g. (2, 4, 5, 8, 9, 18)). The data 
underlying the study from Zimbabwe not only show a higher risk in males, but also 
longer mean registration delays for males as compared to females (3.1 versus 2.1 years).  
A significant excess in grade 2 impairment in impaired females was found in the 
univariate analysis. This excess is difficult to explain (see also Figure 7.4), and its 
significancy disappeared in the multivariate analysis. Comparison with published data 
(4, 8) and data underlying published reports (7, 9) revealed that the proportion with 
grade 2 impairment among the impaired was higher in males than females from 
Thailand (4) and Zimbabwe (7), whereas equal proportions were found for the studies 
from Chad (8) and Bangladesh (9). 
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Other risk factors 
In this study, 92 patients received dapsone treatment for a duration of 1-16 weeks before 
inclusion. In the cohort, significant associations with the risk of impairment were neither 
found in the univariate nor in the multivariate analyses. It has been reported that dapsone 
treatment may enhance the risk of nerve function impairment (35). Development of new 
nerve function impairment after the start of MDT has also been observed (3, 4, 36). 
Other risk factors for impairment which have been identified but which were not 
analysed in the present study include occupation, site of lesions, method of case 
detection, geographic and socio-economic factors, educational attainment and ethnic 
group (6). 
Sources of bias 
Registration delays are obtained by asking the patient when he or she first noticed 
symptoms. In his or her mind, a patient might advance this moment in time, especially in 
cases of long duration of disease. On the other hand, patients or staff could presume that 
the duration of disease is of long duration when impairments are present. Clearly, the 
fallibility of patient’s recall of first awareness of symptoms can bias the relationship 
between delay and risk of impairment, although it is difficult to judge the direction of the 
effect.  
In the present study, the date of registration was combined with the recorded calendar 
year of first notice of symptoms in estimating the registration delay. We used the mid-year 
of this calendar year. This inaccuracy will lead to underestimation of the strength of the 
association between delay and impairment.  
Other sources of bias can also not be excluded. Case detection was of a passive nature 
and differences in awareness of symptoms and in self reporting behaviour can exist. 
Recall of onset of symptoms may also vary between groups of patients. It may be possible 
that certain findings from this study (in particular the lower risks of grade 2 impairment 
amongst the impaired in males and in patients of ages 45 and above) are to some extent 
related to these sources of bias. On the whole, we still found strong associations between 
impairments status and risk factors in this cohort. Studies comparing routinely obtained 
registration delays with delays obtained by carefully designed in depth interviews might 
give valuable information on the reliability of the registration delay. 
Size of the problem 
Individuals with grade 1 impairment are at risk of developing more severe impairments 
and subsequent disabilities. This study has shown that short registration delays are 
associated with less grade 1 impairment. The size of the impairment problem in new cases 
is usually only expressed in terms of the proportion with grade 2 impairment. In a report 
from 1995, this proportion was above 20% in four out of fifteen major endemic countries 
that together contributed 95% of the world wide new case load with grade 2 impairment 
(1). From this perspective, the 23% grade 2 impairment observed in this study is 
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disturbingly high. It is encouraging that the proportion with grade 2 impairment reported 
by ALERT’s control services in central Ethiopia was somewhat lower in 1995, 1996 and 
1997 than in the early 1990s (37). Considering ALERT’s presence in the area for a period 
of over 3 decades, re-thinking of control methodologies is definitely required, although it 
is also clear that public attitudes towards leprosy cannot be changed easily (22). 
Implications for research and control 
The search for ways to reduce delays in diagnosis and treatment should have high priority 
in leprosy research and in leprosy control programmes. Research addressing this challenge 
has recently been conducted in Ethiopia. It was shown that ex-leprosy patients were 
important advisors for seeking early treatment. Also, 21 out of 31 patients (68%) initially 
presenting with grade 2 impairment versus 11 out of 48 non-impaired patients (23%) had 
first sought help from traditional healers instead of directly contacting the general health 
services (unpublished data from the All Africa Leprosy, Tuberculosis and Rehabilitation 
Centre (ALERT), Addis Ababa, Ethiopia). 
A second study broke down the delay until start of treatment into several components 
(22). It was shown that just over 50% of the delay occurs before the patient seeks any 
help. Use of some form of traditional medicine accounted for just under one-third of the 
delay, and delay after attending a recognized clinic accounts for over 10% of the total 
delay. The delay until the patient’s first action and the delay between first action and the 
first visit to a recognized clinic were significantly longer for impaired patients. High levels 
of stigma and use of traditional medicine were found to be associated with more 
impairment when comparing two rural areas of Ethiopia with different impairment rates 
in new patients.  
It is highly questionable whether a shift to active methods of case finding can be 
cost-effective. In addition, there is already a tendency to integrate leprosy services into the 
general health services. This calls for proper management of leprosy suspects, and delays 
in referral for leprosy treatment within the general health services should require special 
attention. In view of problems with referral, Bekri et al suggest that in the Ethiopian 
context, it would be ideal for diagnosis and the start of treatment to be done at the rural 
clinic, with examination by a specialist at a later stage (22). They also state that reducing 
stigma is far more complex than imparting knowledge alone, and that health education 
campaigns must be well planned and sufficiently sophisticated in order to have any 
impact. A recent review already indicated that gender inequalities should be a point of 
concern to health services and in health education (38). A national advertising programme 
involving mass media was an integral part of a successful campaign against leprosy in the 
early 1990s in Sri Lanka (39). The potential benefits of well-researched media campaigns 
need to be investigated. 
In conclusion, a better understanding of factors determining delays is of eminent 
importance for the development of strategies that minimize impairment at registration 
and thus minimize permanent disability in those who develop leprosy. This has also been 
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recognized by the Medico-Social Commission of ILEP, which identified investigation of 
factors influencing delay in diagnosis and treatment for different communities as a major 
research priority in the context of prevention of disability in leprosy (ILEP: Development 
of an ILEP co-ordinated programme of research on nerve damage and reactions in 
leprosy. Internal Report. Draft, June 1998).  
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8.1 Summary 
This study investigates the dynamics of impairment during and after multidrug therapy 
treatment for the patient cohort of the prospective ALERT MDT Field Evaluation Study 
(AMFES). The impairment status was compared at intake, at release from treatment (rft), 
and at the time of the latest survey between 24 and 48 months after release from 
treatment (follow-up). The eye-hand-foot impairment score (EHF score), which is the 
sum of the WHO impairment grades of the eyes, hands, and feet, was used as tool for 
comparison. In all, 433 out of the 592 patients (224 PB and 209 MB) completed 
treatment in time and were assessed at release from treatment. The risk of getting 
impaired was 4% for the 113 PB and 21% for the 91 MB patients who were initially free 
from impairment. Out of the 111 initially impaired PB patients, 41% recovered or 
improved and 13% worsened in EHF score. For the 118 initially impaired MB patients, 
these figures were: recovery or improvement 43% and worsening 13%. Three hundred 
and twenty-three out of the 433 patients (158 PB and 165 MB) had a follow-up 
examination in between the next 24 to 48 months after rft. The risks of impairment at 
follow-up were 6% for the 79 PB and 18% for the 77 MB patients without impairment at 
rft. Out of the 79 PB patients with impairment at rft, 35% recovered or improved and 
28% worsened. For the 88 impaired MB patients, these figures were: recovery or 
improvement 26% and worsening 27%. Patients showed a tendency to compensate EHF 
score improvement before rft by worsening after rft and vice versa. The first main 
conclusion is that the impairment status at intake was by far the most important 
determinant for future impairment. The second one is that the dynamics of impairment 
were less favourable after rft than before. Little is known about the long-term fate of 
leprosy patients with irreversible nerve damage and the associated risk of developing 
severe secondary impairment. Especially in this era of the leprosy elimination goal, we 
should give this accumulating patient group due attention in research and health policy 
agendas.  
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8.2 Introduction 
Newly detected leprosy patients may or may not present with impairments. During and 
after multidrug therapy (MDT), new impairments may develop, and existing impairments 
may worsen, remain stable or improve. Many studies have addressed the presence of 
impairments in newly detected patients (e.g. (1-7)). Less attention has been paid to the 
dynamics of impairment during and especially after MDT treatment. One study addressed 
patients in Malawi (8); other studies were conducted in Asian countries (3, 5, 9, 10). The 
percentage of newly detected patients presenting with impairment varied considerably 
across these studies. Whereas worsening of impairment status was not negligible, the 
studies revealed that a majority of patients with impairment at release from MDT already 
had impairment at registration. In only one of these studies (5), the impairment dynamics 
were evaluated during a follow-up period that extended well beyond release from 
treatment.  
All studies employed WHO disability grades. The use of the term ‘disability’ is however 
questionable. According to the International Classification of Impairments, Disabilities 
and Handicaps (ICIDH) (11), disability refers to inability to perform activities due to 
impairment. Impairment is defined as ‘any loss or abnormality of psychological, 
physiological, or anatomical structure or function’. Under ICIDH, the WHO grades do 
not reflect disability but impairment (10). Following earlier publications (7, 9, 10), this 
paper will therefore use the term ‘WHO impairment grade’ instead of ‘WHO disability 
grade’. In the generally known 1988 WHO system (12), grades are assigned to each eye, 
hand and foot using a scale with three possible outcomes (0,1,2). The maximum of these 
six grades, the ‘maximum WHO impairment grade’, specifies the patient’s overall score. 
The 1988 WHO system has again been updated in 1998 by re-defining the grades for the 
eyes (13).  
The maximum WHO impairment grade recognises both first onset of impairment and 
total recovery of existing impairment. Otherwise, its sensitivity to improvement or 
worsening of impairments is limited. This is of concern because from patient registration 
onwards, the performance of the services of a leprosy control programme is expressed in 
changes in impairment and disability. Accordingly, the 1988 maximum WHO impairment 
grade has primarily been applied to compare impairment profiles of newly detected 
patients across countries (14). De Rijk et al introduced an alternative summary score 
which uses the sum instead of the maximum of the individual grades for eyes, hands and 
feet (15). Further study of impairment dynamics promoted the so called eye-hand-foot 
impairment score (EHF score), as demonstrating a higher sensitivity in registering change 
than the maximum WHO grade (10). The EHF score has also been suggested as tool for 
evaluating the effectiveness of steroid programmes (16). The EHF score and the 
maximum WHO impairment grade share the advantage that their components – the 
individual grades for eyes, hands and feet – are routinely recorded in leprosy control 
programmes.  
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In this paper, the EHF score is applied to investigate the severity and evolution of 
impairment over time for the cohort of the ALERT MDT Field Evaluation Study 
(AMFES). Comparisons are made between EHF scores at intake, at release from 
treatment, and at the latest survey examination between 24 and 48 months after release 
from treatment. Objectives and interim results of the AMFES study, which is conducted 
within a routine leprosy control programme in central Ethiopia, were described before by 
de Rijk et al  (15, 17). 
8.3 Materials and methods 
Methods of enrolment, diagnosis, administration of fixed-duration MDT and case holding 
in AMFES have previously been specified (15) and reviewed (18). The present study 
involves all enrolled newly detected patients except those who had errors in enrolment 
procedures or in diagnosis.  
Recorded patient characteristics include age, sex, clinical classification and bacteriological 
index (BI). The type of treatment (PB or MB) was chosen on the basis of clinical 
classification and skin smears. For clinical classification, the simplified system for field 
workers recommended by Jopling (19) was used. It should be recognized that many 
patients correctly diagnosed as PB in the present study would be classified as MB if 
presently used criteria focussing on number of skin lesions or number of body areas 
affected had been applied (13).  
AMFES patients were scheduled for examination at intake, while on MDT, at release 
from treatment, at 3 and 6 months after release from treatment (rft) and thereafter at 
intervals of 6 months. Examination involved the recording of the WHO impairment 
grades for the eyes, hands and feet according to the 1988 WHO grade definitions (12). 
The maximum WHO impairment grade and the sum of these six impairment grades for 
the eyes, hands and feet – EHF score (ranging from 0 to 12) – follow directly. This paper 
investigates the dynamics of impairment by comparing the EHF scores at three different 
points in time: intake, release from treatment, and the time of the latest survey conducted 
between 24 and 48 months after release from treatment. A considerable number of 
patients did not complete treatment, and some patients did complete treatment in due 
time but were not examined at release from treatment. Patients who did complete 
treatment and who were examined at release from treatment are referred to as 
‘rft-patients’. Those among the ‘rft-patients’ who in addition had a survey examination 
between 24 and 48 months after release from treatment are in this study denoted as 
‘follow-up’ patients. Unless indicated otherwise, the term ‘worsening’ will refer to any 
increase in EHF score (this includes onset of impairment in previously unimpaired 
patients). ‘Improvement’ refers to a decrease in EHF score, while ‘recovery’ indicates that 
the EHF score has decreased to zero from a previously positive score. 
In the data analysis, statistical significance refers to the 5% level. Frequency distributions 
were compared using the Chi-square test. The data analysis was carried out in SPSS. 
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8.4 Results 
A total of 603 new patients were enrolled in the AMFES project. Out of these, 11 
patients were excluded from the present data analysis because of either incorrect 
enrolment procedures or incorrect diagnosis. The resulting study cohort consists of 292 
PB and 300 MB patients.  
The cohort over time 
Out of the 592 patients, 454 patients completed treatment in time. The treatment 
completion rates were higher for PB than for MB patients (PB: 242/292, or 83%, against 
MB: 212/300, or 71%, p<0.001). Thirteen patients died before they could be released 
from treatment, 104 did not complete treatment and were lost to follow-up, and 21 did 
not complete treatment in due time but were seen later. Twenty-one patients completed 
treatment in time but were not examined by the leprosy control supervisor (LCS) at the 
end of treatment. So, 433 (224 PB and 209 MB) patients completed treatment in time and 
were examined by the LCS at release from treatment.  
The 433 rft patients differed from the other 159 patients in the cohort in several respects. 
Summarizing, the rft group included more children (PB: 22% against 7%, p<0.01; MB: 
11% against 5%, p=0.1). As compared to the non-rft group, the MB rft patients more 
often had high BI values (BI ≥ 3; 75% against 63%, p<0.05) and less often had EHF 
scores of 3 or more (28% against 41%, p<0.05). The percentage with EHF score 3 or 
more was 25% for both PB rft and non-rft patients.  
Out of the 433 rft patients, 323 patients had a follow-up examination between 24 and 48 
months after rft (158/224 PB, or 71%, against 165/209 MB, or 79%; p<0.05). In 
comparing these ‘follow-up’ patients with the 110 rft patients without follow-up (66 PB 
and 44 MB), again differences are observed. Females were under-represented in the 
follow-up group of PB rft patients (37% against 52%, p=0.05). The age distributions of 
the PB rft patients with and without follow-up also differed significantly. In the follow-up 
group, children were over-represented (25% against 15%) and young adults (ages 15-29 
years) were under-represented (30% against 52%). In MB patients, the percentages of 
females were similar (31% against 30%), whereas children and young adults together were 
over-represented in the follow-up group (58% against 41%, p=0.05). The rft patients with 
follow-up did not differ significantly from the rft patients without follow-up in percentage 
with BI 3 or more (MB patients only), percentage with EHF-score 3 or more (PB: 27% 
against 20%, MB: 28% against 25%) and percentages improving (including recovery) and 
worsening in EHF score between intake and rft.  
Impairment at intake 
Table 8.1 gives details of impairments at intake. About half of the patients had no 
impairment. Five percent of both PB and MB patients had just one extremity or eye 
affected with WHO grade 1 (EHF score 1). Thirty-three of PB and 39% of MB patients 
had EHF scores ranging from 2 to 4. The percentages with EHF score 5 or more were 
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11% for PB and 12% for MB. Between PB and MB, no significant differences were 
observed in percentage with any impairment (PB: 50%, MB: 56%) and with WHO grade 
2 impairment (PB: 26%, MB: 21%). PB patients with EHF scores ranging from 2 to 4 
more often had at least one extremity or eye affected with WHO grade 2 than MB 
patients (PB: 45%, MB: 21%, p=0.001). All patients with EHF score 5 or more had at 
least one extremity or eye with grade 2 impairment. Further analysis showed that, with 
two exceptions for both PB and MB, they all had at least four extremities affected (for 
this analysis both eyes are included with the hands and feet to give a total of six 
‘extremities’). The large majority of the group of all impaired patients had at least two 
extremities affected (PB: 76%, MB: 87%). 5/224 (2%) PB patients and 3/209 (1.4%) MB 
patients had eye impairment: all these patients, except one PB patient, had only grade 1 
eye impairment. After re-examining patients with eye problems, data on eyes were 
corrected to refer to eye impairment that is due to leprosy only. Eye impairment figures 
earlier presented by de Rijk et al were therefore higher (15). Overall, the distribution of 
EHF-scores did not differ significantly between PB and MB patients. 
Dynamics of impairment in PB patients  
Figure 8.1 summarizes changes in impairment over time for the PB patients. Four of 113 
(4%) patients free from impairment at intake had impairment at rft. At the same time,
Table 8.1 Comparison between maximum WHO impairment grade and eye-hand-foot (EHF) score at intake for 
patients who completed treatment and who were assessed for impairment grades of eyes, hands and feet at 
release from treatment (‘rft patients’). 
EHF score 
Maximum 
WHO grade 0 1 2 3 4 5 6 7+ Total
Percentage 
(%) 
PB patients  
    0 113 113 50% 
    1 11 29 6 6 52 23% 
    2 16 11 7 4 11 10 59 26% 
Total 113 11 45 17 13 4 11 10 224  
Percentage (%) 50% 5% 20% 8% 6% 2% 5% 4% 100% 
MB patients  
    0 91 91 44% 
    1 10 45 11 9 75 36% 
    2 5 5 7 10 11 5 43 21% 
Total 91 10 50 16 16 10 11 5 209  
Percentage (%) 44% 5% 24% 8% 8% 5% 5% 2% 100% 
   
Figure 8.1 Changes over time in impairment status as measured by the eye-hand-foot (EHF) score for PB
patients who completed treatment and whose impairment grades were assessed at release from treatment (‘PB
rft patients’), and for PB rft patients who in addition were assessed for impairment grades between 24 and 48
months after release from treatment (‘PB follow-up patients’). 
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15/111 (14%) initially impaired patients recovered from their impairment. These changes 
imply that the vast majority of patients with impairment at rft (96 out of 100) already had 
impairment at intake. Overall, improvement including recovery was more common than 
worsening (which includes onset of impairment, 46 versus 18 patients). Nearly half of the 
initially impaired patients (46%) did not change in EHF score.  
Between rft and follow-up, the numbers of patients improving or recovering and 
worsening were very similar with 28 and 27. Having impairment at rft is by far the most 
important determinant for having impairment at follow-up: 69/74 (93%) of those with 
impairment at follow-up were already impaired at rft. 
Table 8.2 shows the relation between changes in EHF score in the two consecutive time 
intervals. A tendency for compensating changes is most noteworthy. Out of those who 
improved or recovered during treatment, 33% (12/36) worsened in EHF score after rft, 
compared to 12% (15/122) for those who stayed the same or worsened during treatment 
(p<0.005). Similarly, 62% (8/13) of patients who worsened during treatment improved or 
recovered after rft, versus only 14% (20/145) of the others (p<0.001).  
EHF score change does not necessarily reflect a patient’s impairment dynamics well 
because improvement in one extremity or eye may coincide with worsening in another. 
Between intake and rft, this actually happened in three patients (the EHF score did not 
change in one and improved in two of them). Further analysis revealed the same 
Table 8.2 Relation between changes in eye-hand-foot (EHF) score between intake and treatment completion 
(‘intake → rft’) and between treatment completion and latest assessment between 24 and 48 months after 
treatment completion (‘rft → follow-up’) for patients who completed treatment and were assessed for impairment 
grades at release from treatment and in the post-treatment period (percentages of all patients in brackets). In the 
table, ‘improvement’ refers to any gain and ‘worsening’ to any loss in EHF score. 
 
    Change in EHF score 
    (rft → follow-up)  
Change in EHF score  
(intake → rft) Improvement No change Worsening Total  
PB patients  
Improvement 8 (5%) 16 (10%) 12 (8%) 36 (23%)  
No change 12 (8%) 84 (53%) 13 (8%) 109 (69%)  
Worsening 8 (5%) 3 (2%) 2 (1%) 13 (8%)  
Total 28 (18%) 103 (65%) 27 (17%) 158 (100%)  
MB patients  
Improvement 2 (1%) 20 (12%) 20 (12%) 42 (25%)  
No change 10 (6%) 72 (44%) 14 (8%) 96 (58%)  
Worsening 11 (7%) 12 (7%) 4 (2%) 27 (16%)  
Total 23 (14%) 104 (63%) 38 (23%) 165 (100%)  
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phenomenon in seven patients after rft. One of them worsened, two did not change and 
four improved in EHF score. These opposite changes imply that 35% (28/79) of the 
already impaired follow-up patients worsened in at least one eye or extremity during 
follow-up, against 28% (22/79) who worsened in EHF score.  
Further analysis revealed the maximum change in EHF score between intake and rft to be 
three points: one rft patient worsened, and two rft patients improved by three points. The 
change was at least two points in 33% of all worsening patients, and in 16/39 (41%) of 
improving patients with an initial EHF score of 2 or more (including eight recoveries). 
Between rft and follow-up, two patients worsened, and four patients improved by three 
points or more. The change between rft and follow-up was at least two points in 41% of 
all worsening patients, and in 15/25 (60%) of improving patients with an EHF score of 2 
or more at rft (including seven recoveries). Overall, no important changes occurred over 
time in the distribution of EHF scores for PB patients as a group; the differences 
between intake, rft and follow-up were not statistically significant for the rft patients, nor 
for the follow-up group (EHF score categorization used: 0, 1, 2, 3-4, 5-6, 7-12). 
Dynamics of impairment in MB patients 
The EHF score changes for the MB patients are summarized in Figure 8.2. In the MB 
group, recovery of existing impairment (23 patients) between intake and rft is largely 
compensated by first onset of impairment (19 patients). Still, the vast majority of patients 
with impairment at rft were also already impaired at intake (95/114, or 83%, against 96% 
for PB). Improvement plus recovery again occurred more often than worsening (51 
versus 34 patients). Over 40% of initially impaired patients (44%) did not change in EHF 
score.  
Between rft and follow-up, less patients improved than worsened in EHF score (23 
versus 38 patients). In comparison to earlier change, impaired patients less often 
improved or recovered (23/88, or 26% against 51/118, or 43%, before rft) and about 
twice as often worsened (24/88, or 27%, against 15/118, or 13%). Again, presence of 
impairment at rft is by far the most important determinant for later impairment: 76/90 
(84%, against 93% for PB) patients with impairment at follow-up also had impairment at 
rft.  
A tendency for compensating changes similar to that for PB patients is observed 
(Table 8.2). Out of those who improved or recovered during treatment, 48% (20/42) 
worsened in EHF score after rft, compared to 15% (18/123) for those who stayed the 
same or worsened during treatment (p<0.001). Also, 41% (11/27) of patients who 
worsened during treatment improved or recovered after rft, versus only 9% (12/138) of 
the others (p<0.001). 
WHO impairment grades of extremities and eyes also simultaneously changed in opposite 
directions in MB patients. Out of the nine patients who experienced this before rft, three 
improved in EHF score and six maintained their score. Because 13% (15/118) of the  
 
 Figure 8.2 Changes over time in impairment status as measured by the eye-hand-foot (EHF) score for MB
patients who completed treatment and whose impairment grades were assessed at release from treatment (‘MB
rft patients’), and for MB rft patients who in addition were assessed for impairment grades between 24 and 48
months after release from treatment (‘MB follow-up patients’). 
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patients with impairment at intake worsened in EHF score, this implies that 20% 
(24/118) of them worsened in at least one eye, hand or foot. After rft, only two MB 
patients experienced simultaneous improvement and worsening (one worsened and two 
of them did not change in EHF score). 
Further analysis also demonstrated notable changes in the MB patients. Between intake 
and rft, six rft patients worsened, and eight rft patients improved by three EHF points or 
more. The total change was at least two points in 47% of all worsening patients, and in 
33/47 (70%) of improving patients with an initial EHF score of 2 or more (including 19 
recoveries). Between rft and follow-up, six patients worsened, and one patient improved 
by 3 points or more. The total change between rft and follow-up was at least two points 
in 34% of all worsening patients, and in 10/20 (50%) of improving patients with an EHF 
score of 2 or more at rft (including nine recoveries). Statistically significant differences in 
the EHF score distributions over time were not observed for the MB patients. 
8.5 Discussion 
The present study confirms the earlier indication that the AMFES cohort is severely 
affected by impairment and disability (7). Many patients were impaired at intake, 
frequently with WHO grade 2 and usually with multiple extremities involved. More than 
10% of both PB and MB patients had EHF scores of 5 or more. Such scores imply very 
extensive nerve involvement. 
Dynamics of impairment over time 
The dynamics of impairment over time were illustrated by comparing EHF scores 
between intake and rft, and between rft and follow-up survey. Only a minority of patients 
with impairment at intake recovered completely. Impairment at the previous assessment 
was the most important determinant for impairment at the next. The dynamics of 
impairment were less favourable after rft than before. The risk of becoming impaired was 
both before and after rft significantly lower for PB than MB patients without previous 
impairment. During both periods, more than half of the impaired PB and MB patients 
changed in EHF score. A tendency towards compensation of EHF score improvement 
before rft by worsening after rft and vice versa was observed. Overall, the EHF score 
distributions of the PB and MB groups hardly changed over time. 
Although the differences in the EHF score distributions at the different assessments were 
not statistically significant, the dynamics of impairment after rft deserve special attention. 
Compared with the treatment period, both PB and MB patients with impairment showed 
further worsening of their EHF score after rft twice as often. The EHF score measures 
both primary and secondary impairments. The development of primary impairments 
(sensory loss and muscle weakness) relates to active neuritis which, although it occurs, is 
much less common after rft than before (20). The worsening of the EHF score after rft is 
therefore likely to be due to increasing secondary impairment (wounds, ulcers and tissue 
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loss), although the AMFES database does not contain this information in detail. This is in 
accordance with the suggestion from a study from Thailand that with longer periods after 
rft, changes in impairment status will more and more be due to new/increased tissue 
damage (e.g. wounds, bone loss) than to increases in NFI (5). 
Drop-out rates in our study were considerable. The greatest number of losses occurred at 
the time of the overthrowing of the former Ethiopian government in 1991 (18). Probably, 
the longer duration of MB treatment contributes to the lower treatment completion rates 
in MB as compared to PB patients (71% versus 83%). In contrast, follow-up of rft 
patients was more successful in the MB group (79% examination versus 71% for PB). 
The drops-outs before and after rft differed from the other patients in several respects. 
Significant differences in EHF score change before rft were not observed between 
patients who did and did not drop-out after rft. It must be noted that patients who 
experience complications may at times both be more prone (need for extra care) and less 
prone (due to loss of confidence in the programme, or hiding because of stigma) to 
complete treatment and to present at follow-up examinations.  
Studies that address change in impairment over time (3, 5, 8-10) are difficult to compare 
because of differences in case definitions, treatment durations and scoring systems for 
impairment. Still, all these studies found that clear majorities of patients with impairment 
at rft already had impairment at registration. One study also addressed change after rft (5). 
In contrast to our study, the risks of worsening after rft were lower (but still significant) 
than before for MB patients and similar for PB patients. The EHF score was only utilized 
in two studies from Nepal (9, 10). Both studies addressed the same group of MB patients 
at diagnosis and examination after two years of MDT. The percentage with impairment at 
diagnosis (44%) was identical to our MB group. Although the percentage of patients with 
EHF scores of seven or more was higher in the Nepal group (6% versus 2%), the EHF 
score distributions at diagnosis were overall rather similar. Differences in the EHF score 
dynamics between the Nepal study and our study (usually rft was also two years later than 
intake) were observed, but a consistent pattern was not observed.  
The dynamics of the EHF score after rft are worrisome. In addition, little is known about 
the long-term fate of leprosy patients who have irreversible nerve damage. The years of 
life lost to disability in this patient group, which accumulates over periods of many years, 
represents the real burden of leprosy disease. More insight into the size of this group, in 
the health related problems that they experience, in the care and support that they judge 
appropriate and in the associated resource requirements is urgently required. This patient 
group should get the attention in health policy agendas that it is entitled to. 
Reflection on the use of the EHF score 
We chose the EHF score as the evaluation tool for the present study. The EHF score 
gives a more detailed picture of the impairment status than the maximum WHO grade. In 
one of the two papers from Nepal, van Brakel et al showed the EHF score to be much 
more sensitive than the maximum WHO impairment grade: 37% of patients who 
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changed in EHF score did not change in maximum WHO grade (10). Further analysis 
showed this difference to be more pronounced in our study.  
We agree with van Brakel that the EHF score is not a perfect impairment indicator: it 
remains a simple sum of the WHO impairment grades of the extremities and eyes. A 
point of criticism with respect to summary scores such as the EHF score is that they are 
unable to discriminate between a major change in one component and minor changes in 
several components. But for the WHO grades for extremities and eyes that make up the 
EHF score, van Brakel et al stated that “a change of one point at any site usually 
constitutes a major change in impairment status” (10). In extremities that improved in 
WHO impairment grade upon corticosteroid treatment, Broekhuis et al showed the 
changes in sensory testing (ST) and voluntary muscle testing (VMT) to be important (16). 
Nevertheless, the EHF score may mask simultaneous changes of extremities and eyes in 
opposite directions. The frequency with which this happened in our study group is 
however not alarming.  
The reliability of the EHF score has not yet been established. To our knowledge, the 
retrospective study by Broekhuis et al (16) is the only study that investigated the reliability 
question. They indicated the Hand-Foot impairment score (sum of the WHO grades for 
extremities: HF score) to be a promising device for the evaluation of the effectiveness of 
corticosteroid treatment at programme level. They also demonstrated that the EHF score 
is not a suitable device for supporting individual patient management.  
Unfortunately, it is not possible to validate the EHF score on the basis of the AMFES 
cohort. The main reasons for this are lack of detailed information on secondary 
impairment and the fact that the monitoring of AMFES patients was less close after rft. 
Compared with other scoring systems, the EHF score has some important advantages. It 
is simple, reproducible, and information on its components (the WHO impairment grades 
for extremities) is already routinely collected in many control programmes (16). Although 
we acknowledged a number of deficiencies in the EHF score, we are convinced that they 
are outweighed by the practical usefulness of the EHF score. Following van Brakel (10) 
and Broekhuis (16), we therefore strongly recommend initiation of prospective validation 
studies of the EHF score as tool for the evaluation of activities at programme level. 
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In this chapter, the research questions formulated in Chapter 1 are answered (9.1). Next, 
the prospects for reducing the global prevalence of impairment caused by leprosy are 
evaluated on the basis of the findings presented in this thesis (9.2). Finally, general 
conclusions and recommendations are given (9.3). 
9.1 Answering the research questions 
Question 1  
What were the trends in leprosy case detection rates in recent decades?  
Answer 
The observed trends in leprosy case detection rate (CDR) vary widely between different 
areas and countries. Persistent declines, stable trends and trends with strong fluctuations 
are all observed. One major endemic country, Brazil, differs from all others: its CDR 
increased during almost three decades. In the 1990s, the CDR was stable or increased in 
many countries.  
Comment 
Chapter 2 presents a literature review of trends in leprosy case detection rates (CDRs) 
that were published in international literature. The 16 selected trends all covered at least 
ten years, including 1982-1987. For 13/16 areas and countries, the trends were declining 
by at least 2% per year. A rather stable trend was observed in one area, a district in India, 
and the Brazilian CDR increased from 1970 until the end of the observation period in 
1987. In one country, the CDR did not show a clear pattern. It was already noted in 
Chapter 2 that the literature review may have suffered from publication bias: a tendency 
to publish on high-quality control programs covering long periods of time or indicating 
successful leprosy control cannot be excluded. 
By combining information from different sources, CDRs were also derived from 1985 to 
at least 1998 for 14 countries with high case loads, see Chapter 3. These 14 countries 
accounted for the vast majority of the global case detection during 1985-1998, also when 
India is excluded (in 1998, India accounted for almost 80% of global case detection). The 
CDRs of these 14 countries showed a less favourable picture than the literature review. 
For only four countries, a decreasing tendency was observed, either during 1985-1998 as a 
whole or in more recent years. The CDRs were rather stable or increased for the other 
ten countries, which included India and Brazil. For some of these countries, sudden sharp 
increases in CDR were observed in the late 1990s. The increase in CDR in Brazil that 
started in 1970 persisted until the late 1990s. In terms of annual number of cases 
detected, Brazil always ranked second after India during 1985-1998. Although available 
information is not entirely complete, the data from Chapter 3 suggest that the global 
CDR may have decreased slightly at best. 
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Question 2 
Can the observed trends in leprosy case detection in recent decades be explained, and do 
the available data provide evidence for an impact of leprosy control on transmission? 
Answer 
Available data do not suffice for disentangling possible causes for observed downward 
trends in case detection. BCG vaccination may have been important in some areas, but 
not in others. There is no evidence for an impact of early case detection and 
chemotherapy on transmission. Most likely, the observed increases in case detection in 
the 1990s are the consequence of intensification of case detection efforts.  
Comment 
Both reduced transmission and reduced detection efforts may lead to reductions in case 
detection. The literature review from Chapter 2 suggests that several factors may have 
reduced transmission in different areas/countries, but hard evidence is not provided. 
Findings are summarised below. Case detection trends in the 1990s have undoubtedly 
been influenced by intensification of leprosy control (Chapter 3). 
Socio-economic improvement 
The papers reviewed hardly provide information on socio-economic improvement, 
although it is suggested that geographical differences in economic growth may have led to 
differences in declines in CDR within China. Further information shows that there was 
often at least some socio-economic improvement, which may have contributed to 
declines in CDR. Two crude indicators for improvement, female illiteracy rate and life 
expectancy at birth, improved in both the 1970s and 1980s in almost all countries of the 
literature review (CDR trends up to 1993 were reviewed) (1). A third indicator, the gross 
domestic product (GDP) per capita, increased for most countries in the 1970s but this 
growth often did not persist.  
BCG vaccination 
BCG was incorporated in the Expanded Programme on Immunization (EPI) of infants in 
1974. Infant vaccination can only have a substantial impact on CDRs after many years 
because children constitute a minority in leprosy case detection. The reviewed papers do 
not suggest a general impact of BCG on trends, because there were no indications of high 
BCG coverages before 1974, or of vaccination not being confined to infants, with one or 
two exceptions. BCG probably did influence the decline in CDR in Malawi, because it 
was introduced in 1972 in mass campaigns aiming at individuals under 15 years of age (2) 
and because the protective efficacy of BCG in Malawi was at least 50% (3). The potential 
impact of infant BCG vaccination may be limited because the protective efficacy of BCG 
varies widely between populations, and because the efficacy may wane with time, see 
Chapter 1. 
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Case detection and chemotherapy 
There is no evidence that case detection and chemotherapy reduced transmission, 
although this was claimed in the reviewed papers for two areas with supposedly no 
economic improvement and no systematic BCG vaccination (French Polynesia between 
1946-1966, Ethiopia). Clearance of initial backlogs in case detection may also have 
contributed to the CDR declines in these areas (Ethiopia: see (4)). The literature review 
does not demonstrate a general acceleration of existing declines in CDR following the 
replacement of dapsone monotherapy by MDT. Such an impact is still not visible when 
the CDR time series from the review are augmented with more recent data.  
Interaction with tuberculosis 
We refrained from exploring a possible protective effect against leprosy of tuberculosis 
infection and/or disease, because the interpretation of leprosy trends alone is already 
difficult due to issues such as continuity of data collection and of control activities (see 
Chapters 2 and 5). 
Reductions in case detection efforts 
These might lead to reductions in case detection, but also to later detection of patients 
and thus to increases in transmission. In the literature review, we did not find indications 
for associations between overall declines in CDR and decreases in leprosy control efforts, 
with one possible exception (Bhutan).  
CDR trends since 1985 
Case detection efforts were intensified in the 1990s, see Chapter 3. This is the most likely 
reason for the increases in CDR as observed in the majority of countries addressed in 
Chapter 3, since it is hard to imagine that leprosy transmission increased simultaneously 
in all these countries. Nonetheless, it has been suggested that increased transmission may 
have played a role in the Brazilian increase in CDR which persisted over a period of 
almost three decades, because the main operational changes are said to have occurred 
after 1986 (Chapter 2).  
Question 3 
To what extent have isolation of patients and socio-economic improvement contributed 
to the disappearance of leprosy from Norway? 
Answer 
The with SIMLEP estimated contribution of isolation of patients in hospitals to the total 
decline in the Norwegian case detection rate ranges from 3% to 60%; the corresponding 
contributions of the competing explanation socio-economic improvement are 95% and 
34%, respectively. The joint effect of these explanations is larger than the sum of the 
simulated separate effects. 
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Comment 
The case detection rate of leprosy in Norway steadily declined between 1856 and 1920, 
while detection efforts were rather stable. The decline took place long before effective 
chemotherapy became available, and in absence of BCG vaccination. It has been 
suggested that the following factors may have contributed to the decline: isolation of 
patients, socio-economic improvement, selective emigration and interaction with 
tuberculosis (5). 
Chapter 5 presents an analysis of the relative contributions of isolation of patients in 
hospitals versus socio-economic improvement to the decline of leprosy in Norway with 
the leprosy simulation model SIMLEP. The Norwegian trend in leprosy case detection 
was reproduced adequately, and equally well with contrasting assumptions on uncertain 
aspects of leprosy epidemiology which govern the impact of control on leprosy 
transmission (see under question 4). The estimated contribution of hospital isolation to 
the decline ranged from 3% to 60%, depending on the assumptions made regarding 
transmission (corresponding contribution of socio-economic improvement: from 95% to 
34%).  
We investigated the relative contributions of hospital isolation and socio-economic 
improvement on the decline. We could not assess the importance of the suggested 
alternative explanations – isolation of patients in their own homes, selective emigration of 
individuals at increased risk and/or those incubating, and possible interaction with 
tuberculosis – due to lack of data. SIMLEP has also no provisions for studying an 
interaction between leprosy and tuberculosis. Thus, the predicted contributions of 
hospital isolation and socio-economic improvement may overestimate the true 
contributions. Non-selective emigration did not influence the predictions for hospital 
isolation and socio-economic improvement. 
Inspired by an earlier geographical analysis of declines in the incidence (5), we hoped to 
be able to further narrow down the uncertainty regarding the role that hospital isolation 
may have played. Within Norway, geographical differences existed regarding the start and 
the rates of the decline in the incidence on the one hand, and the ‘degree of isolation’ on 
the other (incidence refers to onset of disease). This degree was introduced as a measure 
of how often and long patients were hospitalised. The earlier analysis showed a strong 
positive association between this degree and the relative fall in the incidence rate in the 
next decade in the different Norwegian counties during 1856-1875, but not during 
1881-1910. Unfortunately, the interpretation of this association is not straightforward, for 
several reasons. Firstly, both the degree of isolation and the relative decline in incidence 
rates increased over time. Secondly, the central office of the National Leprosy Registry of 
Norway was located in the southern region of coastal counties where leprosy was 
predominant, in the city of Bergen which also accommodated a research hospital that was 
completed in 1849. This complicates the interpretation of incidence trends: the decline in 
incidence rate was right from the founding of the registry in 1856 in the southern region, 
but started only around 1870 in the middle and northern region. Thirdly, geographical 
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differences in start and pace of socio-economic improvement can also not be excluded. 
Due to these complications, we refrained from a geographic analysis of the Norwegian 
trend data with SIMLEP. 
Question 4 
Which uncertain aspects of leprosy epidemiology contribute most to the uncertainty 
about the impact of leprosy control on transmission? 
Answer 
In our studies, the most important uncertain aspects are whether contagiousness builds 
up during the incubation period, the importance of close contact in transmission and the 
speed at which close contacts become infected. 
Comment 
In the analysis of the Norwegian data, we started with a very simple model, which was 
refined step by step until an adequate fit of the age-specific trend data was reached 
(Chapter 5). The resulting model neither assumed contagiousness during the incubation 
period, nor decreases in a patient’s transmission opportunities over time due to 
exhaustion of susceptibles. Both possibilities are not implausible. The first because there 
is no reason why the shedding of bacilli would start only at the onset of the first clinical 
sign of leprosy. The second because close contacts of leprosy patients may be infected 
rapidly, and because close contact – either in the own household or through neighbours 
and social contacts – may be important for transmission. We explored these possibilities 
because both transmission during the incubation period and rapid transmission limit the 
fraction of transmission that can be prevented by leprosy control. 
The quality of the fit of the Norwegian data hardly changed when contagiousness was 
assumed to build up during the incubation period, or when transmission opportunities 
were assumed to decrease at different rates. However, these assumptions did have a large 
impact on the estimated contribution of hospital isolation to the Norwegian decline: it 
decreased from 60% to 36% when build-up was assumed, and further down to 17%, 9% 
and 3% upon assuming half-value times of transmission opportunities for patients of 8, 4 
and 2 years, respectively.  
A third assumption that we expected to affect the contribution of isolation is the length 
of the incubation period: the contribution should increase with shorter incubation periods 
because these imply shorter turnaround times of the transmission cycle. However, 
relatively small reductions in the length of the incubation period already led to a 
worsening of the quality of the fit of the trend data: the shorter turnaround time caused 
the simulated declines in Norwegian case detection during the first few decades to be too 
fast. 
The scenario analysis of future trends in the transmission and incidence of leprosy from 
Chapter 6 builds on the Norwegian findings. The trend in case detection rate in major 
endemic countries during 1985-1998 was fitted using various SIMLEP models, and 
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incidence rates were projected up to 2020. The same alternative assumptions regarding 
build-up of contagiousness and decrease of transmission opportunities were made as in 
the Norwegian study, and these influenced heavily the incidence predictions. Other 
uncertain aspects which were varied in a sensitivity analysis hardly mattered, except for 
the length of the incubation period and the trend in detection delay up to 1998. 
Shortening of the incubation period gave a similar effect as in the Norwegian study: the 
predicted declines in incidence rates during 2000-2020 were faster for the various models 
considered, but less models gave a good fit to the historical trend data. Assuming larger 
reductions in the detection delay compared to the baseline trend had the same effect (the 
detection delay was assumed to decrease over time, and was always two years on average 
from 1998 onwards).  
Among the other uncertain aspects that were addressed are the fraction of new infections 
progressing to disease, the type distribution of new cases, the self-healing rate for self-
healing disease, the duration of dapsone monotherapy and relapse rates after dapsone. 
The possibility that cases who eventually self-heal are contagious too was not explored: 
we judge this issue to be much less important for assessing the impact of interventions on 
transmission than the moment (also before onset of disease?) at which transmission takes 
place. A second possibility that was ignored in the scenario analysis of Chapter 6 is that 
individuals first go through an episode of non-contagious disease before developing 
contagious disease (‘downgrading’). Further simulations showed that this assumption 
often resulted in conflicts with the 1985-1998 case detection trend for the major endemic 
countries.  
The introductory Chapter 1 of this thesis already indicated that knowledge on the process 
of leprosy transmission is still very limited. In our studies, we adhered to the common 
notion that leprosy is transmitted predominantly within the human population. But we 
did not explore all hypotheses on possible human sources of leprosy transmission. For 
instance, we ignored the possibility of an important role for individuals with infections 
that self-heal without any manifestation of disease, but only after a transient period of 
nasal excretion. This hypothesis further underlines that three key questions need to be 
answered in order to understand whether and how leprosy transmission can be reduced. 
These questions are: (1) ‘is leprosy predominantly transmitted to close contacts or to the 
general population?, (2) ‘at what rate do contagious individuals transmit M. leprae to 
susceptible individuals (speed of transmission)?’ (3) ‘how much do individuals without 
signs of leprosy contribute to transmission?’.  
Compared to other diseases, the potential yield of a simulation modelling approach for 
leprosy was limited. Our approach has improved the insight in the impact of 
interventions for leprosy, we have identified the gaps in knowledge about leprosy that 
matter most, and we have shown how much these gaps matter: the uncertainty about the 
impact of leprosy control remains high (see questions 3 and 5). Due to its group-
compartmental design, our present modelling framework SIMLEP does not allow for 
detailed description and simulation of how leprosy spreads within populations (see 
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Chapters 1 and 4). Application of a leprosy simulation model which is capable of this 
would enable further narrowing down of the uncertainty about the impact of leprosy 
control, but so far, we have not identified datasets that provide sufficient information for 
developing, quantifying and validating such models.  
In 2002, a large prospective field study was started into the role of close contact in the 
transmission of leprosy and effectiveness of chemoprophylaxis for close contacts of 
leprosy patients (‘COLEP: a prospective (sero-)epidemiological study on contact 
transmission and chemoprophylaxis in leprosy’) (6). The study is unique in that it 
distinguishes various levels of closeness of contact to a leprosy patient, whereas it also 
involves an extensive serological component. Contacts are classified according to both 
physical distance – those living under the same roof and/or eating from the same kitchen, 
neighbours, neighbours of neighbours, social contacts – and genetic distance. Thus, the 
study is expected to provide a wealth of data regarding patterns according to which 
leprosy spreads in a population. Along with this trial, our research group will develop a 
micro-simulation model for leprosy transmission. In a micro-simulation approach, 
relevant aspects of life histories of individual human beings are simulated. The micro-
simulation approach allows for keeping track of whether an individual is a contact of a 
leprosy patient and his/her physical and genetic distance to the patient. Through this 
approach, we hope to further improve knowledge about patterns of leprosy transmission 
in populations and to further narrow down the uncertainty about the impact of present 
day control on time trends in transmission. This approach will also allow for evaluating 
the impact of alternative control policies targeted at close contacts of leprosy patients 
(chemoprophylaxis, immunoprophylaxis) which receive increasing interest. This 
evaluation is not possible with SIMLEP, simply because it does not distinguish close 
contacts from the general population.  
Question 5 
What is the impact of present day control – case detection and chemotherapy, BCG 
vaccination – on the transmission of leprosy? 
Answer 
The impact of case detection and chemotherapy on transmission remains highly 
uncertain: our estimates range from hardly any impact at all up to a reduction in the 
incidence rate of leprosy of 10% per year. Under optimistic assumptions about efficacy 
and coverage, BCG enhances the predicted declines in incidence rates in the next two 
decades with a few percents. Overall, our estimates indicate that present day control will 
reduce leprosy incidence rates up to 2020 with in between 1% and 12% per year. 
Comment 
In the scenario analysis of future leprosy trends reported in Chapter 6, predicted declines 
in leprosy incidence had to be due to leprosy control. This is because the possibility of 
autonomous decreases in transmission, for instance due to socio-economic improvement 
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instead of control, was ignored. First, only case detection and chemotherapy was 
considered. In this case, the predicted annual decline in incidence rate between 2000 and 
2020 varied from 2% to 8% with different assumptions regarding build-up of 
contagiousness and decrease of transmission opportunities (see under question 4). The 
range was from 5% to 10% when BCG vaccination was considered as well. These ranges 
are from 1% to 10% without BCG and from 3% to 12% with BCG, respectively, when 
other aspects of leprosy epidemiology and assumptions about leprosy control are varied 
in a sensitivity analysis (range without BCG not shown in Chapter 6). Thus, the overall 
range for the annual reduction in leprosy incidence rates is from 1% to 12%. 
A reflection on the scenario analysis is required. Scenarios were fitted to the average 
historical trend in CDR over 1985-1998 for 14 major endemic countries before incidence 
projections were made (see question 1). The range from 1% to 12% is based on scenarios 
with good fits to this average CDR. Since the average CDR trend will only in some cases 
be representative for the trend in individual countries, the criterion for classifying fits as 
‘good’ was not very strict: the annual change in CDR was allowed to differ 50% from the 
annual increase in the historical CDR trend. The historical CDR increased from 1.3 to 2.3 
per 10,000 per year. Additional investigations showed that the predicted annual declines 
changed only slightly upon assuming different levels for the historical CDR trend. The 
CDR level for India, which dominates global detection, was quite stable during 
1985-1998, averaging 5.7 per 10,000 per year. The predicted declines in incidence rate 
between 2000 and 2020 were slower when case detection rates were fitted to the stable 
Indian CDR. The assumptions on mean delay in case detection after the year 2000 and on 
efficacy and coverage of BCG vaccination were on the optimistic side, see also Chapter 6. 
These considerations support our estimate that present day control will reduce leprosy 
incidence rates up to 2020 with 1% to 12% per year. 
Autonomous decreases in transmission will accelerate declines in transmission that are the 
consequence of leprosy control. Thus, annual declines in incidence rate that exceed 12% 
per year cannot be excluded. Declines in incidence rate or CDR by more than 12% per 
year have been reported for a number of areas/countries in Chapter 2 and in a review by 
Irgens (7), see Table 9.1. It is suggested that autonomous decreases due to socio-
economic improvement have contributed to the declines in Weifang, Mainland Japan and 
Okinawa. The declines listed in Table 9.1 have to be interpreted with caution. 
Pronounced declines in the first years of the observation period influenced the overall 
rates of decline in Shandong and Weifang (which is part of Shandong), and in Uele 
Region and Ndi Oji Abam. These initial declines may be due to reduction of backlogs in 
the detection of leprosy patients following the initiation of control activities, and 
reduction of false-positives in case ascertainment may have been a contributing factor in 
Uele Region. The annual decline in CDR in Uele Region was only 5% per year during 
1980-1988, versus 19% for 1975-1988 as a whole. The initial CDR in Ndi Oji Abam, 
which had a population of only 3,000 individuals, was extremely high: 13.2 per 1,000 per 
year. CDRs were already below one per 100,000 per year at the start of the observation 
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period in Mainland Japan and Mexico, and the decline in incidence rate (which refers to 
onset of disease) accelerated in Shandong Province once it reached one per 100,000 per 
year. 
Question 6 
What is the relationship between the delay in case detection and the impairment status of 
patients at the time of detection, and how does the impairment status change during 
treatment and after release from treatment? 
Answer 
The prevalence of impairment caused by leprosy in newly detected patients increases 
strongly with longer delays in case detection. Newly detected patients who are initially free 
from impairment may develop impairments over time, and the impairment status of 
impaired patients may both improve and worsen after the time of detection. Still, the 
impairment status of patients at the time of detection is the most important determinant 
for future impairment. 
Comment 
Data from a cohort of newly detected patients from a long-term prospective study into 
the effectiveness of MDT was analysed (ALERT’s AMFES study in Ethiopia). The 
prevalence of any impairment in new patients increased continuously from 36% for 
delays of less than one year to 81% for delays of four years or more, and the prevalence 
of WHO grade 2 impairment increased similarly from 10% to 43% (Chapter 7).  
About half of the patients were detected with impairment. Of those initially impaired, 
around 20% had recovered at release from treatment. A similar percentage of this group 
with impairment at detection was free from impairment at follow-up (24-48 months after 
Table 9.1 Areas and countries with average annual declines in incidence rate or case detection rate of more 
than 12% per year. 
Area / country 
(reference no.) 
Period of decline 
 
Average annual  
decline (%)  
China, Shandong Province (8) 1958 – 1979 14%a 
China, Weifang Prefecture (9) b 1955 – 1993 13%  
Congo, Uele Region (10, 11) b 1975 – 1988 19%  
Japan, Mainland (12) 1950 – 1980 13%  
Japan, Okinawa (13) 1967 – 1980 17%  
Mexico (14)b 1980 – 1989 13%  
Nigeria, Ndi Oji Abam (15) 1941/1945 – 1952/1956 16%  
a Calculated on the basis of rates of leprosy incidence, which denotes onset of disease as reported by patients. 
b See also Chapter 2. 
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release from treatment). Of those initially free from impairment, 11% did have 
impairment at release from treatment, and 14% at the time of follow-up (the latter result 
was not shown in Chapter 8). Looking backwards, about 90% of both those with 
impairment at release from treatment and those with impairment at follow-up already had 
impairment at the time of detection. The dynamics of existing impairment were less 
favourable after release from treatment than before, but important changes over time in 
the cohort’s distribution of the EHF-score – which is the sum of the WHO impairment 
grades for eyes, hands and feet, see Chapter 1 – did not occur.  
The key results from other studies were quite similar, even though these studies differ 
considerably in the percentage of patients that already had impairment at the time of 
detection. Two studies confirmed the found strong positive association between the 
detection delay and impairment in new patients, see Chapter 7. Studies from Bangladesh, 
Malawi, Nepal and Thailand addressed dynamics of impairment, see Chapter 8. Patients 
were reassessed at release from treatment, except in Nepal where the reported 
reassessment took place two years after detection. Further analysis of these studies shows 
that more than 80% of patients with impairment at the time of the reassessment already 
had impairment at the time of detection, except for one study (more than 70%). The 
overall percentage of patients with impairment hardly changed between the times of 
detection and reassessment in Bangladesh and Thailand, and decreased from 56% to 45% 
in Nepal. Comparison was not possible for Malawi. The studies do not enable 
comparison of the impairment status at the start of treatment and several years after 
release from treatment. 
9.2 Impairment caused by leprosy: an exploration of the future  
Leprosy is a public health problem because it causes impairment and disability. Demands 
for care are driven by the number of individuals with impairment. Estimating prevalence 
of impairment was not the subject of any of the previous chapters. Because of the 
importance of this topic, we below present scenarios for global prevalences of 
impairment up to 2020, which are derived by calculating the survival of both existing and 
new impaired cases. Results are in terms of WHO grade 2 impairment, because control 
programmes only routinely report the percentage of newly detected cases having grade 2 
(see Chapter 1; we refer to the grades as ‘impairment grades’ instead of ‘disability grades’). 
The estimates for leprosy incidence rates and CDRs from section 9.1 are used for 
specifying three scenarios of future declines in incidence rates beyond 2000: a worst case 
scenario (constant annual decline: 1%), a medium case scenario (6%) and a best case 
scenario (12%). Table 9.2 shows the number of cases that will be detected globally in 
2010 and 2020, under the assumption that the annual declines in CDR and incidence rate 
will be equal. The global CDR for the period 1994-2000 is used as initial CDR, because 
CDRs in the late 1990s were elevated (see Chapter 3). In the worst case scenario, annual 
case detection hardly changes: population growth and the assumed decline in CDR 
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compensate each other. In the medium case, still about 250,000 new cases will be 
detected in the year 2020 (65% less than in the worst case). The best case scenario shows 
a more than ten-fold reduction in case detection between 2000 and 2020: the global case 
detection has fallen to about 65,000 cases (91% less than in the worst case). Still, even in 
this scenario, nearly four million cases will be detected up to 2010, and over one million 
cases between 2010 and 2020. 
The next step is to calculate the numbers of future new cases that will present with WHO 
grade 2 impairment. To perform this calculation, we assume that 6% of new cases 
detected during each of the years 2001 to 2020 will have grade 2. This 6% is fairly 
optimistic; it is the percentage of new cases with grade 2 that was reported by the 
Bangladesh Acute Nerve Damage Study (BANDS) (16). BANDS is conducted within a 
high quality control programme, and the percentage with grade 2 was always at least 7% 
in the impairment and disability studies reviewed by us (see question 6).  
Results for the 6% WHO grade 2 assumption are as follows (Table 9.3). In the worst case 
scenario, global annual detection of new cases with grade 2 is about constant at 42,000 
cases per year, resulting in 830,000 new cases with grade 2 for 2001-2020 as a whole. In 
the medium case scenario, the annual number of newly detected cases with grade 2 will 
have fallen to 15,000 cases by the year 2020, but the cumulative detection over 2001-2020 
still equals half a million cases. In the best case scenario, 4,000 new cases will be detected 
with grade 2 in 2020, and 300,000 cases over 2001-2020. 
The demands for care are determined by the prevalence of impairment, i.e. the number of 
individuals living with impairment. For a given point in time, we estimate this prevalence 
as the number of new cases that were detected with WHO grade 2 before that point, and 
survived up to that point. Worldwide, about 680,000 new cases were detected with grade 
2 during the period 1985-2000. We use backward extrapolation to estimate numbers of 
new cases with grade 2 up to 1985. Table 9.3 provides the required estimates for the 
global detection of new cases with grade 2 beyond the year 2000. 
Table 9.2 Scenarios for case detection corresponding to a 1% annual decline in the global incidence rate of 
leprosy beyond the year 2000 (worst case scenario), a 6% annual decline (medium case scenario), and a 12% 
annual decline (best case scenario). 
 
No. of cases detected 
(hundred thousands) 
 Cumulative no. of cases detected 
in a 10-year time period 
(hundred thousands) 
 2010 2020 2001-2010 2011-2020 
Worst case scenario 6.9 6.9 69 69 
Medium case scenario 4.1 2.5 52 31 
Best case scenario 2.1 0.7 38 12 
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In the survival calculations, we assume that there is no excess mortality due to leprosy: 
age-specific death rates for the general population of Bangladesh for the year 1994 are 
used (18). The age distribution of new cases presenting with WHO grade 2 in the control 
programme of the Danish Bangladesh Leprosy Mission in Bangladesh is used to 
calculated ages of the impaired cases at the time of their detection (DBLM; unpublished 
data over 1986-1990). The mean age at detection of new cases with WHO grade 2 in 
DBLM was 39 years, and the remaining life expectancy at this age is 31 years.  
In our calculations, 1.3 million individuals were alive with WHO grade 2 impairment by 
the end of the year 2000. This is within the wide range that was estimated by WHO in the 
1990s (1-2 million, see Chapter 1). Due to 72% survival and its size, the group from 2000 
contributes more than 70% to the global WHO grade 2 prevalence in 2010 in all three 
scenarios (Table 9.4). About half of this group survives up to 2020 (0.6 million 
individuals). The situation per scenario varies somewhat more in this year. In the worst 
case scenario, cases detected during 2001-2020 account for about half of the global WHO 
grade 2 prevalence of 1.4 million (this figure is slightly higher than in 2000, which is due 
to growth of the world population). The contributions are about 40% and 30% for the 
medium and best case scenario, respectively. In the best case scenario, the global WHO 
grade 2 prevalence in 2020 is still about 0.9 million, despite of the sharp fall in the 
detection of new cases with WHO grade 2 to only 4,000 cases in this year. 
To our knowledge, this is the first time that projections of future impairment are 
presented, and our projections are rather crude. We assumed stability in the impairment 
status of patients, inspired by studies comparing impairment at diagnosis and release from 
treatment (question 6). However, the follow-up period in these studies was not long, and 
individuals with anaesthetic nerves (grade 1 impairment) remain at risk for developing 
visible deformities or damage (grade 2). The frequency of the reverse, permanent 
improvement of WHO grade 2 impairment after release from treatment, will probably be 
Table 9.3 Estimated global detection of new patients presenting with WHO grade 2 impairment in the years 
2001-2020, according to three scenarios for the annual decline in the global incidence rate and CDR of leprosy 
beyond the year 2000. 
 
No. of grade 2 cases detected 
(hundred thousands) a 
Cumulative no. of grade 2 cases 
detected in a 10-year time period 
(hundred thousands) 
 2010 2020 2001-2010 2011-2020 
Worst case scenario 0.42 0.42 4.1 4.2 
Medium case scenario 0.25 0.15 3.1 1.9 
Best case scenario 0.13 0.04 2.3 0.7 
a Calculated on the basis of projections of the size of the world population (17), scenarios for the annual decline 
in CDR beyond 2000 (see main text and Table 9.2), and 6% WHO grade 2 impairment in cases detected 
during 2001-2020. 
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lower. In addition, awareness and detection efforts may decrease when leprosy becomes 
less frequent, leading to later detection and more impairment at the time of detection. 
Thus, we may have underestimated future prevalences of WHO grade 2 impairment. The 
opposite is also possible, because we assumed that there is no excess mortality in those 
with WHO grade 2 impairment. Although leprosy is in principle non-lethal, excess 
mortality may occur due to inappropriate care. We used a lifetable for the year 1994, 
which implies that we overestimated survival up to 1994, and underestimated survival 
afterwards. However, these considerations will not alter the main conclusion: the 
demands for care posed by individuals with impairment caused by leprosy will at best only 
decrease slowly. 
Table 9.4 Global prevalence of WHO grade 2 impairment in 2010 and 2020, according to three scenarios for the 
annual decline in the global incidence rate and CDR of leprosy during 2000-2020. 
Prevalence of WHO grade 2 impairment 
(hundred thousands) a 
2010 2020 
Resulting from cases from before 1985 b  
    Each scenario 5  2  
Resulting from cases detected during 1985-2000 c   
    Each scenario 5  4  
Resulting from cases detected during 2001-2020 
    Worst case scenario 4  7  
    Medium case scenario 3  4  
    Best case scenario 2  2  
Total prevalence 
    Worst case scenario 14  14  
    Medium case scenario 13  11  
    Best case scenario 12  9  
a Calculated as the number of new cases detected previously with WHO grade 2, and surviving until the end of 
2010 and 2020, respectively.  
b For years before 1985, the number of new cases with WHO grade 2 is estimated by multiplying the world 
population size with the estimated global case detection rate for 1985 and with the percentage of new patients 
detected with grade 2 in the top 32 endemic countries in 1985 (9.6%) (19). The global case detection rate for 
1985 is estimated by dividing the number of new patients detected in 1985 in the top 32 endemic countries by 
the 1985 world population size (see Chapter 3). 
c The estimated number of new cases detected during 1985-2000 with WHO grade 2 impairment is 680,000. 
This estimate is the sum of the reported number of new cases with WHO grade 2 in the top 32 endemic 
countries during 1985-1996 (19), and the estimated number of new cases detected globally with WHO grade 2 
during 1997-2000. The latter estimation is based on the total number of new cases detected globally in the 
years 1997-2000 (20) and percentages of new patients with WHO grade 2 impairment that were reported in 
the years 1996 and 2000 (20, 21). 
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9.3 Conclusions and recommendations 
Conclusions  
• To date, there is no general decline in annual numbers of leprosy patients detected in 
major endemic countries. 
• The impact of chemotherapy and BCG vaccination on trends in the transmission and 
incidence of leprosy is highly uncertain. Chemotherapy, BCG and other factors that 
may have contributed to downward trends in the past cannot be disentangled. 
• This uncertainty is largely due to three unresolved questions regarding infectiousness 
and transmission: 
– is leprosy predominantly transmitted to close contacts or to the general 
population? 
– at what rate do infectious individuals transmit M. leprae to susceptible individuals? 
– to which extent do individuals without signs of leprosy contribute to transmission?  
• The prevalence of impairment caused by leprosy increases strongly with longer delays 
between onset of signs and diagnosis.  
• A patient’s impairment status at diagnosis is the most important determinant for 
impairment in the future. 
• The global prevalence of WHO grade 2 impairment will only decrease very slowly in 
the foreseeable future.  
Recommendations 
• Chemotherapy based control must be sustained at the present level for at least the 
next ten years, after which leprosy trends should be critically reappraised in order to 
judge whether control efforts can be relaxed.  
• Leprosy control programmes should place emphasis on reducing delays in case 
detection, because early detection is essential for prevention of impairment and 
disability and for prevention of transmission. Reduction of delays requires more 
knowledge on health seeking behaviour. Improved knowledge will enable the 
development of new methods that enhance earlier case detection. 
• A research strategy that combines different disciplines of leprosy research 
(epidemiology, microbiology, immunology, genetics, simulation modelling) should be 
developed to address the unresolved questions regarding infectiousness and 
transmission. 
• Simulation modelling has a role in investigating patterns of transmission of M. leprae in 
populations in more detail, and in addressing the potential impact of strategies of 
primary prevention (chemoprophylaxis, immunoprophylaxis) targeted at close 
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contacts of leprosy patients. Models should be developed and used alongside 
prospective epidemiological field studies, enabling in depth analysis and interpretation 
of results. 
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Summary 
 
This thesis addresses the impact of leprosy control on the occurrence of leprosy and its 
associated impairments. 
Chapter 1 introduces leprosy, an infectious disease. Its manifestations vary widely: from 
mild self-healing forms to chronic and destructive disease. Knowledge regarding 
transmission of the leprosy bacterium Mycobacterium leprae is limited. For instance, it is 
unknown to what extent individuals incubating for disease contribute to transmission. 
Leprosy is a public health problem because it may cause nerve function impairment, 
leading to secondary complications of eyes, hands and feet. Disability, handicap and social 
stigma are ultimate consequences. Activities to prevent impairment and disability are very 
important. Early detection of patients followed by chemotherapy is the mainstay of 
leprosy control. The introduction of highly bactericidal multidrug therapy (MDT) in the 
1980s was a strong impetus for control programmes. However, evidence for an impact of 
MDT on transmission and incidence is still lacking.  
Chapter 2 is a review of publications that provide time series for case detection with a 
span of at least ten years, for 16 areas and countries in different parts of the world. Data 
did not extend beyond 1993. Case detection rates (CDRs) decreased in most areas and 
countries. The data did not allow for disentanglement of factors which may have 
contributed to the declines. The declines could not be attributed to relaxation of control 
activities or changes in criteria for the diagnosis of leprosy. There was no general 
acceleration of the declines after the introduction of MDT. The long incubation period of 
leprosy may have masked a possible influence of MDT. 
Publication bias towards high-quality control programmes and downward trends may 
have influenced the review. This is supported by the findings of Chapter 3, which 
describes case detection at regional and national levels using country statistics. Complete 
time series for case detection could be constructed for 1985-1998 for 33 endemic 
countries cumulatively (top 33), and for 14 individual countries in different WHO 
Regions (top 14). Global case detection was only available for 1994-2000. 
The top 33 had a nearly 100% share in global case detection. India accounted for at least 
75% of detection in the top 33 throughout 1985-1998, and the other top 14 countries for 
at least 75% of remaining detection. The CDRs were rather stable or increased for 10/14 
countries. The Indian CDR very slowly decreased up to 1996 and subsequently increased. 
A decreasing tendency in CDR was observed for 4/14 countries. Case detection for the 
top 33 minus India increased gradually during 1985-1998, overall almost doubling. Global 
case detection equalled 560,000 cases in 1994, peaked at 800,000 in 1998, and was 720,000 
in 2000. In conclusion, there is no general decline in case detection so far. Detailed 
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information is lacking, but control programmes were intensified in many countries in the 
1990s. Underlying trends in leprosy transmission and incidence could not be clarified. 
We developed the epidemiological model SIMLEP to investigate the impact of leprosy 
control on transmission and incidence (Chapter 4). SIMLEP has a group-compartmental 
design. The compartments reflect health states regarding leprosy infection and disease. 
Changes in these states are determined by epidemiological parameters. The parameter 
values and a set of mathematical equations determine how an epidemiological situation, 
i.e. the fractions of the total population with the various health states, evolves over time. 
SIMLEP considers two interventions: early case detection followed by chemotherapy, and 
bacille Calmette-Guérin (BCG) vaccination of infants. BCG is part of the Expanded 
Programme on Immunization (EPI) as a preventive measure against tuberculosis, and 
may influence leprosy trends. SIMLEP is age specific, and does not simulate impairment 
and disability. 
SIMLEP was used to analyse the downward trend of leprosy in Norway (Chapter 5). 
Leprosy was endemic in 1850, and had virtually disappeared by 1920. A patient database 
documents the declining trend extremely well. The Norwegian health authorities 
implemented a policy of isolation of patients in hospitals, and Norway experienced 
continuous economic growth during the period of the decline. SIMLEP reproduced the 
declining trend in case detection adequately, and equally well with contrasting 
assumptions regarding build-up of contagiousness during the incubation period of leprosy 
and decreasing transmission opportunities of patients. These opportunities may decrease 
because to a certain extent, close contact may be a prerequisite for transmission, and close 
contacts of a leprosy patient may become infected rapidly. For each set of assumptions 
(scenario), reproducing the declining trend required postulating an autonomous decrease 
in transmission, reflecting socio-economic improvement. The simulated contribution of 
hospital isolation to the decline ranged from 3% to 67%, with socio-economic 
improvement as competing explanation. 
Building on the Norway study, a scenario analysis of future trends in leprosy incidence 
was conducted (Chapter 6). A historical trend in CDR was fitted for each scenario, and 
incidence was projected up to 2020. For the historical CDRs, the average of the CDRs of 
the ‘top 14’ endemic countries for 1985-1998 of Chapter 3 was used. A strategy of early 
case detection and chemotherapy lies at the basis of all simulated scenarios. A gradual 
reduction in the delay between onset of disease and start of treatment, or ‘detection 
delay’, to two years from 1998 onwards was assumed, reflecting that leprosy control 
activities were intensified. Dapsone monotherapy was replaced by MDT in 1990. The 
scenarios differed on the same aspects as in the Norway study. 
The incidence decreased beyond 2000 in all scenarios due to the shortened detection 
delay, but also because MDT has a very low relapse rate. Without infant BCG 
vaccination, the predicted annual decline in incidence rate beyond 2000 ranged from 
2% – 8% for the scenarios with a good fit to the historical CDR trend. The annual decline 
was a few percent higher with favourable assumptions about protection and coverage of 
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BCG: from 4% – 10%. Other uncertain aspects of leprosy epidemiology were varied in a 
sensitivity analysis, leading to an overall range in the annual decline from 1% – 12% (for 
the 1% lower bound, see Chapter 9). Relaxation of control beyond 2005 through longer 
detection delays slowed down the declines. Thus, early case detection and MDT will 
reduce transmission, but the decline may be slow. Relaxation of control in the near future 
is unjustified, and a long-term perspective to leprosy control should be adopted. 
The issue of impairment caused by leprosy was addressed using data from a prospective 
study of a cohort of Ethiopian patients (AMFES). A grade of 0-2 was assigned to each 
eye, hand and foot to measure severity of impairment. The maximum and sum of the six 
grades of a patient are below referred to as the ‘WHO impairment grade’ and 
‘EHF-score’, respectively.  
The prevalence of impairment in new patients increased strongly with longer delays in 
case detection: from 36% for delays of less than one year to 81% for delays of four years 
or more (Chapter 7). The increase was from 10% to 43% for WHO grade 2 impairment. 
The importance of the detection delay as risk factor for any impairment and WHO 
grade 2 impairment was confirmed by multivariate logistic regression. The dynamics of 
existing impairment were less favourable after release from MDT treatment (rft) than 
before (Chapter 8). Important changes over time in the EHF-score distribution of the 
cohort as a whole did not occur. About 90% of patients with impairment at rft and 
patients with impairment at follow-up (24-48 months after rft) already had impairment at 
the time of detection. Thus, the impairment status at the time of detection is by far the 
most important determinant for future impairment.  
In the Discussion of this thesis (Chapter 9), we provide estimates for the number of new 
patients that will present with impairment in the future globally, and for the future global 
prevalence of impairment. The explorations build on the scenario analysis of Chapter 6. 
Three scenarios for declines in incidence rate beyond 2000 are considered: a worst case 
scenario (1% annual decline), a medium case scenario (6%) and a best case scenario 
(12%). Under the assumption that 6% of newly detected cases will have WHO grade 2 
impairment, we predict that cumulatively, 830,000 new cases will be detected with WHO 
grade 2 during 2001-2020 in the worst case scenario, and 500,000 and 300,000 in the 
medium and best case scenario, respectively. 
Future prevalences are predicted on the basis of survival calculations for existing and new 
impaired cases using age-specific death rates. Excess mortality for leprosy is not assumed, 
since leprosy is in principle non-lethal. In the literature, it is reported that during 
1985-1998 worldwide about 680,000 newly detected cases presented with WHO grade 2 
impairment. Backward extrapolation is used to obtain estimates for the period before 
1985. According to the survival calculations, the global prevalence of WHO grade 2 
impairment by the end of 2000 was 1.3 million. In the worst case scenario, the predicted 
global prevalence for 2020 is 1.4 million. The predictions are 1.1 million and 0.9 million 
for the medium and best case scenario, respectively. These results indicate that at best, the 
demands for care posed by individuals with impairment will only decrease slowly. 
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The conclusions and recommendations that follow from the research for this thesis are 
formulated in the Discussion chapter (Chapter 9), and are summarized below. 
Conclusions  
• To date, there is no general decline in annual numbers of leprosy patients detected in 
major endemic countries. 
• The impact of chemotherapy and BCG vaccination on trends in the transmission and 
incidence of leprosy is highly uncertain. 
• This uncertainty is largely due to three unresolved questions regarding infectiousness 
and transmission: 
– is leprosy predominantly transmitted to close contacts or to the general 
population? 
– at what rate do infectious individuals transmit M. leprae to susceptible individuals? 
– to which extent do individuals without signs of leprosy contribute to transmission?  
• The prevalence of impairment caused by leprosy increases strongly with longer delays 
between onset of signs and diagnosis.  
• A patient’s impairment status at diagnosis is the most important determinant for 
impairment in the future. 
• The global prevalence of WHO grade 2 impairment will only decrease very slowly in 
the foreseeable future.  
Recommendations 
• Chemotherapy based control must be sustained at the present level for at least the 
next ten years, after which leprosy trends should be critically reappraised in order to 
judge whether control efforts can be relaxed.  
• Leprosy control programmes should place emphasis on reducing delays in case 
detection, because early detection is essential for prevention of impairment and 
disability and for prevention of transmission. 
• A research strategy that combines different disciplines of leprosy research should be 
developed to address the unresolved questions regarding infectiousness and 
transmission. 
• Simulation modelling has a role in investigating patterns of transmission of M. leprae in 
populations in more detail, and in addressing the potential impact of strategies of 
primary prevention targeted at close contacts of leprosy patients.  
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Samenvatting 
 
Dit proefschrift behandelt de invloed van leprabestrijding op het vóórkomen van lepra en 
de met lepra samenhangende zenuwbeschadigingen en gebreken. 
Het inleidende Hoofdstuk 1 geeft algemene informatie over de besmettelijke ziekte lepra. 
Lepra kent een breed scala van verschijningsvormen, van milde en zelfgenezende vormen 
tot chronische en destructieve ziektebeelden. De kennis over transmissie van de 
leprabacterie Mycbacterium leprae is beperkt. Het is bijvoorbeeld onbekend hoe besmettelijk 
iemand is gedurende de incubatietijd. Lepra is een volksgezondheidprobleem omdat het 
zenuwen kan beschadigen, wat kan leiden tot secundaire complicaties in vooral de ogen, 
handen en voeten. Fysieke beperkingen, invaliditeit en sociaal stigma zijn de uiterste 
gevolgen. Activiteiten om zenuwbeschadigingen en fysieke beperkingen te voorkomen 
zijn dan ook een belangrijk onderdeel van bestrijdingsprogramma’s. De pijler waarop 
leprabestrijding rust is vroege opsporing van patiënten, gevolgd door het geven van 
antibiotica (chemotherapie). De bestrijding kreeg rond 1980 een sterke impuls met het 
beschikbaar komen van een combinatie van effectieve antibiotica, in de vorm van 
multidrug therapie (MDT). Tot op heden is echter nog niet aangetoond dat MDT de 
transmissie van de bacterie en het ontstaan van nieuwe patiënten (incidentie) beïnvloedt. 
Hoofdstuk 2 is een studie van publicaties die tijdreeksen van aantallen nieuw 
opgespoorde patiënten bevatten voor 16 gebieden en landen in verschillende delen van de 
wereld. De gegevens betroffen de periode vóór 1994. Het aantal opgespoorde patiënten 
per hoofd van de bevolking, de ‘case detection rate’ (CDR), nam af in de meeste gebieden 
en landen. De gegevens bleken het niet mogelijk te maken om de factoren te ontrafelen 
die bijgedragen kunnen hebben aan de afnames. Pogingen om leprapatiënten op te sporen 
waren niet minder geworden, en de afnames in CDR konden ook niet worden 
toegeschreven aan veranderingen in de criteria voor de diagnose van lepra. Er was geen 
algehele versnelling in de afnames na de introductie van MDT. De lange incubatietijd van 
lepra kan een mogelijke invloed van MDT aan het zicht hebben onttrokken.  
De studie kan hebben geleden onder publicatiebias: gegevens van goede bestrijdings-
programma’s en gunstige trends zullen eerder gerapporteerd worden. De bevindingen van 
Hoofdstuk 3 wijzen in deze richting. In dat hoofstuk worden trends in de opsporing op 
regionale en nationale niveaus beschreven aan de hand van op jaarbasis gerapporteerde 
landelijke gegevens. Tijdreeksen konden worden geconstrueerd voor 1985-1998 voor 33 
endemische landen tezamen (top 33), en voor 14 individuele landen in verschillende 
WHO Regio’s (top 14). Over de opsporing op wereldniveau waren alleen gegevens 
beschikbaar voor 1994-2000. 
Van de wereldwijd opgespoorde patiënten kwam bijna 100% uit landen die tot de top 33 
behoorden. Gedurende de gehele periode 1985-1998 werd minstens 75% van de in de 
top 33 opgespoorde patiënten ontdekt in India. De andere top 14 landen namen minstens
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75% van het overblijvende deel voor hun rekening. De CDRs waren vrij stabiel of namen 
toe voor 10/14 landen. De Indiase CDR daalde heel langzaam tot 1996 en nam 
vervolgens weer toe. De CDR liet een neergaande tendens zien in 4/14 landen. Er was in 
de periode 1985-1998 bijna sprake van een verdubbeling van het aantal opgespoorde 
patiënten in de top 33 minus India. De toename was geleidelijk. De wereldwijde 
opsporing besloeg 560.000 patiënten in 1994, piekte tot 800.000 in 1998, en was 720.000 
patiënten in 2000. Er is dus geen algemene afname in het aantal opgespoorde 
leprapatiënten. Na 1990 werd de leprabestrijding in veel landen geïntensiveerd. 
Gedetailleerde informatie hierover is echter niet beschikbaar. Verheldering van 
onderliggende trends in de transmissie en incidentie van lepra was niet mogelijk.  
Om de invloed van leprabestrijding op de transmissie en incidentie te onderzoeken 
ontwierpen wij het epidemiologische simulatiemodel SIMLEP (Hoofdstuk 4). SIMLEP 
is een groeps-compartimenten model. De compartimenten representeren stadia van 
infectie en ziekte. Epidemiologische parameters bepalen de stadiaveranderingen. De 
parameterwaarden en een stelsel van wiskundige vergelijkingen bepalen hoe een 
epidemiologische situatie, d.w.z. de fracties van de totale bevolking in ieder stadium, 
verandert over de tijd. In SIMLEP worden twee controlemaatregelen beschouwd: vroege 
opsporing gevolgd door chemotherapie, en bacille Calmette-Guérin (BCG) vaccinatie van 
pasgeborenen. BCG is opgenomen in het ‘Expanded Programme on Immunization’ 
(EPI) om tuberculose tegen te gaan, en zou ook het vóórkomen van lepra kunnen 
beïnvloeden. 
De neergaande Noorse lepratrend werd geanalyseerd met SIMLEP (Hoofdstuk 5). Lepra 
was endemisch in Noorwegen in 1850, en was vrijwel verdwenen in 1920. De daling is 
zeer goed gedocumenteerd in een electronisch patiëntenbestand. De Noorse overheid 
voerde een beleid waarbij patiënten werden geïsoleerd in ziekenhuizen. Voorts groeide de 
Noorse economie onafgebroken in de periode dat lepra afnam. Met SIMLEP kon de 
neergaande trend in het aantal opgespoorde leprapatiënten per jaar adequaat worden 
nagebootst. De rol die het Noorse isolatiebeleid heeft gespeeld bleef echter onzeker. De 
neergaande trend kon namelijk even goed worden nagebootst met tegenovergestelde 
aannames met betrekking tot de opbouw van besmettelijkheid gedurende de 
incubatieperiode en afnemende mogelijkheden voor patiënten om anderen te besmetten. 
De mogelijkheid om anderen te besmetten neemt misschien af omdat nauw contact 
tussen mensen een vereiste kan zijn voor transmissie, en omdat de nabije contacten van 
een leprapatiënt snel besmet kunnen raken. Om de neergaande trend na te kunnen 
bootsen moest voor iedere combinatie van bovengenoemde aannames (scenario) een 
autonome afname in transmissie worden gepostuleerd. Hiermee wordt rekening 
gehouden met sociaal-economische vooruitgang. Voor de verschillende scenario’s lag het 
gesimuleerde aandeel van het isolatiebeleid aan de verdwijning van lepra uit Noorwegen 
tussen 3% en 67%, met sociaal-economische vooruitgang als alternatieve verklaring voor 
deze verdwijning.  
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Voortbouwend op de Noorse studie werd een scenario-analyse uitgevoerd naar de 
toekomstige incidentie van lepra (Hoofdstuk 6). Een historische trend in CDR werd 
voor ieder scenario nagebootst, waarna de incidentie tot 2020 werd voorspeld. Voor de 
historische CDR werd het gemiddelde gebruikt van de CDRs van de ‘top 14’ endemische 
landen voor 1985-1998 van Hoofstuk 3. Een strategie van vroege opsporing en het 
verstrekken van chemotherapie lag aan de basis van alle gesimuleerde scenario’s. Een 
geleidelijke afname in de duur tussen aanvang van ziekte en start van behandeling 
(opsporingsduur) werd aangenomen, wat een weerspiegeling is van intensivering van de 
leprabestrijding. De veronderstelde opsporingsduur was twee jaar vanaf 1998. Dapsone 
monotherapie werd vervangen door MDT in 1990. De verschillen in aannames tussen de 
scenario’s waren hetzelfde als in de Noorse studie. 
De incidentie van lepra nam in alle scenario’s af na 2000, vooral door de verkorte 
opsporingsduur. Een andere factor die bijdroeg was dat patiënten na MDT slechts zelden 
opnieuw ziek en besmettelijk worden. Zonder BCG vaccinatie van pasgeborenen 
varieerde de voorspelde afname in het jaarlijkse aantal nieuw ontstane patiënten per hoofd 
van de bevolking (‘incidence rate’) tussen 2% en 8% per jaar voor de scenario’s waarvoor 
de historische CDR goed was nagebootst. Onder gunstige aannames over bescherming en 
dekkingsgraad van BCG was de jaarlijkse afname iets hoger: tussen 4% en 10%. In een 
gevoeligheidsanalyse werden andere onzekerheden in de epidemiologie van lepra 
gevarieerd, hetgeen leidde tot een uiteindelijke variatie in de jaarlijkse afname tussen 
1% en 12%. Door langere opsporingsduren aan te nemen na 2005, wat ontspanning van 
de bestrijding weerspiegelt, vertraagden de afnames in incidentie. De conclusie is dat de 
transmissie van lepra inderdaad afneemt door vroege opsporing en MDT, maar ook dat 
de afname traag kan verlopen. De bestrijding mag in de nabije toekomst niet worden 
verslapt, en in de leprabestrijding moet worden vastgehouden aan een lange termijn visie.  
De problematiek van zenuwbeschadiging en secundaire complicaties, tezamen hieronder 
aangeduid als 'gebreken', werd onderzocht met gegevens uit een prospectieve studie onder 
Ethiopische patiënten. Om de ernst van gebreken weer te geven kreeg ieder oog, en 
iedere hand en voet een score van 0, 1 of 2. Deze scores worden in dit proefschrift 
‘WHO impairment grades’ genoemd. Volgens dit scoresysteem heeft een patiënt een 
gebrek als minstens één van de ogen, handen of voeten de score 1 of 2 heeft. Een 
'WHO grade 2' wordt toegekend als minstens één van de ogen, handen of voeten de 
score 2 heeft. De som van de zes scores van ieder oog, iedere hand en iedere voet wordt 
de ‘eye-hand-foot’ (EHF) score genoemd. 
De aanwezigheid van gebreken (prevalentie) in nieuw opgespoorde patiënten nam sterk 
toe met de opsporingsduur: bij een opsporingsduur korter dan een jaar had 36% van de 
patiënten gebreken en bij een opsporingsduur van vier jaar of meer was dit 81% 
(Hoofdstuk 7). Voor het hebben van WHO grade 2 waren deze percentages 
respectievelijk 10% en 43%. Het belang van de opsporingsduur voor het hebben van 
gebreken en het hebben van WHO grade 2 werd bevestigd door multivariate logistische 
regressie. Analyse van de EHF-score op verschillende momenten in de tijd liet zien dat 
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veranderingen in bestaande gebreken minder gunstig waren na voltooiing van MDT, wat 
‘slechts’ de bacterie doodt, dan daarvoor. In de tijd deden zich echter geen belangrijke 
wijzigingen voor in de EHF-score verdeling van het cohort Ethiopische patiënten als 
geheel. Ongeveer 90% van de patiënten met gebreken bij voltooiing van MDT en van de 
patiënten met gebreken bij heronderzoek 24-48 maanden later had al gebreken op het 
moment van opsporing. Het hebben van gebreken op het moment van opsporing is dus 
verreweg de belangrijkste determinant voor het hebben van gebreken op een later 
moment. 
In de Discussie (Hoofdstuk 9) maken wij een schatting van het aantal nieuwe patiënten 
dat in de toekomst zal worden opgespoord met gebreken, en de toekomstige wereldwijde 
prevalentie van patiënten met gebreken. Deze verkenning bouwt voort op de scenario-
analyse van Hoofdstuk 6. Drie scenario’s worden gebruikt voor de afname in het jaarlijkse 
aantal nieuw ontstane patiënten per hoofd van de bevolking (‘incidence rate’) na het jaar 
2000: een ‘worst case’ scenario (1% jaarlijkse afname), een doorsnee scenario (6%) en een 
‘best case’ scenario (12%). De aanname is dat 6% van de nieuw opgespoorde patiënten 
WHO grade 2 zal hebben. Onder deze aanname voorspellen wij dat in het ‘worst case’ 
scenario 830.000 nieuwe patiënten zullen worden opgespoord met WHO grade 2 
gedurende 2001-2020. De voorspelde aantallen voor het doorsnee en het ‘best case’ 
scenario zijn respectievelijk 500.000 en 300.000. 
De prevalentie van personen met gebreken volgt door te berekenen hoe lang al bestaande 
en nieuwe patiënten met WHO grade 2 zullen blijven leven. Leeftijdsspecifieke 
sterftekansen zijn toegepast en er is geen oversterfte aangenomen omdat lepra in principe 
niet dodelijk is. Volgens de literatuur bedraagt het aantal opgespoorde nieuwe patiënten 
met WHO grade 2 tussen 1985-1998 680.000. Schattingen voor de jaren voor 1985 zijn 
verkregen via extrapolatie terug in de tijd. Volgens de overlevingsberekeningen bedroeg 
de wereldwijde prevalentie van personen met WHO grade 2 aan het eind van 2000 
1,3 miljoen. De voorspelde wereldwijde prevalentie in het jaar 2020 is 1,4 miljoen in het 
‘worst case’ scenario, 1,1 miljoen in het doorsnee scenario en 0,9 miljoen in het ‘best case’ 
scenario. Deze resultaten geven aan dat de vereiste zorg voor personen met gebreken in 
het beste geval slechts langzaam zal verminderen. 
De conclusies en aanbevelingen die volgen uit het onderzoek voor dit proefschrift zijn 
geformuleerd in de Discussie (Hoofdstuk 9), en worden hieronder samengevat.  
Conclusies  
• Er is tot nu toe geen algemene afname in de jaarlijkse aantallen opgespoorde 
leprapatiënten in de belangrijkste endemische landen. 
• De invloed van chemotherapie en BCG vaccinatie op de transmissie en incidentie van 
lepra is hoogst onzeker. 
• Deze onzekerheid wordt grotendeels veroorzaakt door drie openstaande vragen over 
besmettelijkheid en transmissie: 
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– vindt de transmissie van lepra voornamelijk plaats naar nauwe contacten van 
besmettelijke individuen of naar de bevolking in het algemeen? 
– in welk tempo besmetten besmettelijke individuen vatbare individuen? 
– in welke mate dragen individuen zonder symptomen van lepra bij aan transmissie?  
• De prevalentie van zenuwbeschadigingen en lichamelijke gebreken onder nieuw 
gediagnostiseerde leprapatiënten neemt sterk toe met een langere duur van opsporing.  
• Het reeds aanwezig zijn en de ernst van zenuwbeschadigingen en lichamelijke 
gebreken bij diagnose van een leprapatiënt is de belangrijkste determinant voor het 
hebben van gebreken op een later tijdstip. 
• Het aantal individuen in de wereld met zenuwbeschadigingen en lichamelijke gebreken 
ten gevolge van lepra zal in de nabije toekomst in het beste geval slechts zeer 
langzaam afnemen.  
Aanbevelingen 
• Het peil van de huidige leprabestrijding op basis van chemotherapie moet nog 
minstens tien jaar worden vastgehouden. Daarna moeten lepratrends opnieuw worden 
geanalyseerd om te beoordelen of de bestrijding minder intensief kan worden. 
• Bestrijdingsprogramma’s moeten nadruk leggen op de verkorting van de opsporings-
duur omdat vroege opsporing essentieel is voor de preventie van zenuw-
beschadigingen en lichamelijke gebreken èn voor de preventie van transmissie. 
• Een strategie waarbij verschillende disciplines van lepraonderzoek worden gecombi-
neerd is noodzakelijk om de openstaande vragen over besmettelijkheid en transmissie 
te onderzoeken. 
• Voor simulatiemodellering is een rol weggelegd in het gedetailleerd onderzoeken van 
transmissiepatronen van lepra in populaties, en in de bestudering van de potentiële 
invloed van primaire preventie gericht op nabije contacten van leprapatiënten.  
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